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ABSTRACT 
 Since the 1990s, academic physicians have been subjected to increased requirements for 
disclosure in their roles as educators and researchers and for conflict of interest (COI) resolution in their 
financial relationships with pharmaceutical, medical device, and biotech companies, collectively referred 
to as industry. The requirements are the result of the convergence of federal regulations, accreditation 
guidelines, professional and industry codes of ethics and conduct, and institutional policies.  The 
disclosure and COI resolution requirements are managed and resolved by a review of forms and 
compliance with relevant guidance documents and policies.  In the context of this environmental 
oversight, the purpose of the qualitative study was to explore physicians’ perspectives of how they 
manage and resolve conflicts of interest in their academic roles of teaching, research, and patient care. 
 Minimal evidence-based research exists in the literature from the physician’s viewpoint.  The 
grounded theory study examined the research question by using an issue-contingent, ethical decision-
making theoretical framework from the management literature.  The data were collected using a general 
interview guide that consisted of three sections – general questions regarding purpose and demographics, 
discussion of three case scenarios (teaching, research, and clinical practice), and finally, general 
concluding questions to assess the environment that is indicative of the context of the study. 
 The theory emerged from the interview data as a refined theory representing a four-step ethical 
decision-making process with emphasis on the characteristics of physicians as moral agents.  The study’s 
findings further indicated that bias is a significant concern.  The study identified reasons physicians enter 
into financial relationships with industry, the risks and benefits associated with those relationships, 
methods for avoiding bias, and the need for healthy academic-industry collaborative research.  
 
 
 
Key words:  Ethics, ethical decision-making, bias, influence, conflict of interest, disclosure, academic 
medicine, industry, medical research, qualitative research, grounded theory.
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Truth or Consequences— 
Academic Physicians’ Perspective 
in the Management of Commercially-influenced Conflicts of Interest 
Chapter I 
Introduction 
Background 
For over twenty years, there has been an ever-increasing public concern of 
pharmaceutical and medical device companies influencing physicians’ prescribing power and its 
effect on patient care and safety (Association of American Medical Colleges, 2007, 2008, 2010; 
American Medical Association, 2011; U. S. Food and Drug Administration Office of Policy, 
1997; U. S. Department of Health and Human Services, Office of Inspector General, 2003).  This 
concern is evidenced by a growing body of literature, ethical and professional codes, regulations, 
federal investigations, opinions, changes in accreditation guidelines, more stringent disclosure 
processes, heightened institutional compliance requirements, policies, and enactment of federal 
and state patient protection legislation and physician sunshine laws. Direction through these 
oversight mechanisms is intended to guide physicians through a robust disclosure process and, 
more importantly, manage and resolve without bias, any perceived or potential conflicts of 
interest (COIs) from financial relationships with pharmaceutical or medical device companies 
and biotech firms, collectively referred to as industry.  
A physician’s financial relationship with industry may consist of being a consultant, 
stockholder, member of a speakers’ bureau, research grantee, patent holder, board of directors’ 
presence, or employee as well as other arrangements that may create a potential COI.  
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Additionally, the physician’s financial relationship extends to immediate family members 
(Accreditation Council for Continuing Medical Education, 2004; U. S. FDA, 1997; U. S. DHHS, 
OIG, 2003).   Contributing a legislatively-driven transparency to the above oversight and 
governing systems is the recent Physician Payment Sunshine Act (H.R. 3590, Section 6002) 
which is a provision under the Patient Protection and Affordable Care Act (PPACA, Pub. L. 111-
148, 2010).  The Sunshine Act went into effect March 23, 2010 and requires pharmaceutical, 
medical device, and biotech firms to post on their websites (a) all funding recipients, institutional 
or individual, (b) the purpose or nature of the funding, e.g. research, support of continuing 
medical education (CME) activities, or physicians in any one or more of the roles listed above, 
and (c) the value of the financial relationship.  The need for improved transparency, beyond the 
self-reported disclosure requirement, is a result of congressional investigations into an 
environment that has experienced significantly increased oversight and scrutiny. 
Statement of the Problem 
In the midst of this complex and scrutinized environment is the physician or institution 
that has financial relationships with industry creating potential conflicts of interest (COI).  The 
following cases and examples epitomize the concern over physicians’ relationships with industry 
and recognition of the issue affecting individuals, institutions, and specialty associations.  The 
first example involves the case of a Baylor College of Medicine faculty member who allowed his 
name to be used on a ghostwritten article about a GlaxoSmithKline’s diabetic drug.  A 
ghostwritten article is generally written by the company that a key opinion leader (KOL) presents 
to a journal as his or her own (Basken, 2010; Leo & Lacasse, 2010). Another example involved 
Merck and Schering-Plough’s payment of $400,000 distributed among fourteen prominent 
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university-affiliated physicians (KOLs) to promote the use of their cholesterol-lowering drug 
over lesser expensive alternatives (Basken, 2009b).   
In 2010, several physicians in Stanford University’s School of Medicine received 
payment for being on speakers’ bureaus for pharmaceutical companies, violating Stanford’s very 
strict industry policy that bans certain interactions with industry including free lunches, gifts, and 
giving promotional presentations on industry’s behalf (Mangan, 2010).   Emory University’s 
psychiatry department experienced two incidents of faculty’s inappropriate involvement with 
industry that created significant conflicts-of-interest, both with GlaxoSmithKline (Basken, 
2009a).  In one incident, the faculty member was receiving payment from the company while 
conducting a federally-funded study on the use of antidepressants in pregnant women; 
GlaxoSmithKline manufactures antidepressant drugs.  The second incident was another faculty’s 
failure to disclose to the university over $800,000 that he had received from GlaxoSmithKline 
over seven years.  As a result, Emory updated its institutional COI policy to ban industry 
compensation and other forms of industry interaction.  In 2007, a physician received an 
unsolicited $10,000 payment for the accompanying ‘consulting’ agreement that required his 
commitment to prescribe Schering-Plough’s drugs (Harris, 2004). 
Another example that may also have posed a threat to academic freedom involved a 
University of California Berkeley faculty member’s research finding of the negative effects of a 
pesticide.  The company that funded the University of California at Berkeley study, Ecorisk, 
attempted to influence the research outcome that the company “paid for” (Blumenstyk, 2003).    
These case examples involving payments for ghostwriting, prescribing power, speakers bureaus, 
and skewed research results are only a sample of many incidences of inappropriate financial 
relationships with industry and illustrate evidence of reciprocity, ingratiation, industry-
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influenced control of decisions made by physicians who are considered KOLs in their specialties, 
and the potential lack of independence of thought and expertise in their decisions through, in 
some cases, failure to disclose. 
According to various stakeholders, there has been an increasing need to resolve COIs in a 
manner that is commercially-unbiased, independent, and free from the commercial influence of 
pharmaceutical, medical device, or biotech companies.  The current resolution process is 
determined by organizations or agencies that are responsible for the management of the 
disclosure and COI resolution process. As the literature review and environmental scanning 
through documentation suggests, there are many institutional industry and COI policies, federal 
regulations, accreditation guidelines and standards, professional recommendations, industry 
voluntary codes of ethics and professionalism that provide, for the most part, concrete rules, 
regulations, and guidance in managing and resolving COIs (ACCME, 2004; U. S. FDA, 1997; U. 
S. DHHS, OIG, 2003). 
Unlike the codes of behavior issued by the organizations referenced above and others, 
Jones’ (1991) decision-making model addresses the dependent nature of an issue on the decision 
process by viewing it through a lens of the six characteristics of moral intensity that are 
presented and discussed in chapter two.   Moral intensity is then applied to the four sequential 
stages of making an ethical decision: (1) recognizing the moral issue, (2) making a moral 
judgment, (3) establishing moral intent, and (4) engaging in moral behavior based on Rest’s 1986 
model.  Jones’ (1991) model provides the missing component in independent, unbiased decisions 
by focusing on the moral aspect of the decision made by an individual who, in this study, is the 
academic physician involved in teaching, research, and patient care.  Additionally, his model 
establishes the link between an individual’s ethics and actions by determining the correct thing to 
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do within a situation, following through by acting upon one’s ethical assessment without 
influence of environmental factors such as those previously stated, and seeking approval by 
oneself and/or from peers (Jones & Ryan, 1997). 
Research Gap 
While there is a substantial number of mechanisms offered in the resolution of COIs as 
represented above, the literature suggests that there is a gap in the literature and research 
regarding an individual perspective of making an ethical decision through identifying and 
resolving a COI as a moral issue (AAMC, 2010; Lo & Field, 2009).  Therefore, for the purpose 
of the study, the focus was on a process, and more specifically the academic physician’s ethical 
decision-making process, as the unit of analysis with individual physician interviews as one data 
source.  The study explored their approaches to and moral considerations in making ethical 
decisions as well as perceived COI implications with respect to their faculty roles of teaching, 
research, and patient care.  
In any of the above-mentioned primary roles, academic physicians’ financial relationship 
could influence a decision that affects their interaction with students, research subjects, the 
general population, and patients.  The following hypothetical examples demonstrate the potential 
commercial influence and bias in each of the three roles.  A faculty member may teach an 
equipment-based simulation skills course while owning stock in an equipment company known 
as Company Alpha.  The pieces of equipment used in the course were from Company Alpha, 
Company Beta, and Company Delta.  Throughout the course, the faculty member favored 
Company Alpha’s equipment and features over the other two companies although similar.  The 
students, as they progressed through their medical student education curriculum into residency 
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and then into private practice could act upon the faculty member’s influence while potentially 
increasing the value of Company Alpha’s stock.  The students, now in private practice, may also 
not be giving their patients the benefit of determining the best equipment for their treatments. 
In a research scenario, a faculty member could be the principal investigator (PI) for a 
diabetes research study funded by Company Epsilon, a pharmaceutical company that specializes 
in drugs for the treatment of diabetes.  The faculty member, while conducting industry-funded 
research, is also on the speakers’ bureau for and a consultant to Company Epsilon for which the 
faculty member receives financial compensation.  Although the study is progressing in an 
unfavorable manner for Company Epsilon, the faculty member may feel obligated to the 
company due to the existing and generous financial relationships. Consequently, the faculty 
member may also feel obligated to manipulate the data in the company’s favor to the possible 
detriment of the study participants and subsequently to the patient population-at-large. 
In a third and final scenario, faculty members in an academic medical center also see 
patients to fulfill their clinical responsibilities.  Using the financial relationships of consultant 
and speakers bureau in the diabetes research example above, the generous financial 
compensation of Company Epsilon could influence the prescribing power of faculty members to 
favor Company Epsilon’s drug over another company whose drug may be the better choice in 
treating patients with certain diabetic conditions. 
Moral Intensity, Ethics, and Academic Freedom 
As expressed by the three examples, there are two factors that may be in conflict 
regarding their influence on ethical decisions – the moral intensity of the issue and academic 
freedom.  The moral intensity of the issue is represented by the teacher’s biased equipment 
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preference, the researcher’s desire to manipulate data in a manner favorable to the company, and 
the clinician’s compromised prescribing power.  Conversely, academic freedom which is 
intended to protect faculty autonomy, ensure integrity, serve the public interest, contribute to the 
public good, and is “a particular kind of liberty in a moral order” (Ryan, 1949) may be 
compromised in favor of the faculty members’ financial gain (AAUP, 1940; Jones, 1991; 
Lieberwitz, 2005; Livingstone, 1974; Mangan, 1999; Rochford, 2003; Rosovsky, 1990; Ryan, 
1949; Shuger, 1990).   
 In addition to the moral intensity and academic freedom concerns, the internal and 
external forces’ effect on an institution and its faculty contribute to the context of the study.  
Among these forces that are discussed in chapter two and that were explored in my 2005 
qualitative pilot study are the consequences of the commercialization of higher education, the 
implementation of a decentralized responsibility center model, university-industry relationships, 
and the need for external funding (Bok, 2003; Whalen, 1991). 
Environmental and Organizational Change 
Pilot Study Overview 
The purpose of the qualitative pilot study was to identify and explore the effect of 
commercialization on the university departmental level.  The specific emphasis was on 
continuing medical education (CME) departments in schools of medicine or academic medical 
centers within a decentralized organizational structure.  Furthermore, the study examined 
through audio-recorded individual and focus group interviews how the various regulatory 
demands infused control on CME in a commercialized environment and how CME negotiated a 
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balance of the fiscal need for commercial involvement with the university’s decentralized 
structure.  
The literature review for the study revealed that commercial interests, partnerships, and 
influences have had an increasingly strong presence in higher education institutions since the 
1980s (Bok, 2003).  This trend had increased the need for external funding to replace 
diminishing internal and governmental sources of funding.  While some post-secondary 
institutions were emphasizing departmental fiscal accountability through a decentralized, “every-
tub-on-its-own-bottom” structure; internal stakeholders, including continuing medical education 
(CME) staff, were learning how to navigate a changing environment (Bok, 2003; Duderstadt & 
Womack, 2003; Robbins, 2003). 
Bok (2003), Campbell (1997), and Stilwell (2003) identified underlying themes involved 
in the process and results of change.  While the focus of the study was not on change itself; Bok, 
Campbell, and Stilwell recognized the undercurrent of change embedded in the trend of 
commercialization.  Therefore, it was important to understand the construct of change motivating 
the study.  The forces and results of environmental and organizational change were best 
exemplified by Kurt Lewin’s Three-Step Change Model approach (Robbins, 2003). 
Lewin’s model consists of three steps – (1) unfreezing the status quo, (2) movement to a 
new state, and (3) refreezing the new status to make it permanent.  The unfreezing step is 
necessary due to pressures which may occur by increasing driving forces (motivators) which 
direct behavior away from the status quo, by decreasing restraining forces (constraints) that 
hinder movement from the status quo, or by a combination of the two.  The movement phase 
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may appear as failing and not visible since the constraining voices are more vocal.  The 
refreezing phase provides stabilization and accomplishment. 
Figure 1: Kurt Lewin’s Three-Step Change Model 
Restraining forces 
 
 
     
 
 
Driving forces 
   TIME 
 
Source: Robbins, S. P. (2003). Organizational behavior (10th ed.).  Upper Saddle River, NJ: 
Prentice-Hall. 
 
Definitions in Lewin’s Model: 
 Unfreezing –  Change efforts to overcome the pressures of both individual resistance and 
group conformity. 
 Refreezing – Stabilizing a change intervention by balancing driving and restraining 
forces. 
 Driving Forces – Forces that direct behavior away from the status quo 
 Restraining Forces – Forces that hinder movement from the existing equilibrium. 
In the context of Lewin’s resistant forces, the three steps of his model were defined for 
the purpose of the pilot study as follows – 
 Step 1:  Unfreezing the status quo – (a) Ratification of the new ACCME Standards of 
Commercial Support on September 28, 2004 establishing greater distance and control 
between industry and CME; (b) change to a decentralized university structure dictating a 
cost-recovery fiscal climate.   
Unfreezing the 
status quo  
      
Movement 
      
Refreezing 
 10 
 Step 2:  Movement to a new state – (a) Preparation for full implementation of the new 
Standards by May 1, 2005 which required new policies and procedures for monitoring 
CME-industry relationships in addition to mechanisms for resolving conflicts of interest 
in the environment; and (b) developing strategic plans for seeking external funding for 
educational activities from the same industry relationships. 
 Step 3: Refreezing the new change to make it permanent – (a) Implementation of new 
Standards with accomplished goals established in the Step 2 movement; (b) balance of 
and compliance with federal, institutional, and accreditation regulations; and (c) 
adjustment to a cost-recovery structure with no or significantly decreased institutional 
support (Robbins, 2003). 
Lewin’s approach is a force-field analysis and categorizes resistant forces as technical 
(technology, structure, and organizational interaction), political (power, money, opportunities, 
and recognition), and cultural (values, norms, biases, and underlying organizational assumptions) 
(Robbins, 2003).  The three categories of resistant forces were respectively represented by the 
decentralized university structure as technical resistant forces, the need for funding sources and 
university-industry collaborations as political resistant forces, and the preservation of the 
traditional culture and core values of higher education as cultural resistant forces.  The driving 
forces or motivators to direct behavior away from the status quo (Step #1 in Lewin’s model) 
were represented by increased federal regulations and resulting policies, and the need for funding 
precipitated by a trend towards a decentralized structure. 
 As the review of current literature and discussion of the change framework reflected, the 
effects of commercialization on continuing medical education were complex.  The environment 
 11 
was changing as demonstrated through Kurt Lewin’s three-step model of change (Robbins, 
2003).  Lewin’s change model confirmed the volatility of CME and the effects it was 
experiencing as commercialization and decentralized institutional structures continued to 
position CME between a ‘rock and a hard place.’ 
The literature review examined three aspects of the study:  (1) continuing medical 
education (CME) – history and regulatory environment, (2) commercial influence and funding 
issues, and (3) context of higher education commercialization.  Universities requiring CME 
departments to be self-supporting coupled with a more restrictive, regulatory external 
environment could impact how and if CME departments were able to survive. 
Pilot Study Findings 
 The research participants in the individual interviews and focus group interviews 
provided experiential, perceptive, and constructive commentary on the issue of 
commercialization and its interaction with a decentralized university structure.  Each of the 
interviewees and focus group participants contributed perspectives that were reflective of their 
professional backgrounds which added depth to the findings. 
The findings from the pilot study, in which CME was the unit of analysis, confirmed that 
the convergence of a decentralized institutional structure and the effects of commercialization 
increased the need for funding for CME programs and their activities.  It was supported by data 
over a four-year period indicating a trend of increased commercial funding from 34% in 1998 to 
60% in 2002 (Canadian Medical Association Journal, 2004; Croasdale, 2004; Schaffer, 2000).   
 Two themes emerged from the interviews and focus group.  The first theme in the 
findings addressed the effect of commercialization on university-industry relationships and 
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relationship building.  It demonstrated that, as the structure of universities has become more 
corporate, they have promoted establishing external partnerships with industry to supplement 
departmental budgets.  
The second theme acknowledged a conflict between ethics and fiscal accountability.  
Because fiscal accountability is fundamental in a decentralized university structure, CME 
departments depend upon external funding sources for financial stability. The conflict occurs 
between the CME departmental need for securing funding and its ethical responsibility to 
separate the management of the funds from the potential influence on educational content by the 
funding source.  In essence and as stipulated by the ACCME® Standards for Commercial 
Support; even though commercial interests have donated funding for a CME activity as a 
conference grant, they are not allowed to participate in the development or review of content or 
in the selection of speakers with the intent of promoting companies or their products.  Influence 
and promotion cannot be conditions of grants. 
The research participants expressed concerns over the effects and risks of the funding 
environment on relationships between physicians and commercial interests and between 
ACCME-accredited providers and commercial interests.  These effects and risks were confirmed 
in the literature and were reflected in terms of commercial influence on physician behavior, 
research integrity, professional education of physicians and other healthcare professional, ethics, 
professionalism, and bias (Bok,  2003; Harrison, 2003; Relman, 2001).  Participants appreciated 
the regulatory safeguards the agencies have put in place because, as one commented, “…it levels 
the playing field.”  However, with the need for external funding on the increase, it creates a 
delicate balance in determining how to build relationships free of bias, influence, and control and 
in developing a collaborative environment for the common good and for the benefit of the patient 
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population (Bok, 2003; Harris, 2004; Harrison; 2003; Hosansky, 2003b; Pelletier, 2004; Wilson, 
2003).   
Representative of the context of the study, the pilot study findings supported the 
environment in which the study was conducted.  The findings also contributed to the focus of the 
study which was to investigate the process of how academic physicians make ethical decisions in 
their roles as teachers, researchers, and clinicians without the influence of their financial 
relationships with industry, i.e. “no strings attached,” or through their avoidance of financial 
relationships. 
Purpose of the Study 
 The purpose of this grounded theory study was to identify and investigate how physicians 
manage and resolve their perceived conflicts of interest (COI) in their roles as teachers, 
researchers, and clinicians in a changing environment of individual financial relationships with 
industry as well as university-industry relationships.  The purpose was also to explore the 
process of ethical decision-making in the management and resolution of conflicts of interest, the 
potential moral intensity of the issue at the heart of the conflict, and the role of faculty, as moral 
agents, in the process.   
Research Questions 
The study examined the following research question – How do physicians as 
academicians manage or resolve potential conflicts of interest in their roles as teachers, 
researchers, and clinicians? 
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Secondarily, the study examined: 
 Factors that may influence ethical, commercially-unbiased academic decisions; 
 Characteristics of ethical, evidence-based decisions v. commercially-influenced 
decisions; and 
 Assessments of how relationships with industry may threaten academic freedom in 
ethical decision-making. 
Significance 
The task force on clinical decision-making (AAMC, 2010) and the Institute of Medicine 
(Lo & Field, 2009) noted that there is a paucity of evidence-based COI research in the body of 
literature, including policy and systematic studies, thereby contributing to the significance of the 
study.   The literature and research gap appeared to exist as it related to how physicians 
themselves, as moral agents, resolve a conflict of interest by making an ethical decision about a 
moral issue (Jones, 1991; Lo & Field, 2009).   
 Conflicts of interest are currently managed and resolved through questionnaires, surveys, 
and third-party evaluations, which have been created by regulators, accreditation bodies, and 
others who are charged with similar documentation responsibilities.  The data indicating various 
levels of bias and influence in physicians’ decisions are presented by those organizations that 
represent a top-down, summative view of the environment.  Furthermore, the environment 
continues to be increasingly scrutinized by regulators, Congress, and professional organizations. 
The environment is also complex with numerous viewpoints and interpretations.  Therefore, to 
minimize ambiguity of meaning, the following definitions are offered to provide clarity. 
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Definitions 
These definitions contribute to an understanding of concepts that are presented in 
discussion or explanations: 
1. Academic Freedom – the custom, practice, and ideal, by which faculties may best 
flourish in their work as teachers and researchers; the liberty to speak, freely without 
persecution, in one way rather than in another, in the open and without fear or coercion; 
not an excuse for avoiding moral responsibility or moral debate and… a particular kind of 
liberty in a moral order.  It is essential to researchers for the advancement of truth, to 
teachers for freedom in classroom discussions while avoiding controversial topics 
unrelated to the subject matter, and to students for freedom in learning.  Academic 
priorities should not be influence by external interests without reviewing the 
consequences and consideration of the faculty (AAUP, 1940; AAUP, 1990; Kaplan & 
Lee, 1995; Ryan, 1949; Shuger, 1990). 
2. Commercial support – financial, or in-kind, contributions given by a commercial interest, 
which is used to pay all or part of the costs of a continuing medical education (CME) 
activity or in support of research studies (ACCME, 2004; FDA, 1997). 
3. (a) Conflict of interest – financial or economic issues that stem from use of funds, 
inappropriate influence, and the ownership of patents and licensing (Campbell, 1997).  
(b) Conflict of interest – circumstances that create a conflict of interest when an 
individual has an opportunity to affect CME content about products or services of a 
commercial interest with which he/she has a financial relationship (ACCME, 2004)  
Updated definition – “The ACCME considers financial relationships to create conflicts of 
interest in CME when individuals have both a financial relationship with a commercial 
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interest and the opportunity to affect the content of CME about the products or services 
of that commercial interest. The potential for maintaining or increasing the value of the 
financial relationship with the commercial interest creates an incentive to influence the 
content of the CME—an incentive to insert commercial bias” (ACCME, January 31, 
2012). 
(c) Conflict of interest – (FDA, 463F, 2d 600, 602)…legally, a situation in which regard 
for one duty leads to disregard of another (Kurt, 1990, p.6) 
(d) Conflict of interest – (Institute of Medicine-IOM) “a conflict of interest is a set of 
circumstances that creates a risk that professional judgment or actions regarding a 
primary interest will be unduly influenced by a secondary interest” (Lo & Field, 2009, 
p.46) 
4. Decentralized Responsibility Center Model (RCM) – an organizational entity directly 
involved in accomplishing the mission of the university or in providing support that 
enables mission accomplishment; primary organizational unit in an RCM budgeting 
system that functions in a decentralized operational and financial decision-making 
environment (Whalen, 1991). An example of a university setting would be one of self-
sufficient or cost-recovery departments that are responsible for all direct and indirect 
costs associated with their operating budgets and that are allowed to keep surplus 
revenues. 
5. Ethical decision – a decision that is both legal and morally acceptable to the larger 
community (Jones, 1991, p. 367) 
6. “Every tub on its own bottom” – Expression that originated at Harvard University.  The 
‘tub’ is an academic unit of a college or university and the ‘bottom’ refers to each unit 
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being responsible for its own bottom line including all costs it produces and all revenue it 
generates (Dubeck, 1997; Whalen, 1991). 
7. Faculty – physicians in academic medicine whose academic roles include teaching, 
research, and patient care. 
8. Financial Relationship – generally, it refers to those relationships in which the individual 
benefits financially, e.g. by receiving a salary, royalty, intellectual property rights from 
industry; is a consultant to or on a speakers’ bureau for industry; has stock or stock 
options; or has a presence on a board or advisory panel.  This also extends to the 
individual’s spouse or partner and is applicable within the previous twelve months 
(ACCME, 2004; FDA, 1997). 
9. Industry – pharmaceutical, medical device, or biotech companies or firms. 
10. Moral agent – person who makes a moral decision, even though he/she may not 
recognize that moral issues are at stake (Jones, 1991, p. 367). 
11. Moral issue – an issue central to the action or decision which must have consequences for 
others and must involve choice, i.e. volition on the part of the decision maker (Jones, 
1991, p. 367).  
Among the definitions above are four variations on what defines a conflict of interest 
(COI). Conflicts of interest exist in virtually all professions and organizations both of which 
provide policy and procedural guidance in determining what circumstances or external 
relationships require disclosure and how individuals and organizations may resolve potential 
COIs that result from disclosure.  In conducting research for this study through review of the 
literature and face-to-face interviews, I identified fundamental, core characteristics of a COI that 
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could be relevant to all disciplines, not just medicine.  A conflict-of-interest that stems from a 
financial relationship with an external entity with a vested interest in a shared goal may: 
 Cloud an individual’s professional judgment, objectivity, and behavior; 
 Suggest the presence of undue bias and influence; 
 Result in harmful consequences; and 
 Require an ethical, moral resolution process. 
The definition of a conflict of interest (COI) can be as narrow or as broad as 
circumstances or the environment dictates; but through my professional experience and research, 
I construed that these characteristics capture the essence of what constitutes a COI and, as such, 
warranted a thoughtful, qualitative study to further explore the COI resolution process.  The 
other defined constructs or components given above represent factors that can influence faculty 
and institutions which may include commercial support, a decentralized structure, the ‘tub’ 
metaphor, and industry.  The remaining definitions of academic freedom, ethical decision, moral 
agent, and moral issue place an observable focus on the individual faculty member in his or her 
decision-making role.  
Overview of Methodology 
As discussed in chapter three, I conducted the study using a qualitative, grounded theory 
approach which Strauss & Corbin (1998) define as an existing or emerging theory that is 
grounded in the participants’ perspectives and observations and could provide insight, enhance 
understanding, or generate action.  The purpose of the study was to examine the process by 
which academic physicians, as moral agents, in their roles as teachers, researchers, and 
clinicians, may resolve and manage conflicts of interest which may result from their financial 
relationships with industry.  Therefore, Strauss & Corbin’s definition of grounded theory 
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confirmed that perspectives of physicians as interview participants were essential to studying an 
ethical decision-making process which is represented by the theoretical model and validated the 
use of a grounded theory methodology for the study.   
The study design incorporated purposeful sampling of ten academic physicians from two 
academic medical centers.  In order to collect rich, descriptive data for analysis, the interviewees 
should have participated or currently were participating in one or more financial relationships 
with industry.  The interview protocol (Appendix I) included questions that collected 
demographic information to verify the academic physician profile of the de-identified research 
participants.  Secondly, the interview participants responded to a set of questions that were based 
on the characteristics of moral intensity in Jones’ (1991) issue-contingent ethical decision-
making model and were addressed in the context of three case scenarios.  Each of the case 
scenarios represented one of the three academic medicine roles of teaching, research, and patient 
care.  Finally, the concluding general questions collected the participants’ current viewpoints of 
the environment.  The interviewees assessed reasons for entering into financial relationships with 
industry, benefits and risks, obstacles or barriers, methods of avoiding bias and conflicts of 
interest, the Sunshine Act effect, and factors that may influence ethical, unbiased decisions. 
I applied an open coding process and constant comparison of interview data (Creswell, 
2009) from which the codes evolved into nine categories (honesty, morality, human nature, bias, 
objectivity, proximity, volition, beliefs and actions, and decisions) and three core categories of 
morality, bias, and familiarity. Additionally, nine characteristics of a moral agent emerged in the 
refined theory.    
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Limitations 
I took precautions to minimize risks by bracketing my beliefs and opinions and allowing 
the voices of the participants to be heard in their own words reflecting an “insider’s” perspective 
or what the participants believe is true.  Individuals also tend to act upon their beliefs for which 
there can be consequences.  This philosophy also reinforces the elements of the theoretical 
framework (Creswell, 1998). 
 An additional limitation for the study evolved around the use of theoretical sampling, a 
purposeful sampling strategy.  By using theoretical sampling, the number of interviews, ten out 
of a possible twenty, was conceivably small.  The original goal was to conduct between twelve 
and twenty as long as saturation was accomplished.  Saturation occurs when no new or relevant 
data or theoretical insights seem to emerge or add to the understanding and validation of 
categories (Charmaz, 2006; Corbin & Strauss, 2008; Creswell, 1998; Strauss & Corbin, 1998).  
The data collected from conducting ten interviews suggested that saturation was achieved.  A 
few of the remaining ten did not respond, and others indicated that their schedules were such that 
they were unable to participate but were interested in the study.  This was an anticipated 
response since physicians maintain very busy schedules in their concurrent roles of teaching, 
research, patient care, and sometimes the added responsibility of institutional administration. If 
saturation had not been reached, I would have requested a second set of interviews at each of the 
two institutions (Creswell, 1998; Strauss & Corbin, 1998). 
Organization of the Dissertation 
 Chapter one presents an overview of the study, providing background and rationale for 
conducting the study, a brief look at the literature that informed the study, a summary of the pilot 
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study that contributed to the context of the study, the research questions that were explored, 
disclosure of my limitations, and an overview of the methodology.  Chapter two presents an in-
depth review and synthesis of the bodies of literature in the fields of higher education, 
organization, and management that are pertinent to the study topic.  The literature in chapter two 
also submits a current view of the environment, external forces and internal pressures that 
institutions are encountering in their navigation of the environment, the influence of historical 
principles that inform academic decision-making and avoidance or resolution of conflicts of 
interest, and finally, a discussion of the theoretical framework, an issue-contingent ethical 
decision-making model that provided a lens through which the reader may view the study and its 
findings. 
 Chapter three discusses the grounded theory methodology by which the study was 
conducted and introduces the rationale for a qualitative design by restating the purpose of the 
study and the research questions.  The rationale justifies a constructivist, grounded theory 
methodology and the elimination of other qualitative methods.   I present my role as the research 
instrument by describing my academic career, background and knowledge and by disclosing my 
assumptions and biases.  Chapter three provides descriptions of the two institutions of higher 
education that were the settings for the study and outlines the research plan and process.   
 The research plan details the choice of purposeful sampling, participant selection, gaining 
institutional access, data collection, and data analysis.  The data collection section describes the 
rationale for a general interview guide method, and the section on data analysis discusses the 
procedures for coding and conclusion drawing.  Lastly, chapter three describes the importance of 
establishing trustworthiness of the study by addressing elements of credibility, confirmability, 
dependability, and transferability.  
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 Chapter four presents the findings of the study and suggests a modified theory of an 
ethical decision-making process as it relates to academic physicians who have financial 
relationships with industry and how consequential conflicts of interest may affect their roles in 
teaching, research, and patient care.  From the interviews and case discussions emerged reasons 
physicians enter into financial relationships with industry, individual and institutional benefits 
and risks of those relationships, suggestions of how to avoid bias, and a refined theory.  The 
refined theory places primary emphasis on the moral agent characteristics existent in each of the 
four stages of the decision process and secondary emphasis on the moral intensity characteristics 
of the issue at the heart of the decision. 
 Chapter five reviews the purpose and significance of the study and discusses a summary 
of the methodology, a summary of findings, and the more recent, anticipated effect of the 
Sunshine Act (Open Payments), a provision of the Affordable Care Act.  Chapter five also 
presents opportunities for future research that are either based on the findings or the existing 
environment in which physicians resolve perceived conflicts of interest in their academic roles of 
teaching, research, and patient care.  Finally, I discuss implications for policy and reform.  
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Chapter II 
Review of the Literature 
Introduction 
 The purpose of chapter two is to bring together and synthesize bodies of literature 
relevant to the grounded theory study from the fields of higher education, organizational theory, 
and management.  The literature review establishes the context of the study by presenting 
discussions on the current higher education environment, including the effect of 
commercialization, a decentralized institutional structure, and university-industry relationships.  
The discussions present the external forces that were impacting the study and viewed them from 
the perspectives of various stakeholder groups. 
The literature presents the evolution of the current higher education environment and 
specifically academic medicine, how it contributes to the setting of the study, and how aspects of 
the commercialization of higher education and of university-industry collaborations have 
inherently influenced faculty, creating conflicts of interest and the need for ethical resolution 
without commercially-influenced bias.  To establish an understanding of the need and 
significance for the study as well as an appreciation of the setting of the study, this chapter 
describes the current environment prior to reflecting on the past, discussing the ethics and 
elements of the current COI resolution process, and exploring the theoretical framework of 
ethical decision-making and the moral intensity of the study. 
A brief history presents how society, institutional mission, organizational culture and 
climate, academic freedom, and ethics have influenced the role of faculty and academic decision-
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making over time.  This section of chapter two also reviews aspects of conflicts of interest and 
efforts of various stakeholders in managing COIs or offering guidance for resolving COIs. 
Individual resolution is at the heart of the study.  The literature describes unambiguous 
resolution requirements, recommendations, codes, and guidelines issued by federal regulatory 
agencies, accreditation bodies, professional societies, and industry, some of which include 
punitive or professional consequences.  Moreover, this portion of the literature does not address 
the individual morality that is involved in the process of resolving a potential COI and that may 
result from a faculty member’s financial relationship with industry. 
The ethics and COI discussion introduces Jones’ (1991) ethical decision-making model 
that may inform thoughtful consideration by the academic physician in assessing the issue and 
subsequent decisions.  Literature from the field of management through Jones’ ethical decision-
making model and others suggested how an individual faculty member may approach the 
resolution process by identifying the issue at hand, assessing its moral intensity, and reaching an 
unbiased conclusion. 
Jones’ (1991) model is used as the theoretical framework for the study, and the moral 
essence of Jones’ model is supported by two examples.  The first example involved a psychiatrist 
who was being handsomely paid by Wyeth Pharmaceuticals to promote its new drug for treating 
depression over the use of S.S.R.I.s by giving “Lunch and Learn” presentations in doctors’ 
offices and using slides prepared by Wyeth. Over time and becoming aware of undisclosed data 
regarding some of its side effects, he realized that he was minimizing discussion of hypertension 
risks and withdrawal symptoms, for example, because they were not part of the canned 
presentation.  This was one of two defining moments that ended his speakers’ bureau 
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involvement.  Following a talk and being challenged by a member of the audience about 
hypertension risks: 
I felt rattled.  That psychiatrist’s frown stayed with me – a mixture of skepticism and 
contempt.  I wondered if he [audience member] saw me for what I feared I had become – 
a drug rep with an M.D.  I began to think that the money was affecting my critical 
judgement (Carlat, 2007). 
The other moment followed an observation by the company reps of a less-than-enthusiastic talk: 
At that moment, I decided my career as an industry-sponsored speaker was over.  The 
manager’s message couldn’t be clearer:  I was being paid to enthusiastically endorse their 
drug.  Once I stopped doing that, I was of little value to them, no matter how much 
“medical education” I provided.  (Carlat, 2007) 
In 2001, there were approximately 25% or 200,000 physicians who were receiving 
payment from drug companies to speak on behalf of the companies or promote their drugs in 
other manners.  Since Dr. Carlat’s experience in 2001, trade groups for both the pharmaceutical 
and medical device industries have written voluntary codes of conduct and ethics that limit this 
type of with physicians. 
 The second example from the 2010 NPR/ProPublica report corroborates the moral 
essence of Jones’ (1991) model with the following quote from a gastroenterologist in the report: 
It would really bother me.  Because I perceive myself as always prescribing in the best 
interest of my patient, and even unconsciously if I was unduly influenced, that would 
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really bother me.  I usually pride myself on keeping up my guard to prevent undue 
influence’ (NPR/ProPublica, 2010, p. 4).   
The physician indicates that his prescribing power could not be affected by his financial 
relationship with industry but, after being informed of the findings, began to wonder if he could 
be affected.   Finally, the NPR/ProPublica (2010) report set the tone for the study and introduces 
chapter two by illustrating the magnitude of the issue as well as the essence of the theoretical 
framework through which the study was conducted. 
 On October 19, 2010, ProPublica, Inc. and National Public Radio (NPR) released a 
comprehensive report indicating that seven pharmaceutical companies paid $257.8 million to 384 
physicians and other health providers over an 18-month period during 2009-2010.   For the 
purpose of the report, ProPublica and NPR included physicians, nurses, pharmacists, and other 
healthcare providers, who received a minimum of $100,000 in fees for consulting, speaking, and 
other compensated activities.  The seven companies of an estimated seventy-seven 
pharmaceutical companies have voluntarily disclosed this information in advance of the 2013 
implementation of the Physician Payment Sunshine Act (H.R. 3590, Section 6002, Patient 
Protection and Affordable Care Act of 2009, 2010) requiring disclosure of 2012 data regarding 
the nature and value of the financial relationships between physicians and pharmaceutical, 
medical device, and biotech firms.  The Physician Payment Sunshine Act became law on March 
23, 2010 as part of the Patient Protection and Affordable Care Act of 2009 (PPACA, Pub. L. 
111-148, 2010) and requires that companies begin collecting 2012 data by March 31, 2013 and 
make the information available to the public on their respective websites by September 30, 2013. 
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To place the magnitude of the 2010 ProPublica/NPR report into perspective; the 
Federation of State Medical Board (FSMB), comprised of seventy medical and osteopathic 
licensing boards in the U.S. and its territories, reported in its 2011 Annual Report that there were 
more than 850,000 licensed U.S. physicians in 2010 for whom they have verified licensing, 
credentialing, and disciplinary information.   The 2010 ProPublica/NPR report data represents 
nine per cent of the estimated seventy-seven pharmaceutical companies and approximately .0005 
of the approximately 850,000 licensed physician population.  The report did not include 
population numbers for nurses and pharmacists (FSMB, 2011). 
While all physicians, industry, and other healthcare professionals, to a lesser degree, are 
the unmistakable and observable players in a complicated environment; there are other 
significant players and forces involved in its evolution, context, and resolution, discussions of 
which follow.  Additionally, and for the purpose of this qualitative study, the focus is narrowed 
to academic physicians, their financial relationships with industry, the potential for 
commercially-influenced bias in teaching, research, and patient care as well as the management 
and resolution of apparent conflicts of interest (COIs) that result from their financial 
relationships with industry.   
Higher Education Environment 
 The current higher education environment encourages medical faculty-industry financial 
relationships through various aspects of one’s academic career – promotion and tenure, securing 
grants, decentralized university structures, recognition among peers, tech transfer, and 
collaborations that promote the recognition and reputation of the institution.  In the faculty’s 
efforts to contribute to institutional recognition and reputation, professional conflicts of interest 
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and commitment often emerge related to financial rewards and fees that accompany their 
involvement and obligations.  The inherent conflict may create a tension between faculty and the 
tenets of academic freedom that give them the ability to responsibly and freely express 
themselves in research and teaching based on knowledge, research, and evidence that promote 
scholarly inquiry within an academic field.  The tension may also be attributed to feeling 
ingratiated to the source of the financial relationship which may lead a faculty member to 
express views that may contradict scholarly evidence or his or her own professional viewpoint.  
This issue was a point of discussion in the 2007 symposium co-sponsored by the Association of 
American Medical Colleges and Baylor College of Medicine entitled “The Scientific Basis of 
Influence and Reciprocity.”  Substantiated by the literature, my study examined this issue using 
Jones’ (1991) ethical decision-making model.  The following background was essential in 
confirming the need for and significance of the study as well as providing a thorough 
understanding of an individual faculty member’s ethical resolution of conflicts of interest. 
Commercialization  
Commercial interests, partnerships, and influences have been present in higher education 
institutions, both private and public, for decades but gained a stronger presence beginning in the 
1970s and 1980s.  This trend was due to a spectrum of environmental factors but was primarily 
attributed to a need for external funding to replace diminishing internal and governmental 
funding cutbacks.  No longer could entities within the university structure support a fiscal 
climate that was not financially secure.  A consequential second trend was a structural shift in 
higher education to a more decentralized or responsibility-centered budgeting model forcing 
departments to be held accountable for their bottom line.  This structural shift was a change from 
departments having either partial or full institutional fiscal support to one that required 
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departmental responsibility for at least some portion of total revenues needed to conduct their 
academic work and cover operating budgets.  It increased institutional and individual pressures 
to focus on the bottom line thereby initiating new perspectives regarding professional 
responsibilities, obligations, and expectations (AAMC & Baylor, 2007; Bok, 2003; Duderstadt & 
Womack, 2003; Robbins, 2003).   
Faculty members who had commercial ties to one or more companies through research 
grants, speakers’ bureaus, stock holdings, royalties or patents, and/or other financial interests 
were also at the core of the funding dilemma.  Their financial relationships with industry had the 
potential of generating conflicts of interest and bias in teaching, research, and patient care.  For 
example, medical researchers participating as PIs in studies with commercially-funded grants 
may either consciously or subliminally feel obligated to produce or skew findings in favor of the 
company.  Another example would be physicians who participate on industry speakers’ bureau 
for which they are trained to speak on behalf of the companies and promote their products.  
Additionally, participation on speakers’ bureaus can present a difficult task of speaking on a 
topic from a scientific, evidence-based, non-promotional, educational perspective versus 
promotional on behalf of the company and its products.     
Among the three accrediting bodies in the medical education continuum, the 
Accreditation Council for Continuing Medical Education (ACCME) requires all who participate 
in a Continuing Medical Education (CME) activity, regardless of role, to disclose all financial 
relationships with commercial interests. Disclosures are then vetted through a conflict of interest 
(COI) resolution process prior to faculty participation and disclosing the information to the 
audience (ACCME® Standards for Commercial Support, Appendix A).  Additionally, the 
commercial supporter, pharmaceutical or medical device company, is required to complete a 
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letter of agreement acknowledging independent use of funds.  Industry also must comply with 
the ACCME® Standards for Commercial Support (Appendix A) as well as relevant federal 
regulations, American Medical Association (AMA) Ethical Opinions (Appendix C), and 
voluntary industry codes of ethics.  These documented safeguards are in place for the benefit of 
providing balanced and unbiased content being presented to the physician audience in a CME 
activity. The content of faculty presentations is subject to scrutiny not only by the accredited 
providers who hold the responsibility of maintaining balance and independence of content but 
also by the audiences attending the activity through the post-activity evaluation process.  Control 
of the content of a presentation lies with the faculty and the ACCME® accredited provider to 
assure balance and lack of commercial bias which some would argue threatens freedom of 
speech and expression provisions of the First Amendment for industry (Harris, 2004; Samp, 
2004). 
Commercial influence and the need for balanced, unbiased content contribute to the 
struggle between the growing commercialized environment of higher education and its core 
academic mission and values. It is this larger issue for which the case of CME through the pilot 
study was but one illustration.   The concern which is documented in the literature and discussed 
later in chapter two is that the traditional academic function of research may have also been 
compromised by commercial influence with consequences such as impairment of reputable 
research, pharmaceutical companies’ manipulation of clinical trial data, lack of disclosure by 
faculty in controversial publications, ghostwriting, etc.  The reality is that, in the area of research, 
industry funding is often the only source of support for a study, and these commercial ties may or 
may not cloud the physician’s or researcher’s judgment (Bok, 2003 & U. S. Senate Committee 
on Finance, 2010; Zuger, 2004). 
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Academic Freedom and Commercialization 
 The First Amendment to the Constitution of the United States allows for freedom of 
speech and freedom of expression not only for individuals but, in this case, the companies as 
well.  In 1976, a sequence of court rulings in favor of the companies’ free-speech rights limited 
the FDA’s authority over drug marketing by industry.  The companies took advantage of the 
opportunity to increase marketing efforts and physicians’ involvement as consultants or speakers 
who spoke on behalf of the company promoting product lines.  The original tenets of academic 
freedom, scholarly and scientific inquiry, are grounded in the First Amendment.  However, 
within the environment of commercialization and industry-academic relationships that exist, the 
principles may be at risk for both the academic physician and the companies providing funding 
for research, teaching, or clinical care. Among these could be allegations of fraud, kickback, or 
antitrust that could emerge from financial relationships between the academic physician and 
companies.  In the higher education context and in professional practice, academic freedom 
principles afford faculty certain rights in the search and advancement of knowledge.  Moral and 
ethical responsibilities to the public to seek the truth for the common good accompany those 
rights (AAUP, 1940; Bok, 2003; Harris, 2004; Samp, 2004). 
Academic freedom’s original purpose and its power provide security and protection to 
faculty views and institutional actions. John K. Ryan’s (1949) philosophy concerning academic 
freedom stated that it is a particular kind of liberty in a moral order, possessing intellect, reason, 
and will without consequential restriction and destruction as well as freedom of expression 
without fear or coercion.  His emphasis on academic freedom’s foundation and essence in the 
First Amendment – freedom of expression, information, and communication in accordance with 
truth and justice and the faculty’s moral power and obligation to teach the truth – support the 
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ethical decision-making theoretical framework within which I conducted the study.  Quoting 19th 
century English philosopher John Stuart Mill, Shuger (1990) noted that freedom of action, unlike 
freedom of thought, is subject to the consequences of the “social harm” test.  Balance of thought 
through intellectual objectivity is essential with the trend of universities becoming corporate in 
structure and function as well as a greater need for risk avoidance (Bok, 2003; Kaplan & Lee, 
1995; Ryan, 1949; Shuger, 1990).   The potential consequences of the social harm test were 
assessed through the theoretical framework’s six characteristics of moral intensity — magnitude 
of consequences, social consensus, probability of effect, temporal immediacy, proximity, and 
concentration of effect—which are defined and discussed later in this chapter.   
 Consistent with faculty responsibility expressed in the principles of academic freedom, 
personal opinion when stated as a professional, expert opinion also possesses consequences.  
This is especially true when opinions are expressed with political and moral overtones and 
involve substantial sums of money, thereby establishing potential conflicts of interest.  Placed in 
the context of medical education, a physician faculty’s personal opinion may create a conflict of 
interest (COI) influenced by commercial interests.   The COI risk may be growing within 
medical schools because schools and faculty appear to increasingly rely on external sources of 
revenues such as corporate funding.  This trend may be due to reduction of institutional support, 
decreased funding in research dollars, cuts in Medicare, and competition for patients (Bok, 2003; 
Mangan, 1999; Ryan 1949; Shuger, 1990). 
Recognition and concern of the COI risk is evidenced by the collective and collaborative 
actions of stakeholder groups to mitigate the risk.  An extensive list of stakeholder groups is 
given below and includes organizations with release dates relevant to their respective 
contributions in COI risk reduction.  Their actions have been expressed through university 
 33 
policies, ethical opinions and recommendations from professional associations, accreditation 
guidelines and standards, educational initiatives, increased congressional oversight and 
legislation, federal regulations, and voluntary industry codes of ethics all of which are discussed 
later in this chapter as important background in establishing the significance of the study.  
Among the stakeholders and stakeholder professional groups are physicians, patients, industry, 
society, the Accreditation Council for Continuing Medical Education, 2004; Accreditation 
Council for Graduate Medical Education, 2011; Advanced Medical Technology Association, 
2009; Alliance for CME & Society for Academic Continuing Medical Education, 2008; 
American Medical Association, 2011; Association of American Medical Colleges, 2007, 2008, 
& 2010; Institute of Medicine of the National Academy of Sciences, 2009; Liaison Committee 
for Medical Education, 2011; Pharmaceutical Research and Manufacturers of America, 2009; U. 
S. Department of Health and Human Services, Office of the Inspector General, 2003; U. S. Food 
and Drug Administration Office of Policy, 1997; and the U.S. Senate Committee on Finance, 
2004 & 2010.  A list of organizations and acronyms used throughout the manuscript is provided 
in List of Organizational Acronyms (p. x). 
To begin the stakeholder discussion, it should be noted that university-industry 
relationships could intensify the First Amendment issue thereby reinforcing the need for 
disclosure from faculty.  Disclosure alone does not guarantee balance, objectivity, and unbiased 
research or professional speaking presentations.  Under the free speech provision of the First 
Amendment, the Washington Legal Foundation defended industry’s financial support of 
continuing medical education (CME) programs as well as industry’s right to be heard through 
truthful speech about products, research, and off-label use of FDA-approved products being 
presented (Harris, 2004; Samp, 2004).  On the opposing side, Croasdale (2004) and Relman 
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(2003) criticized the notion of ACCME-accredited providers’ accessibility to drug company 
speakers’ bureaus for recommendations of speakers for CME activities whose views were 
presumed to be tainted by the company’s perspective.  Even though speakers for CME activities 
are required to disclose commercial interests and relationships, the influence may not be 
apparent.  The concern was whether the speakers’ presentations were product promotional or 
non-promotional without commercial bias and offered a balance of therapeutic options (FDA, 
1997; ACCME, 2004).   
As illustrated above, academic freedom’s interaction with commercialization and the 
consequential issues related to COIs, mitigation efforts by stakeholders, and the ensuing need for 
external sources of funding creates an unpredictable environment yet one that is supportive of 
university-industry relationships.  One of the characteristics of university-industry relationships 
and universities’ becoming more commercialized or corporate in their organizational mission is 
adopting a decentralized model as described by Whalen (1991).  Whalen’s model places the 
fiscal responsibility on institutional units, departments or divisions within a college. 
Decentralized Institutional Environment 
 “Every tub on its own bottom”…the expression that originated at Harvard University 
epitomizes the essence of a decentralized institution.  As defined in chapter one, the ‘tub’ is an 
academic unit of a college or university and the ‘bottom’ refers to each unit being responsible for 
its own bottom line and all costs it produces and all revenue it generates.  A decentralized 
Responsibility Center Model (RCM) is defined by Whalen (1991) as an organizational entity 
directly involved in accomplishing the mission of the university or in providing services or 
support that enables mission accomplishment.  In a decentralized RCM, institutions give their 
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departments greater budget authority and responsibility over themselves.  The cost-recovery 
environment encourages innovation to increase revenue flow with an incentive to cut costs since 
departments keep all revenues that are generated.  The departments are also responsible for all 
expenditures.  Budgets are revenue-based so deficits must be eliminated.  Dubeck (1997) 
describes three categories fundamental to a decentralized RCM – (1) departments with core 
missions of research, teaching, and public service, e.g. departments, colleges or schools within a 
university, (2) units that provide services to the primary mission departments, e.g. physical plant, 
library, and (3) executive management, e.g. the president’s office (Dubeck, 1997; Whalen, 
1991). 
Shifting the bottom-line responsibility to the department may cause two institutional-
level conflicts.  The first conflict could place a profit incentive against academic needs (Dubeck, 
1997).  Relevant to the profit-academic conflict, the second conflict could suggest a requirement 
to seek external funding to recover costs.  This obligation can present a challenge to departments 
that must seek funding while complying with federal and state regulations and adhering to 
professional standards and guidelines.  As examined in the pilot study, both conflicts do occur in 
the continuing medical education (CME) arena in an effort to recover or offset costs for 
professional medical conferences, symposia, seminars, and other types of educational activities.  
The CME unit has historically been considered a profit center, or at minimum a cost-recovery 
unit, within a university setting and generally in a school of medicine.  CME is significant in 
academic medicine through its role in providing professional educational opportunities for 
physicians in practice that contribute to their maintenance of licensure and certification.  The 
educational opportunities offer current and relevant content delivered by experts in the field of 
medicine and areas of specialty and sub-specialty. 
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It is important to note, however, that the field of academic medicine as a segment of the 
commercialized higher education environment is being increasingly scrutinized due, in most 
part, to the financial relationships that had been traditionally embraced by both the institution 
and individual faculty members.  The second conflict, seeking external funding, promotes 
university-industry collaborative relationships but can also result in individual conflicts of 
interest for which a robust resolution process should exist (AAMC, 2008, 2010; ACCME, 2004; 
U.S. FDA Office of Policy, 1997; & U.S. DHHS OIG, 2003). 
University-industry Relationships 
Many university-industry relationships have been formed for the benefit of the public 
good and serve a valuable purpose of which technology transfer is only one example.  
University-industry relationships began in the post-World War II era; but under the Bayh-Dole 
Act of 1980, the technology transfer process flourished.  The Bayh-Dole Act offered a means of 
moving university research into the marketplace by encouraging university-corporate 
partnerships that offered tax breaks to businesses.  It allows academic institutions to become 
conduits for cutting-edge research, to patent their research discoveries that were funded by 
federal money, and to license them to corporations for product development and distribution in 
the marketplace by replacing industrial research labs.  This academic capitalism can also create 
conflicts among colleagues about ownership of patents and publishing as well as industry’s 
potential influence of both (Slaughter and Rhoades, 2004).  In their analysis of thirty-eight 
faculty interviews, Slaughter and Rhoades “found them [faculty] uncertain about the boundaries 
between public and private spheres, enticed by market opportunities, and plagued by conflict of 
interest issues” (p.31).  Citing the recent BP oil spill in the Gulf of Mexico, Sheldon Krimsky 
(2010) raised concerns about unexpected consequences that result from federal policies, such as 
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Bayh-Dole, which were intended to promote university-industry research relationships.  Krimsky 
(in Schmidt, 2010, para. 3) referred to one “unanticipated side effect as reducing public 
confidence in the objectivity and trustworthiness of the science” (Bok, 2003; Brainard, 2007; 
Dill, 1995; Lieberwitz, 2005; Slaughter & Rhoades, 2004). 
The commercialized environment in which higher education is functioning with 
increasing university-industry relationships may undermine the traditional, core academic 
mission and values of the academy by making scientific knowledge and expert opinions products 
of higher education.  The implications for institutional policy and governance evolve from the 
perceived tendency of industry to determine research focus that is representative in the 
development of a knowledge economy.  It can also be argued that such effects may force faculty 
to forfeit core scholarly ideology and essential autonomy and that conflicts of interest, 
commitment, and internal equity may occur with industry collaboration (Bok, 2003; Campbell, 
1997; Stilwell, 2003; Washburn, 2005b).  Cary Nelson, president of the American Association of 
University Professors (AAUP), captures the essence of the concern: 
Increased reliance on corporate funding—combined with the sheer power of corporations 
whose financial resources in some cases dwarf those of entire nations—requires us to 
rethink the advice we give and the policies we recommend.  More detailed guidelines 
from the AAUP should help professors and their institutions negotiate better contracts 
with corporations and with the government, thereby securing faculty interests, protecting 
universities’ missions, and serving the public good (in Schmidt, 2010, para 4) 
The environment also has implications for broad institutional policies and processes of 
governance as well as implications for detailed economic incentives. The economic incentives 
 38 
may generate competition for the same funds between universities or between departments or 
faculty within the same institution (Bok, 2003; Campbell, 1997; & Stilwell, 2003). 
Advocates of university-industry research collaborations acknowledge the concerns and 
deficiencies in the relationships but also recognize the economic and societal benefits of 
technological innovation and that universities and industry can work together in a cooperative 
and productive manner (Dill, 1995; Washburn, 2005a).  However, if this is not possible, 
Washburn (2005a) proposed a series of four federal reforms for the benefit of universities, 
industry, and society:  (1) independent, third-party licensing; (2) amended Bayh-Dole Act; (3) 
new conflict-of-interest regulations; and (4) more federal oversight of clinical research.   
University-industry relationships have created a new set of norms including three types of 
potential conflicts. These conflicts may take the form of (1) conflict of interest – use of funds, 
inappropriate influence, and commingling of federal and private funds, (2) conflict of 
commitment or mission – misallocation of time and energy in teaching, research and public 
service, and (3) conflict of internal equity – departments that are favored based on ability to 
secure external funding and partnerships (Campbell, 1997).   
Faculty and Academic Decisions 
Review of the literature thus far has presented an assessment of the current higher 
education and academic medicine environments on an institutional level.  It is appropriate and 
informative at this point to engage in an historical reflection of faculty and how institutional 
mission, organizational culture and climate, ethics, and academic freedom have influenced 
academic decision-making over time.  Secondly, an historical perspective may provide effective 
tools for navigating the current environment and ethically resolving conflicts of interest that may 
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present themselves in the academic physician’s professional decisions regarding research, 
teaching, and patient care.  Lastly, reviewing a scholarly perspective of conflicts of interest and 
ethics contribute to a subsequent discussion of external forces, institutional pressures, and the 
theoretical framework of the study. 
Institutional Mission and Organizational Culture 
 Mission and society. 
Throughout history, society has been generally satisfied with the missions of higher 
education – teaching, research, and public service with teaching the undergraduate student 
population as the principal goal.  Examples of society’s satisfaction include robust medical 
research, accessibility of community colleges, and prestige that accompanies attending land-
grant and elite private universities.  However, public opinion of higher education appears to have 
been waning based on a conflict between college being an absolute necessity and the rapidly 
increasing tuition costs in addition to the diminishing public appreciation of higher education’s 
philanthropic mission.  With declining public opinion, smaller budgets, fewer resources, and 
other influencing external factors; it is apparent that universities are being subjected to 
governmental, societal, political, and economic pressures (Callan & Immerwahr, 2008; Tierney, 
1988; Weisbrod, Ballou, & Asch, 2008). 
In an effort to be more responsive to these pressures, the trend for higher education 
accountability has forced universities to revisit their educational mission and policies that the 
commercialization of higher education appears to be influencing. The tension between a 
university’s culture, values, and mission with the marketplace does not necessarily mean that 
either should be sacrificed.  Universities can balance a mission-centered philosophy while being 
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market-wise in their engagement with the external community.  This concern was emphasized by 
several of the interviewees in the focus groups conducted by Callan and Immerwahr (2008) who 
referred to higher education as a business with abundant revenue sources.  The concern further 
confirmed the need for increased institutional transparency, efficiency, productivity, and 
accountability to society (Alexander, 2000; Bok, 2003; Callan & Immerwahr, 2008; Fitzpatrick, 
2003; Zemsky, Wegner, & Massy, 2005).  
“The university is expected to provide guidance for society” (Perkins, 1973a, p. 11) yet 
this expectation may cause difficulties for faculty and departments such as (1) acting upon an 
institutional commitment for which there has been no faculty involvement and (2) maintaining 
institutional autonomy including academic freedom for the faculty without the impact of societal 
demands.  The institutional relationship with and commitment to society falls under public 
service, the third goal of a university mission.  This goal came to light through the “Wisconsin 
Idea” in 1904 that fostered the university’s influence on families and society through the benefits 
of the teaching and research missions. The other goals, teaching and research, have also 
encountered difficulties and challenges such as obtaining sufficient tuition and donor funding as 
well as competing within a larger research community for funding and patent opportunities with 
private companies from advanced research since basic research cannot be patented. This 
challenge can create a conflict between mission and funding (Weisbrod, Ballou, & Asch, 2008).  
The agricultural programs established with the land-grant universities is a quintessential example 
of a successful mission in which all three goals of teaching, research, and public service to 
society have been achieved and continue to prosper in a cohesive manner.  Relevant to the 
ethical decision-making model used for the study, Perkins’ (1973) assertion regarding society’s 
expectation of universities conveys an implicit trust that society has in higher education. 
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These observations and viewpoints concern higher education in general.  However, the 
perspectives and challenges they present are applicable to academic medicine as evidenced in the 
discussions concerning university-industry relationships; the increasing regulatory, accreditation, 
and professional oversight of the environment; and the inherent tension that the environment 
presents to faculty and institutional missions.  In the context of performance-based 
accountability, universities and society should never be too comfortable with each other.  A 
certain amount of tension is healthy to the academic intellect and gives faculty and institutions 
opportunities to give knowledge back to society for the public good (Alexander, 2000).    It may, 
however, be a perceived contradiction of institutional mission when academic physicians 
personally benefit from financial relationships with industry.  This perception has influenced the 
need for and significance of this study.  The study may reveal an understanding of how faculty 
should uphold institutional missions while in financial relationships with industry. 
Institutional missions. 
From an organizational perspective, universities struggle because they strive to conduct 
conflicting missions within an organizational structure originally designed to support the transfer 
of knowledge.  However, the later integration of research, public service, and a democratic 
community into the institutional mission created the above-mentioned conflict between mission 
and organizational structure and its functions.  In medieval times, the original mission of 
teaching provided the collegial and scholarly connection between professor and student.  By the 
nineteenth century, however, the research mission’s primary purpose was to influence teaching, 
turning the attention of scholarship from the transfer of knowledge (teaching) to the search for 
new knowledge.  It was large-scale research, not individual scholarship, with its external funding 
and partnerships that created the conflict with teaching.   Opposing views existed regarding the 
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economic argument for transferring large-scale research outside of the university – (1) 
transferring to an external organization may eliminate the conflict of institutional missions, but 
(2) retaining within the institution may provide financial support for salaries and courses.  
Teaching and research, however, ultimately have become two separate institutional missions that 
often oppose each other in support of institutional needs (Perkins, 1973).  
In research, ideas become more important than people…and external funding more 
important than internal budget allocations.  The judgment of peers in one’s field of 
specialization, rather than the progress of the student, becomes the critical measure of 
performance [of the faculty] (Perkins, 1973a, p. 7). 
This quote expresses the essence of the current commercialized environment, university-industry 
relationships, and the importance that institutions have placed on those partnerships. The advent 
of large-scale research supported by external funds has affected the peer relationships among 
faculty and created competition among departments, has changed internal administrative and 
management organizational structures, and has encouraged entrepreneurial approaches and 
establishing relationships with members of the external funding community such as government, 
industry, and foundations.  Organizational structures and institutional missions can be complex; 
however, they have provided opportunities for scholars and cultures to interact throughout 
history for the common good (Duryea, 1973; Perkins, 1973).  
Organizational culture and climate. 
As with institutional missions, organizational culture and climate can influence faculty 
and academic decisions.  To distinguish between the two concepts, Peterson and Spencer (1990, 
pp. 6-7) state that culture “focuses on the deeply embedded patterns of ideologies that members 
 43 
have about their organization or its work,” and climate refers to “the current common patterns of 
important dimensions of organizational life or its members’ perceptions of and attitudes toward 
those dimensions.”  Culture emphasizes the uniqueness of the institution, endures time, and is 
not easily or readily changed; whereas, climate focuses more on current attitude and is more 
easily and quickly changed by its members.  Austin (1990) expands the definition of culture into 
four primary cultures that effect faculty values and behavior: 
(1) Academic Profession (core values) – its mission is to pursue, discover, produce, and 
disseminate knowledge, truth, and understanding; autonomy and academic freedom in 
research and teaching are valued in protecting creative and controversial ideas; 
commitment to intellectual integrity; and collegiality is the ideal framework for 
faculty interactions as well as institutional decision-making (p. 62). 
(2) Discipline – offers primary identification and socialization of the faculty; frames the 
beliefs and behaviors of the faculty (pp. 63-64). 
(3) Academy as an Organization – espouses two core values:  (a) universities and 
colleges are involved in “good work” – knowledge for society and development of 
students and (b) faculty collegiality coupled with autonomy within the institution; is 
characterized by a compliance system, bureaucratic system resulting in accountability 
demands and performance outcomes of faculty; and threatens core values through 
external pressures (Austin & Gamson, 1983, in Austin, p. 65). 
(4) Institutional Types – typified by strong missions to produce knowledge and highly 
specialized research; is a strong force affecting faculty values and activities (pp. 66-
67). 
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As discussed, missions, culture, and climate can affect faculty-student relationships; 
faculty institutional responsibilities of teaching and research; faculty participation in institutional 
decisions; and core values, customs, and traditions.  Additionally, they may influence the 
independence of thought, freedom of inquiry and expression of faculty and community of 
scholars as well as the effective function of higher education that are protected by academic 
freedom (Austin, 1990; Millett, 1962; Perkins, 1973; Peterson & Spencer, 1990; & Sanders, 
1973). 
Academic freedom. 
In 1940, the American Association of University Professors (AAUP) released its 
Statement of Principles on Academic Freedom and Tenure (Appendix D).  Academic freedom, 
with some limitations, applies to teaching and research but may also refer to the autonomy of the 
institution from governmental influence on policy and institutional self-governance.  Faculty 
view academic freedom more as a professional norm, without fear of reprisal, grounded in the 
First Amendment of the U. S. Constitution.  The statement describes the values of academic 
freedom that are the underpinnings to the protection of the rights of the teacher’s responsibility 
in the transference of knowledge, the researcher’s responsibility in the advancement of truth, the 
student’s freedom to learn, and institutional autonomy (AAUP, 1940; Glenny & Dalglish, 1973; 
Lieberwitz, 2005; Livingstone, 1974; Mangan, 1999; Rochford, 2003; & Rosovsky, 1990).  
Secondly, 
The origins of the AAUP demonstrate the potential power of private corporate donors to 
pressure universities to serve their economic interests, as a scale of corporate donations 
grew from thousands to millions of dollars during the industrialization period of the early 
twentieth century (Hofstadter & Metzger, in Lieberwitz, 2005, p. 117-118). 
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In a commercialized higher education environment, protecting the independence of 
teaching and academic research from potential conflicting external influences is at the core of 
academic freedom.  Due to an increased reliance on corporate funding, the spirit of academic 
freedom in academic medicine, particularly in research, may be affected.   In response to the 
increased corporate involvement and influence in research, the AAUP released the following in 
1999: 
The freedom to pursue research and the correlative right to transmit the fruits of inquiry 
to the wider community—without limitations from corporate or political interests and 
without prior restraint or fear of subsequent punishment—are essential in the 
advancement of knowledge. (Mangan, 1999, p. A14). 
  Academic freedom is intended to protect faculty autonomy, ensure integrity, serve the 
public interest, and contribute to the public good without serving other interests and without 
recourse.  To reiterate Ryan’s 1949 view of academic freedom, he stated that academic freedom 
is a particular kind of liberty in a moral order.  It possesses intellect, reason, and will without 
consequential restriction and destruction as well as freedom of expression without fear or 
coercion.  It is the moral order that connected faculty decisions and perceived conflicts of interest 
within the protection of academic freedom to Jones’ (1991) theoretical framework (Lieberwitz, 
2005; Livingstone, 1974; Mangan, 1999; Rochford, 2003; Rosovsky, 1990; & Shuger, 1990). 
Conflicts of Interest and Ethics  
 To be discussed in the section on external environmental forces, Congress, professional 
associations and accreditation bodies have put forth much effort to establish mechanisms to 
manage conflicts of interest in medicine through existing and pending federal legislation, 
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voluntary industry codes of ethics and professionalism, and recommendations, opinions, and 
guidelines.  The Pew Prescription Project (2007 & 2008) offered academic medical centers 
guidance and policy considerations in addressing conflicts of interest (COIs) in institutions in the 
areas of gifts, drug samples, formularies, continuing medical education, speakers bureaus, 
ghostwriting, consulting, and research funding.  They presented model institutional policies in 
addition to potential external threats, internal barriers, and strategies to overcome them, much of 
which has been previously discussed in the areas of decentralized structures, effects of 
organizational culture, dependencies on external funding, faculty resistance to change, and lack 
of disclosure and COI knowledge. 
 In a broader sense, the AAUP (1990) issued its Statement on Conflicts of Interest and 
Research (Appendix E) due in part to increasing university-industry relationships that have 
resulted from reduced university budgets and a need for external funding.  A key goal of the 
statement was to create awareness of the potential for faculty who are involved in collaborative 
industry research to consciously or unconsciously affect the design and outcome of research.  In 
an effort to prevent such action, the AAUP offered the following considerations for use in the 
development or revision of institutional conflict-of-interest guidelines: 
(1) Any requirements for disclosure of potential conflicts of interest should be carefully 
focused on legitimate areas of concern and not improperly interfere with the privacy 
rights of faculty members and their families (AAUP, 1990, para. 4); 
(2) Faculties should ensure that any cooperative venture between members of the faculty 
and outside agencies, whether public or private, respects the primacy of the 
university’s principal mission, with regard to the choice of subjects of research and 
the reaching and publication of results (AAUP, 1990, para. 5); 
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(3) Pursuit of such joint ventures does not become an end in itself and so introduce 
distortions into traditional university understandings and arrangements, and external 
interests should not be allowed to shift the balance of academic priorities in a 
university without thorough debate about the consequences and without the 
considered judgment of appropriate faculty bodies…and a commitment to fairness 
(AAUP, 1990, para. 6); and 
(4) Private or government funding must be kept in proper proportion and be consistent 
with criteria established by the faculty (AAUP, 1990, para. 7) 
The AAUP offered these safeguards for faculty. The role of the faculty, however, in 
promoting the institutional mission and protecting the principles of academic freedom may be 
affected by conflicts that are created by decisions they make when involved in institutional-
industry or faculty-industry financial relationships (Lieberwitz, 2005).  Dill (1982) referred to 
these faculty roles as value conflicts that are inherent in the relationships with industry which 
increase the constituencies that they serve and their influences.  These value conflicts may 
further result in a decrease of faculty autonomy and ethical judgment.   
External Forces and Institutional Pressures 
An historical understanding of faculty and institutional mission, culture, and academic 
freedom contributes to the evolution of the United States higher education system.  The existing 
higher education environment, however, typifies commercialization, decentralized structures, 
and university-industry relationships that inherently foster individual and institutional conflicts 
of interest.  Specific environmental characteristics that informed the focus of the study included 
an institutional need for external revenue sources, individual decision-making influenced by 
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commercial funding sources, and individual and institutional conflicts of interests.  The 1990 
AAUP Statement on Conflicts of Interest and Research (Appendix E) emphasizes the need for 
fairness and holding true to the institution’s academic mission when engaged in research or other 
interaction with external organizations.   Therefore, the study warranted a review of some of the 
external forces and institutional pressures that can affect academic medicine and physicians. 
Beginning in 1997 with the U.S. FDA Office of Policy’s release of its Guidance for 
Industry: Industry-supported Scientific and Educational Activities, physician-industry financial 
relationships have been increasingly monitored by three primary external forces:  (1) federal 
regulations and congressional oversight, (2) voluntary industry codes of ethics and conduct, and 
(3) accreditation guidelines, professional recommendations and ethical opinions, the last of 
which may place institutional peer pressure on academic medical centers and their medical 
faculty.  Regardless of the external or internal nature of the oversight, at the heart of financial 
relationships is industry’s potential influence on physicians’ decision-making in teaching, 
research, and patient care. 
Among the most common reasons physicians may receive fees from industry include 
their roles as consultants, speakers trained to speak on behalf of a company, recipients of funding 
for research or clinical trials, members on companies’ scientific advisory boards, paid 
researchers in industry-sponsored studies, stockholders, royalties from patents sold or assigned to 
companies, or being co-authors on peer-reviewed journal articles, a role recently investigated due 
to evidence of ghostwriting.  Ghostwriting is a practice by which physicians, who are well-
known as key opinion leaders (KOLs) in their specialties, lend their names as sole or lead 
authors to articles that were written by company employees.  The U. S. Senate Committee on 
Finance brought this unethical practice to the attention of the National Institutes of Health (NIH) 
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and urged the NIH to issue conflict-of-interest guidelines for researchers (ACCME, 2004; 
NPR/ProPublica, 2010; Pew Prescription Project, 2007 & 2008; and U. S. Senate Committee on 
Finance, 2010).   
The following overview of external forces and institutional pressures offers insight into 
the perspectives through which physicians’ relationships with industry are monitored and 
regulated.  It also provides background for the study from the viewpoints of congressional 
legislation and federal regulatory oversight, industry voluntary codes, accreditation guidelines 
and standards, ethical opinions, and professional association recommendations. 
Federal Regulatory Oversight and Congressional Legislation 
 United States Senate Committee on Finance. 
Since 2004, the United States Senate Committee on Finance has been investigating 
financial relationships between physicians and industry and releasing its findings to the public.  
This congressional oversight contributed to the writing and passing of the Physician Payment 
Sunshine Act (H.R. 3590, Section 6002) as a provision under the Patient Protection and 
Affordable Care Act (PPACA, Pub. L. 111-148, 2010) that went into effect March 23, 2010.  
The essence of the Sunshine Act is transparency, requiring industry to make all financial 
relationships with individuals and organizations public including the amount and nature of the 
compensation accessible on companies’ websites.  Prior to the need for legislating transparency, 
governmental agencies were addressing the financial relationship issue with the 1997 FDA 
Guidance for Industry that focused on industry-supported scientific and education activities.  In a 
subsequent action in 2003, the Office of Inspector General of the Department of Health and 
Human Services released a compliance program guidance to reinforce the need for transparency 
 50 
and management of physician-industry financial relationships.  As described below, the OIG 
guidance is broader in scope than the FDA guidance but embraces its intent. 
1997 FDA Guidance for Industry. 
In November 1997, the Office of Policy of the U.S. Department of Health and Human 
Services’ Food and Drug Administration (FDA) issued its Guidance for Industry – “Industry-
Supported Scientific and Educational Activities.”  The 1997 FDA Guidance evolved from 
concern that industry was influencing content of medical education that should be independent 
and non-promotional, either directly through selection of speakers and/or topics or indirectly 
through industry’s relationship with the educational provider.  As a result, the FDA Guidance 
issued twelve factors to be used in evaluating programs and determining the independent nature 
of the content of medical education.  Of the twelve factors described below, disclosure (#2) is the 
factor that requires identification and resolution of potential conflicts of interest for faculty: 
1. Control of Content and Selection of Presenters and Moderators: the educational provider 
must maintain and document full control while avoiding industry-favored bias. 
2. Disclosure:  when applicable, this factor requires three forms of disclosure to the 
audience prior to delivery of the content of medical education – (a) company funding of 
the program in the form of educational grants to the provider; (b) the nature of financial 
relationships with industry or that none exists by anyone who is in a position to influence 
content, and (c) discussion of off-label or unapproved uses of products. 
3. The Focus of the Program:  the educational content must be free from commercial 
influence or bias, the title must accurately reflect the scope of the content, and all 
reasonable and relevant therapeutic options and treatment modalities must be discussed. 
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4. Relationship between Provider and Supporting Company:  are there legal, business, or 
other relationships between companies and providers that would commercially influence 
content, e.g. company ownership of a provider? 
5. Provider Involvement in Sales or Marketing:  this factor considers if the provider 
assumes a second relationship with a company by assisting in the promotion of its 
products while, in its primary role, the educational provider is developing educational 
programs free of commercial influence, thereby creating a conflict of purpose. 
6. Provider’s Demonstrated Failure to Meet Standards:  educational programs must meet 
standards of independence, balance, objectivity, or scientific rigor. 
7. Multiple Presentations:  this factor is encouraged by the FDA when based on an urgent 
topic and/or serving public health interests. 
8. Audience Selection:  companies may not generate lists or invitations, the intent of which 
may reflect sales and marketing goals, rewarding high prescribers of the companies’ 
products or influencing key opinion leaders (KOLs). 
9. Opportunity for Discussion:  meaningful discussion must be provided during live 
programs. 
10. Dissemination:  this factor considers intentional, additional distribution of product 
information after the educational program. 
11. Ancillary Promotional Activities:  sales presentations, exhibits, and product promotion 
may not take place in the meeting space. 
12. Complaints:  this mechanism allows for reporting companies’ attempts to influence 
content (U. S. DHHS FDA Office of Policy, 1997, pp 64096-64099). 
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The FDA Guidance further recommended documenting compliance by both companies and 
educational providers with the twelve factors and other parties, as appropriate, in a written, co-
signed letter of agreement, which is a current standard of practice. 
2003 DHHS OIG Compliance Program Guidance. 
In April 2003, the Office of Inspector General of the U. S. Department of Health and 
Human Services (OIG) issued the OIG Compliance Program Guidance for Pharmaceutical 
Manufacturers.  The intent of the compliance guidance embraced reducing the cost of health 
care, improving quality of care, and preventing fraud and abuse in the federal Medicare and 
Medicaid healthcare programs.  The OIG guidance consists of seven fundamental elements for 
implementation by the pharmaceutical companies for an effective compliance program: 
1. Implementing written policies and procedures regarding standards of conduct, 
commitment to compliance, addressing issues of fraud and abuse, and sales and 
marketing practices; 
2. Designating a compliance officer and compliance committee to develop, operate, and 
monitor the compliance program noted above; 
3. Conducting effective training and education for industry employees; 
4. Developing effective lines of communication between the compliance 
officer/committee and employees including a process for complaints or questions and 
procedures for the protection and anonymity of complainants and whistleblowers; 
5. Conducting internal monitoring and auditing of compliance programs for risk 
mitigation; 
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6. Enforcing policies, standards, and procedures communicated to employees through 
well-publicized guidelines for those employees or entities, due to violations of the 
OIG Compliance Program Guidance, who are excluded from participating in federal 
healthcare programs; and  
7. Responding promptly to detected problems or offenses of non-compliance or 
misconduct per the OIG Compliance Program Guidance and undertaking preventive 
corrective action (U.S. DHHS OIG, 2003, p. 23731-23733). 
The OIG intended for compliance guidelines to be benchmarks for companies in 
establishing a compliance program or evaluating an existing federal compliance program.  They 
developed the guidelines with representation and input from four major industry stakeholder 
groups – physicians, pharmaceutical industry, health plans, and pharmacy benefit managers. The 
OIG recommended that companies write a code of conduct to reiterate the ethical and legal 
standards that function as the underpinnings of the companies’ commitment to and 
implementation of a compliance program that enforces compliance with federal regulations 
expressed in the OIG Compliance Program Guidance.  
Additionally, the OIG guidance identified specific risks of fraud and abuse in the federal 
Medicare and Medicaid healthcare programs.  Examples of such risk included the integrity of 
data in determining government reimbursement rates, kickbacks, and other illegal payments.  It 
also identified three areas of potential risks and abuse that should be monitored.  These included 
(1) the companies’ relationships with purchasers and their agents, (2) the companies’ 
relationships with physicians and other persons and entities in a position to make or influence 
referrals, and (3) the companies’ relationships with their sales forces.  The OIG addressed the 
last area of companies’ sales and marketing efforts by encouraging companies to commit to an 
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OIG-mandated compliance program that includes (a) training and monitoring its sales force for 
compliance with the OIG Compliance Program Guidance, (b) understanding relevant industry 
standards, and (c) disciplinary policies as a pre-emptive measure to avoid inappropriate, illegal, 
or unethical actions.  It is the second relationship, companies’ relationships with physicians and 
other persons and entities in a position to make or influence patient referrals and prescribing 
power, which contributed to an understanding of the environment of the study and also 
reinforced the FDA guidance previously discussed.  As described in a prior section of this 
chapter, academic physicians may enter into financial relationships with industry for which the 
compensation can be very generous.  Examples of physician-industry relationships are 
consultants, members of speakers’ bureaus, or members of scientific advisory panels.  The 
physicians who are in these financial relationships may feel an obligation to consult in the 
company’s favor, to speak more on behalf of the company than solely from scientific evidence, 
or to advise in a manner that promotes the company or its products, regardless of the ethical or 
moral implications.  Therefore, the physician-industry financial relationships may affect the 
physician’s ethical decision-making process that was focus of the study. 
As with the 1997 FDA guidance, the 2003 DHHS OIG guidance gave the following 
factors against which the physician-industry financial relationship should be assessed in order to 
fit within an existing safe harbor for appropriate personal services or management contracts: 
 Nature of the relationship between the company and physician including any direct or 
indirect influence the company may have on the physician to generate business; 
 Manner in which the payment is determined, whether based on the volume of value of 
the business, referrals, or services generated; 
 Is the value of the payment in excess of fair market value? 
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 Potential federal program impact of the payment, affecting federal healthcare 
programs and utilization; and 
 Potential conflicts of interest (COIs) that may diminish objectivity and professional 
judgment or affect patient safety or quality of care and that may encourage 
propagation of incomplete, inaccurate, or misleading information (U. S. DHHS OIG, 
2003, p. 23737). 
The final factor, potential conflicts of interest (COIs) and the effect on objectivity and 
professional judgment, reflects the essence of the study and theoretical framework by raising 
ethical and moral concerns.  As discussed in this chapter, these concerns were and continue to be 
addressed by several stakeholder groups represented by federal legislative bodies and regulatory 
agencies, accreditation bodies, professional associations, industry, and physicians.  The OIG 
guidance states that potential COIs may present themselves in various physician-industry 
financial relationships including: 
 switching arrangements which involve payments for changing a patient’s prescription 
to the requesting company’s product from a competing product and may also have 
implications under the federal anti-kickback statute; 
 consultancies and advisory boards which may also emerge in the physicians’ roles in 
speaking on behalf of the company, certain research, preceptor/shadowing services, 
or ghostwriting articles which is also suspect under the anti-kickback statute; 
 detailing, a manner by which company sales representatives educate prescribing 
physicians about their products, is discouraged due to anti-kickback and fraud-and-
abuse implications. 
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 business courtesies and other gratuities that appear under the broad categories of 
entertainment and gifts that are bestowed upon physicians who are in a position to 
make or influence referrals. 
 educational and research funding should be determined as being used for bona fide 
educational or research purposes and not conditioned on selection of content or 
faculty (U.S. DHHS OIG, 2003, p. 23738).   
With reference to consultant and advisory board relationships and their related roles, the 
OIG suggested that full disclosure by physicians of these relationships may only mitigate, not 
fully eliminate, the risk of abuse.  The OIG also recommended documenting the relationship in a 
written agreement prior to payment that verifies a legitimate need for professional services, that 
these services actually occurred, and that payment for the services was fair market value. 
As explained in the following section and in response to the OIG recommendation, the 
Pharmaceutical Research and Manufacturers of America (PhRMA) and Advanced Medical 
Technology Association (AdvaMed) voluntary industry codes of ethics and conduct as well as 
institutional policies on physicians’ interaction with industry; recommendations, guidelines and 
opinions issued by leading medical associations; and standards set forth by relevant accreditation 
bodies reinforce the FDA program guidance and the OIG compliance guidance. 
Industry Voluntary Codes 
In support of the 2003 OIG Compliance Guidance, there are two predominant industry 
codes of ethical conduct that, albeit voluntary in nature, encourage compliance by the companies 
and their employees.  The two codes contain similar principles although they are specific to two 
different segments of industry:  (1) research-based pharmaceutical and biotechnology companies 
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and (2) medical equipment and device companies.  The website for each code maintains a list of 
the companies who have voluntarily agreed that all of their employees will comply with the 
relevant code. 
The code for the research-based pharmaceutical and biotechnology companies is the 
“Code on Interactions with Healthcare Professionals” and generally referred to as the PhRMA 
Code.  The Pharmaceutical Research and Manufacturers of America (PhRMA), an organization 
that represents the research-based pharmaceutical and biotechnology companies, originally 
released its code in 2002.  The PhRMA Code was adopted on April 18, 2002 with an effective 
date of July 1, 2002 and was revised in 2008 with an effective date of January 1, 2009. 
The second code, “Code of Ethics on Interactions with Health Care Professionals,” is 
applicable to the medical equipment and device companies and generally referred to as the 
AdvaMed Code.  The Advanced Medical Technology Association originally released the 
AdvaMed Code in 2005 and later revised it with an effective date of July 1, 2009.  Both codes 
are comparable in purpose which is to support industry engagement in ethical relationships with 
physicians and other healthcare providers and share similarities among the following principles: 
 Encouragement of member companies to adopt and comply with their respective codes; 
 Effective compliance program that includes annual certification based on specific 
criteria, including evidence of a compliance officer, policies and procedures; 
 Appropriate financial support of bona fide independent CME or third-party conferences, 
given as educational grants with conditions of modest meals and refreshments, speakers’ 
honoraria and travel expenses, independent control of content, faculty, and educational 
materials. Honoraria should be based on fair market value.  The financial support 
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principle is consistent with the ACCME® Standards for Commercial Support (ACCME, 
2004). 
 Modest meals may be provided by representatives for informational (PhRMA Code) or 
business-related (AdvaMed Code) presentations. 
 Consultancies must be documented by a written agreement indicating the nature of the 
services to be provided; compensation should be fair market value.  This principle is 
consistent with the OIG Compliance Program Guidance (2003). 
 The provision of entertainment and recreational items to physicians and other health care 
providers are no longer allowed. 
 Gifts to physicians and other health care providers are no longer permitted except under 
the following conditions:  of patient benefit or healthcare providers’ educational benefit, 
including medical textbooks or anatomical model.  $100 maximum value applies under 
certain circumstances (PhRMA & AdvaMed, 2009). 
The differences between the PhRMA code and AdvaMed code generally exist in the 
specific details related to a principle, or the code may contain a principle that is only applicable 
to their segment of the industry.  The AdvaMed Code is broader in scope due to the equipment 
and device nature of the companies’ product lines.  For example, the AdvaMed code contains a 
section that details the terms and conditions for equipment training and education of healthcare 
providers and one that discusses evaluation and demonstration of equipment. Neither is pertinent 
to the pharmaceutical industry.  The PhRMA Code also does not address issues related to 
research grants or the engagement in fraudulent practices that the AdvaMed Code addresses. 
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Recommendations, Opinions, and Accreditation Guidelines 
 In addition to the regulatory oversight and the two voluntary industry codes, accreditation 
bodies, professional medical associations, and institutes or foundations with patient-centered care 
and public health foci in their missions have, to date, approached the COI environment in a 
policy-and-procedural manner.  These organizations have offered and encouraged, for adoption 
and implementation, recommendations, opinions, standards, and guidelines regarding healthcare 
professionals’ interactions with industry representatives and the potential COIs that financial 
relationships may create and ultimately impact patient care.  Compliance with accreditation 
standards and guidelines is required of the accredited school or program. The intent of these 
organizations is to prevent inappropriate relationships and undue commercial influence and bias 
in research, patient care, and medical education as the following section explains.  
Accreditation for the medical education continuum. 
There are three relevant accreditation bodies that have established criteria, standards, and 
policies for the purpose of providing continuity among all medical undergraduate, graduate, and 
continuing education programs and curricula within the United States.  Oversight for the 
undergraduate medical education programs and curricula for the approximately 125 U.S.-based 
medical schools is through the Liaison Committee for Medical Education (LCME, 2011).  
Secondly, the Accreditation Council for Graduate Medical Education governs residency and 
fellowship programs, commonly referred to as graduate medical education (ACGME, 2011).  
Lastly, providers accredited by the Accreditation Council for Continuing Medical Education 
(ACCME) present continuing medical education activities to support maintenance of licensure 
and certification for physicians in practice.  
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Accreditation Council for Continuing Medical Education (ACCME).  Accredited 
providers must adhere to the Accreditation Council for Continuing Medical Education’s 
(ACCME) Essential Areas and Elements, Standards for Commercial Support, and supplemental 
policies.  The ACCME® is a seven organization member council consisting of the American 
Board of Medical Specialties (ABMS), American Hospital Association (AHA), American 
Medical Association (AMA), Association for Hospital Medical Education (AHME), Association 
of American Medical Colleges (AAMC), Council of Medical Specialty Societies (CMSS), and 
the Federation of State Medical Boards of the U.S., Inc. (FSMB).  
Of the three accreditation bodies, the ACCME has specific requirements for disclosure 
and COI resolution as detailed in Standard 2 of the ACCME® Standards for Commercial 
SupportSM, Standards to Ensure the Independence of CME activities (ACCME, 2011) (Appendix 
A).  Among these requirements and responsibilities are (1) the provider’s documentation that, 
regardless of role, everyone in a position to control the content of an educational activity has 
either disclosed financial relationships with commercial interests or documented the 
nonexistence of such; (2) disqualification of participation by individuals who refuse to disclose; 
(3) a mechanism developed by the provider to resolve all conflicts of interest prior to an 
educational activity; (4) informing the learners of all disclosures prior to an activity, and (5) 
management of the interaction with commercial interests to reduce potential undue commercial 
influence of the content. Furthermore, the ACCME® Standards for Commercial Support, 
grounded in the 1997 FDA Guidance, inherently establish a firewall between educational 
activities and promotional opportunities. 
Accreditation Council for Graduate Medical Education (ACGME).  Even though the 
LCME and ACGME do not have comparable documents and policies, they fundamentally 
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discourage student, faculty, and staff interactions with commercial interests.  The ACGME, 
through its Institutional Requirements, states that the institutional Graduate Medical Educational 
Committee (GMEC) is “…responsible for establishing and implementing policies and 
procedures regarding the quality of education and the work environment for all residents in all 
programs” (ACGME, 2011, p. 9).  For example and relevant to the study, the ACGME 
Institutional Requirements (III.B.13) expects the GMEC to document the existence of a position 
statement or institutional policy that addresses residents’ interaction with industry. 
In 2002, the ACGME released a white paper entitled “Principles to Guide the 
Relationship between Graduate Medical Education and Industry.” In the white paper, the 
ACGME discussed the role of professionalism, one of its six general competencies, in support of 
a more restrictive interaction of residents with industry representatives by defining 
professionalism as: 
 [...] an expression of the norms that guide the relationships in which physicians are 
engaged (Kuczewski, 2001, in ACGME, 2002, p. 4)… and identifying those traits 
commonly associated with professionalism as altruism, respect for others as embodied in 
humanistic qualities, honor, integrity, ethical behavior, accountability, excellence, a sense 
of duty, and advocacy (Arnold, 2001, in ACGME, 2002, p.5).  
Kuczewski (2001) emphasized that medical education curricula should be inclusive of ethics and 
orientation to established guidelines and principles espoused by the associations and specialty 
societies that represent the medical profession.  The ACGME 2002 white paper also encouraged 
emulating and exceeding the ACCME® disclosure requirements as well as abiding by the 
AAMC’s recommendations regarding the management of COIs in human subjects’ research. 
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On February 13, 2007, the ACGME Board of Directors approved the integration of six 
general competencies into the curriculum as a residency program requirement. The expanded 
definition of each competency described the expectations of residents and their responsibilities to 
the medical profession and the patient population.   Specific to the definition of professionalism 
and reinforcing the principles advocated by the ACGME in its 2002 white paper, 
“…residents must demonstrate a commitment to carrying out professional responsibilities 
and an adherence to ethical principles.  Residents are expected to demonstrate:  
compassion, integrity, and respect for others; responsiveness to patient needs that 
supersedes self-interest; respect for patient privacy and autonomy; accountability to 
patients, society and the profession; and sensitivity and responsiveness to a diverse 
patient population, including but not limited to diversity in gender, age, culture, race, 
religion, disabilities, and sexual orientation” (ACGME, 2007) (Appendix B). 
Liaison Committee for Medical Education (LCME).  The Association of American 
Medical Colleges (AAMC) and the American Medical Association (AMA) are collaborative 
sponsors of the LCME and have issued reports and opinions that address disclosure policies, 
mechanisms for COI resolution, and an individual’s conduct and interaction with industry while 
engaged in the practice of medicine. The implementation of industry policies in the majority of 
medical schools, which is discussed in a succeeding section of this chapter, reinforces the 
position that the AAMC and AMA have taken on these issues.   
American Medical Association (AMA). 
The American Medical Association originally released its 168-year-old AMA Code of 
Medical Ethics (Appendix C) in 1847 at the first AMA meeting in Philadelphia.  As a dynamic 
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document, it is updated frequently by the AMA’s Council on Ethical and Judicial Affairs (CEJA) 
as the environment and profession dictate.  The code presents opinions in ten ethical areas related 
to the medical profession and informs physicians’ ethical and professional conduct in medical 
education, research, and patient care.  The AMA opinions relevant to this study are those 
regarding practice matters (Opinion 8.00), professional rights and responsibilities (Opinion 9.00), 
and reference to definitions of the terms “ethical” and “unethical” as used in the remaining nine 
areas of the code (Opinion 1.01).  According to CEJA’s Opinion 1.01,“ethical” refers to one’s 
respect of moral principles and social policy involving issues of morality, and “unethical” refers 
to one’s failure of professional conduct by not abiding by moral standards.  Both descriptions 
strengthen the significance of the moral agent in Jones (1991) ethical decision-making model 
used as the theoretical framework of this study. 
Within Opinions on Practice Matters (8.00), Opinion 8.03 addresses physicians’ potential 
conflicts of interest (COIs) by stressing patient welfare and service to humanity above their 
financial gain and further states that COIs must be resolved to the benefit of patients.  Opinions 
8.031 and 8.0315 continue by addressing resolution of COIs in biomedical research and clinical 
trials respectively. Physicians may partner with industry in research, but the AMA stresses the 
necessity of ensuring objectivity, maintaining integrity, and assuring the safety of human 
subjects.  In CEJA’s Opinion 8.061, Gifts to Physicians from Industry, the AMA recognizes the 
importance of physicians’ appropriate interaction, cautions physicians in the inappropriate 
acceptance of gifts, and offers ethical direction through seven detailed guidelines.   In summary, 
the guidelines state that gifts should be of professional or patient benefit as the 2009 revised 
PhRMA and AdvaMed codes stipulate.  The guidelines also promote scientific and objective 
dissemination of knowledge in professional conferences.  This opinion also reflects the 
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disclosure requirement and other parameters governing the interaction of physicians with 
industry as stipulated in the 1997 FDA Guidance and Standard 3: Appropriate Use of 
Commercial Support of the ACCME® Standards for Commercial Support (Appendix A). 
The ACCME® criteria and standards are further reflected in Opinion 9.011, Continuing 
Medical Education, which offers guidance to attendees, faculty, and sponsors regarding ethical 
participation in CME activities.  Opinion 9.011 promotes participation in balanced and unbiased 
CME activities for the purpose and benefit of better serving patients, upholding professional 
standards, and sustaining ethical responsibility.  It also cross references Opinion 8.061, Gifts to 
Physicians from Industry, as it relates to honoraria and expenses for faculty. 
Association of American Medical Colleges (AAMC). 
Consistent with the AMA’s and accreditation bodies’ views of academic medicine’s 
interaction with industry, the Association of American Medical Colleges (AAMC) has in recent 
years investigated the ethical nature of physicians’ financial relationships on two levels – 
individual and institutional.  While the focus of the study is narrowed to the individual healthcare 
professional and, more specifically, the academic physician; application of a similar study on the 
institutional level would be of equal benefit and should be considered for future research.  With 
funding from the Robert Wood Johnson Foundation and Pew Charitable Trusts, the AAMC and 
Baylor College of Medicine sponsored a symposium on June 12, 2007 entitled “The Scientific 
Basis of Influence and Reciprocity.”  The four major goals of the symposium were to: 
1) Identify, quantify, and understand influence, reciprocity, and conflicts of interest; 
2) Develop responsible practices to manage and mitigate these conflicts; 
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3) Sustain and enhance the important contributions of industry to biomedical discovery, 
product development, and education through evidence-based medicine; and 
4) Earn the public trust and protect the patient.  (AAMC, 2007, p. 8) 
The participants examined the goals from the following four perspectives providing conceptual 
clarity as well as case-based and research-based evidence to generate further inquiry: 
 Neuroscience:  concepts of individual trust and how special treatment can influence 
decisions; 
 Psychology:  moral standards, degrees of freedom, an individual’s choice to be honest or 
dishonest and its effect on self-concept; 
 Behavioral economics: “conflicts of interest…a clash between professional 
responsibilities and economic interests” (AAMC, 2007, p. 19), disclosure as a “moral 
license” (AAMC, 2007, p. 22), and elimination of gifts to mitigate biased decision 
making; and 
 Implications for Public Policy:  importance of understanding concepts of bounded 
awareness, which may be expressed as the ability to ignore what one wishes not to see 
and confirm what one wants to believe, unconscious bias in decision making, and 
bounded ethicality which Chugh, Bazerman & Banaji (2005, in AAMC, 2007, p. 25) 
define as “systematic and predictable ways in which humans act unethically beyond their 
own awareness.”  
The symposium generated three task forces which convened in each of the three areas of 
industry funding — medical education, financial conflicts of interest in human subjects’ 
research, and conflicts of interest in clinical care.  They subsequently released the following 
reports with recommendations for the profession of medicine:  (a) AAMC in conjunction with 
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the AAU on COI policies to protect patients, preserve integrity, and advance health in human 
subjects’ research in February 2008, (b) industry funding of medical education in June 2008, and 
(c) physician financial relationships and clinical decision making in June 2010.  The third task 
force responsible for clinical decision-making (AAMC, 2010) and the Institute of Medicine (Lo 
& Field, 2009) confirmed that there is a paucity of evidence-based COI research in the body of 
literature, including policy and systematic studies which contributed to the significance of this 
study.  The need for COI research was specifically noted in the IOM consensus report as 
Recommendation 9.2 which suggested that the National Institutes of Health, Agency for 
Healthcare Research and Quality, and Department of Health and Human Services develop a 
research agenda on conflict of interest (Lo & Field, 2009).   Collectively, the AAMC task force 
 defined professionalism consistent with the ACGME’s definition as involving “…a set of 
ethical standards and motivations on the part of individual practitioners.  Among 
medicine’s ethical principles are autonomy, objectivity, altruism, and the avoidance of 
conflicts of interest” (AAMC, 2008, p. 3); 
 endorsed and adopted the Institute of Medicine’s definition of COI which states that “a 
conflict of interest is a set of circumstances that creates a risk that professional judgment 
or actions regarding a primary interest will be unduly influenced by a secondary interest” 
(Lo & Field, 2009, p.46); 
 supported the appropriate and well-managed academic medicine-industry interaction for 
the public good; 
 identified the need for future research related to decision-making in these relationships; 
 exposed the potential negative effect of conflicts of interest in medical education, 
research, and patient/clinical care; 
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 encouraged academic medical centers to create and implement institutional policies, 
commonly referred to as “industry policies,” that provide specific guidance for 
interaction with industry by faculty, staff, trainees, and students; and finally, 
 made recommendations for academic medical centers as they move forward to resolve 
these issues (AAMC, 2008; AAMC & AAU, 2008; AAMC, 2010; & Croasdale, 2008). 
National Faculty Education Initiative (NFEI).  In support of the recommendations, 
federal regulations, and other organizational efforts to establish a thorough understanding of the 
environment and how to avoid COIs and inappropriate interaction with industry, the Alliance for 
CME (Alliance) and the Society for Academic Continuing Medical Education (SACME), in 
collaboration with the AAMC, launched the National Faculty Education Initiative (NFEI) in 
October 2008.  The online educational activity which may be found at www.nfeinitiative.org 
offers “cased-based content to quickly and effectively educate medical faculty about federal 
regulations, accreditation and professional standards, and their roles and responsibilities when 
presenting in certified CME or commercial programs” (Alliance & SACME, 2008).  The online 
course is beneficial to individuals’ understanding of the distinction between promotional and 
evidence-based content and is also designed to protect individual and organizational stakeholders 
and the public. 
Institutional industry policies.  One of the AAMC (2010) recommendations encouraged 
academic medical centers to develop and implement institutional policies that offer guidance for 
interaction of industry with students, trainees, faculty, and staff and are commonly referred to as 
“industry policies.”  The policies generally follow the institutional faculty or staff member on or 
off campus and include sections that provide guidance on gifts, meals and entertainment, drug 
samples, speaking and consulting arrangements with industry, disclosure, access and registration 
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procedures, and restrictions for sales representatives on the academic medical center’s property 
or campus. 
Prior to AAMC issuing the 2010 recommendations, the American Medical Student 
Association (AMSA) released its initial, yet subjective, “PharmFree Scorecard” in 2007.  AMSA 
graded medical schools on an A to F scale based on whether they had a conflict of interest or 
industry policy that controlled the interaction of faculty and students with industry 
representatives.  Since 2007, AMSA has collaborated with the Pew Prescription Project to 
develop a more thorough assessment to suggest elements that should be included in an effective 
policy.  The purpose behind AMSA’s campaign that began in 2002 was to advocate for 
evidence-based medicine and physicians’ prescribing power that is free from the influence of 
industry and to implement institutional conflict-of-interest policies. 
As of December 15, 2010, 140 of 152 medical institutions have participated in the 
Scorecard, a 92% rate, improved from 88% in 2009.  Of 152 = medical schools, 19 
received As (13%), 60 Bs (39%), 24 Cs (16%), 18 Ds (12%), 26 Fs (17%), and 5 ‘In 
Process’ (AMSA, 2011, para 4-8). 
In 2010, AMSA’s grading system assessed the strength and restrictive nature of the key elements 
of a policy.  The 2010 summary data indicated trends towards strengthening policies, thereby 
receiving a higher grade, as well as improvement trends by domains, e.g. gifts or samples.  
AMSA’s efforts were intended to support the AAMC’s task force recommendations released in 
2008 and the Institute of Medicine’s 2009 consensus report discussed below. 
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Institute of Medicine of the National Academy of Sciences (IOM). 
Consistent with the positions of the AMA, AAMC, and accreditation bodies; the Institute 
of Medicine of the National Academy of Sciences released a consensus report in 2009 defining 
the elements of a conflict of interest (COI) and identifying the need for further COI research in 
medical education, research and practice.  The Institute of Medicine’s definition of COI states 
that “a conflict of interest is a set of circumstances that creates a risk that professional judgment 
or actions regarding a primary interest will be unduly influenced by a secondary interest” (Lo & 
Field, 2009, p.46).  Also referred to as goals, obligations or rights, “primary interests include 
promoting and protecting the integrity of research, the welfare of patients, and the quality of 
education” (Lo & Field, 2009, p.47).  Secondary interests are referred to as financial gain, desire 
for professional advancement, recognition for personal achievement, or favors to friends, family, 
students, or colleagues.  As such, secondary interests create conflicts and potential harm when 
the weight of the secondary interest is inappropriate and greater than the primary interest, 
exercising undue influence on professional decisions and distorting the pursuit of the primary 
interest (Lo & Field, 2009, p.47).   The IOM report also suggested that commercial support of 
continuing medical education (CME) activities may promote a physician faculty’s sense of 
entitlement due to medical school debt and other financial factors (Lo & Field, 2009). 
The IOM report addressed mechanisms designed to identify and assess COIs; motives 
and unconscious bias in decision-making; cases that demonstrate the specific nature of conflicts 
in education, research, and practice; and existing accreditation disclosure and COI guidelines and 
policies.  Specific to this study and Jones’ (1991) ethical decision-making model, the IOM’s 
description of the secondary interests, e.g. unconscious bias in decision-making, supports the 
behavioral economics perspective explored in the AAMC / Baylor symposium (2007).  For 
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example, both noted that some social science research suggests that even gifts of small value 
from industry, e.g. pens, pads, etc. may cause unconscious bias or undue commercial influence in 
professional judgment and decision-making (AAMC, 2007; Lo & Field, 2009; Dana & 
Loewenstein, 2003). 
Based on its findings, the IOM concluded by offering sixteen recommendations for a 
spectrum of stakeholders to mitigate undue bias and commercial influence and to inform stronger 
COI policies.   The stakeholder groups that could be affected by or involved in the 
implementation of the recommendations included individual healthcare professionals; academic 
medical centers, medical research and teaching institutions, faculty, residents, fellows, and 
students; pharmaceutical, medical device and biotech companies; accreditation and certification 
bodies; healthcare professional societies; U. S. Congress, National Institutes of Health, other 
federal and public agencies; and community physicians. 
Two significant purposes underlying the IOM recommendations, which are outlined and 
classified among seven categories, include (1) protecting the integrity of professional judgment 
and (2) preserving public trust in a proactive versus reactive manner: 
I. General Policy – adopt and implement COI policies; strengthen disclosure policies; 
standardize disclosure content and formats; and create a national program for the 
reporting of company payments. 
II. Medical Research – restrict participation of researchers with COIs in research with 
human participation. 
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III. Medical Education – reform relationships with industry in medical education; provide 
education on conflict of interest; reform the financing system for continuing medical 
education. 
IV. Medical Practice – reform financial relationships with industry for community 
physicians; reform industry interactions with physicians. 
V. Clinical Practice Guidelines – restrict industry funding and conflicts in clinical 
practice guideline development; create incentives for reducing conflicts for reducing 
conflicts in clinical practice guideline development. 
VI. Institutional Conflict of Interest Policies – create board-level responsibility for 
institutional COIs; revise PHS regulations to require policies on institutional COIs. 
VII. Supporting Organizations – provide additional incentives for institutions to adopt and 
implement policies; develop research agenda on conflict of interest (Lo & Field, 
2009, pp.16-17). 
Theoretical Framework 
The professional fields of organizational behavior and management have generated a 
number of ethical-decision making models for individuals in organizations.  Thomas M. Jones 
(1991) developed one such model using J. R. Rest’s 1986 model as the foundation.   Jones’ 
model centers on the issue-contingency nature of a decision with an emphasis on the moral 
intensity of the issue.  Jones’ model of ethical decision making (Figure 2) was the theoretical 
framework within which I conducted the study for the purpose of exploring physicians’ 
individual perceptions of resolving potential or perceived conflicts of interest (COI).  
Additionally, for the purpose of this study, I excluded the organizational factors in his model 
which should present an opportunity for future research.  The context of COIs relate to the 
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interaction of the physicians’ relationships with industry, defined as pharmaceutical, medical 
device, or biotech firms.  The model placed emphasis on physicians as moral decision-makers or 
moral agents and their ability to tap into embedded ethics and morals that influence decisions 
regarding research, teaching, and patient care.   
Figure 2: Adapted from An Issue-Contingent Model of Ethical Decision Making in 
Organizations. 
 
 
 
   
 
 
 
 
 
 
 
 
Source: Adapted from An Issue-Contingent Model of Ethical Decision Making in Organizations. Jones, T. M. 
(1991, April).  Ethical decision making by individuals in organizations: An issue-contingent model.  The Academy 
of Management Review, 16(2), p. 379.  Used with permission from the author, Thomas M. Jones, PhD (Appendix 
J). 
As discussed earlier in this chapter, there are regulatory agencies including the U. S. 
DHHS FDA and U. S. DHHS OIG; accreditation bodies, LCME, ACGME, ACCME; relevant 
professional and ethical recommendations and opinions by the AMA, AAMC, and IOM; 
voluntary industry codes, PhRMA and AdvaMed Codes; and institutional conflicts of interest or 
Moral Intensity 
Magnitude of Consequences 
Social Consensus 
Probability of Effect 
Temporal Immediacy 
Proximity 
Concentration of Effect 
Recognize 
Moral 
Issue 
Make 
Moral 
Judgment 
Engage in 
Moral 
Behavior 
Establish 
Moral 
Intent 
Organizational 
Factors 
     
Group Dynamics 
Authority Factors 
Socialization  
    Processes 
 73 
industry policies that guide physicians in managing and resolving conflicts of interest (COIs).  
The lack of literature regarding the role of the individual in COI resolution suggested exploring 
the ethical nature and moral intensity of physicians’ decision-making process used to resolve 
perceived COIs and to proceed with commercially unbiased responsibilities in the areas of 
research, teaching, and patient care (AAMC, 2008; AAMC, 2010; Lo & Field, 2009). 
In developing his model, Jones (1991) conducted a synthesis of existing models among 
which he identified collective strengths and weaknesses.  As a result, he identified the gap in the 
literature as the absence of the explicit moral issue itself and its characteristics which he referred 
to as moral intensity.  He also discussed the implicit presence of the moral issue in the synthesis.  
Using J. R. Rest’s 1986 four-component model for individual ethical decision-making and 
behavior as the foundation of the synthesis; he incorporated elements of L. K. Trevino’s 1986 
person-situation interactionist model (in Jones, 1991; Hayibor & Wasieleski, 2009) which is 
similar to Rest’s model; Ferrell and Gresham’s 1985 model of ethical decision-making in 
marketing relative to professional codes, corporate policy, and rewards and punishment (in 
Jones, 1991); Hunt and Vitell’s 1986 model of ethical decision-making in marketing with an 
emphasis on the effect of environmental factors and personal experiences (in Jones, 1991); and 
Dubinsky and Loken’s 1989 model of ethical decision-making in marketing based on the theory 
of reasoned action (in Jones, 1991).  All of the models in the synthesis have elements of 
applicability to the study, but in researching Jones’ model (1991), I determined that it was the 
most comprehensive and relevant framework for thoroughly exploring the research questions 
through examination of the process. 
The four components of Rest’s 1986 model were the theoretical foundation for Jones’ 
1991 model and required the moral agent who, in this case, is the physician to (1) recognize the 
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moral issue, (2) make a moral judgment, (3) establish moral intent, and (4) act on the moral 
concerns.  The first component of recognizing the moral issue requires (a) the individual to 
acknowledge one’s role as a moral agent, (b) that the decision involves choices (volition), and (c) 
that the decision or action produces consequences for or have an effect on others.  In Jones’ 
(1991, p.391) conclusions regarding his proposed issue-contingent model of ethical-decision 
making, he suggested that future research “should include consideration of the effect of the 
moral agent’s failure to recognize the moral issue.”  The suspected failure, whether an inability 
to identify a moral issue or an intentional disregard of a moral issue, was taken into account. 
The second component of the process requires the moral agent to make a moral 
judgment.  Based on the varied models of moral judgment stages, social cognition, and the effect 
of context by Kohlberg and others; Jones (p. 384) contended that “moral reasoning is issue 
dependent.”  He validated his argument with the studies of Velasquez, Fiske and Taylor, Taylor, 
Weber, and others indicating that, in summary, moral reasoning is proportional to whether the 
moral stakes are high or low.  Therefore, it is essential to understand the issue that is central to an 
ethical decision and how it is affected by the characteristics of moral intensity.  
The third component, establish moral intent, and fourth component, act on the moral 
concerns, are interrelated. Jones (1991) asserted that moral intent influences moral decision-
making and moral behavior which is supported by Fishbein and Ajzen’s (1975, p. 381, in Jones, 
1991, pp. 386, 387) arguments that “the best predictor of a person’s behavior is [one’s] intention 
to perform the behavior” and that a moral judgment, what is morally correct, is not the same as 
the decision to act upon the moral judgment.  Harrington (1997) also supported Rest’s moral 
intent component in Jones’ model and the reasons for the inconsistency between what an 
individual knows is wrong versus one’s unethical actions. 
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Engaging in moral behavior, the fourth component in Rest’s model, may also be 
influenced by several factors including what Fiske and Taylor (1984, in Jones, 1991) refer to as 
situational forces, which are not always evident to the moral agent, such as self-serving bias 
based on an individual’s knowledge of one’s own attitudes, feelings, and intentions.  Secondly, 
social, cultural, psychological, and physical proximity may play a considerable influencing role.  
The more distant an individual is from a situation and its effects, the less influence proximity 
will have on the moral decision.  In support of the fourth component of Rest’s model, Detert, 
Trevino, and Sweitzer (2008) explored Bandura’s assertion and argument (1986, in Detert, 
Trevino, and Sweitzer, 2008, p. 374) “that moral disengagement explains why otherwise normal 
people are able to engage in unethical behavior without apparent guilt or self-censure.”  Bandura 
also suggested that individuals can “morally justify” harm to others although they know it is 
wrong.  The authors also tied moral disengagement to Jones’ 1991 model, indicating that moral 
intensity may be dependent upon the potential harm as a result of the decision. 
Through faculty interviews, Jones’ integrated model determines if and how the 
characteristics of the moral issue bring perceived conflicts of interest to the heart of the conflict-
of-interest resolution process.  Therefore, it is important to understand the evolution of the gap 
Jones identified as moral intensity through the characteristics of the moral issue and how moral 
intensity relates to supporting the evidence presented and to the context of the study (Jones, 
1991; Harrington, 1997; Hayibor & Wasieleski, 2009). 
Moral Intensity 
Moral intensity is a construct identified by Jones (1991) that focuses on the issue at the 
center of a decision and how it is assessed by the person making the decision without 
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consideration of the context of the professional organization or environment.  Furthermore, the 
level of moral intensity may vary depending on the issue.  Jones supported the significance of the 
moral issue through intuitive, observational, and empirical factors.  The intuitive nature of the 
issue suggests an increased concern for decisions involving moral issues that may have an effect 
on individuals close to the decision-maker.  Observationally, physical, psychological, cultural, or 
social distance affects the decision maker’s perspective of the moral issue.  Finally, empirical 
evidence suggests that ethical decision-making may be proportional to the level of the decision 
maker’s anticipated consequences or risks (Fritzsche and Becker, 1983; Fritzsche, 1988; and 
Weber, 1990; in Jones, 1991). 
Hayibor and Wasieleski (2009) reinforced Jones’ (1991) intuitive, observational, and 
empirical factors through their application and probable effect of the availability heuristic on the 
perception of moral intensity in his model.  According to Tversky & Kahneman (1973, in 
Hayibor & Wasieleski, 2009, p. 154; Jones, 1991), an availability heuristic “in uncertain 
contexts…is used to facilitate estimation of frequencies and probabilities of events,” a judgment 
call, evaluating the probability of events or risks, based on what can easily be brought to mind or 
rationalized.  Physicians, for example, may not perceive that they have conflicts of interest 
(COIs) that stem from financials relationship with industry as was demonstrated by the examples 
in chapter one.  They may not immediately be able to recall colleagues that found themselves 
within circumstances that created COIs and subsequently encountered barriers to effective 
research, teaching, or patient care with minimal or no negative effects.   Hayibor and Wasieleski 
(2009, p. 155) further proposed that “the availability heuristic effects ethical decision-making by 
its influence on the moral intensity of the issue” basing their research on two of the six 
characteristics of a moral issue identified by Jones – magnitude of consequences and social 
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consensus.  Hayibor and Wasieleski enhanced Jones’ research by concluding that by “identifying 
the availability of particular phenomena as potential determinants of the moral intensity of 
ethical issues,” the availability heuristic has significant consequences for ethical decision making 
and promoting ethical behavior (pp.163-164).  Jones (1991) identified six characteristics of 
moral intensity as (1) magnitude of consequences, (2) social consensus, (3) probability of effect, 
(4) temporal immediacy, (5) proximity, and (6) concentration of effect, each of which is defined 
and discussed below.  The interview protocol for the study presented an opportunity to assess 
each case scenario and determine if there was a moral issue at the center of the decision process 
by taking each of the six characteristics of moral intensity into consideration. 
Magnitude of consequences. 
Jones (1991, p. 374) defined magnitude of consequences as “the sum of the harms (or 
benefits) done to victims (or beneficiaries) of the moral act in question.” There are underlying 
assumptions that ethical decision-making is directly proportional to the level and nature of 
consequences, that a link exists between consequences and reasoning, and that a moral agent as 
the decision-maker has a moral component.  Jones presented empirical evidence by Fritzsche and 
Becker (1983), Weber (1990), Fritzsche (1989), and York (1989) to support the assumptions 
underlying the inclusion of this characteristic.  Collectively, their research suggested that serious 
consequences encourage ethical behavior more so than consequences of a lesser degree.  
Social consensus. 
Jones (1991, p. 375) defined social consensus as “the degree of social agreement that a 
proposed act is evil (or good).”  In essence, “it is difficult to act ethically if a person does not 
know what good ethics prescribes in a situation; a high degree of social consensus reduces the 
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likelihood that ambiguity will exist.”  Laczniak & Inderrieden’s (1987, p. 304, in Jones, p. 375) 
assertion supported Jones’ logic that “in order for individuals to respond appropriately to a given 
situation, agreement must exist as to whether or not the behavior is appropriate.” In exploring 
Jones’ decision-making model, Harrington (1997, p. 364) examined the social consensus 
characteristic of moral intensity and suggested that “the greater the level of seriousness, the more 
likely it is that laws will be created, as evidenced by laws for murder, theft, etc.”    
While hopefully not in the same category as murder and theft, the principle still applies.  
Harrington’s (1997) study supported Jones’ 1991 model indicating that social consensus 
influences moral judgment and moral intent.  In the context of this study, the increasing number 
of regulations, recommendations, codes of conduct, and accreditation guidelines have been 
established or revised in recent years. They represent the social consensus characteristic and are 
based on an assessment of the seriousness of potential consequences. The interview protocol 
further examines this effect through the case scenarios.  The increased oversight is intended to 
shape and control ethical guidance in the interaction of physicians and industry. 
Probability of effect. 
Probability of effect represents logic in a decision and is “a joint function of the 
probability that the [moral] act in question will actually take place and the [moral] act in question 
will actually cause the harm (benefit) predicted (Jones, 1991, p. 375).”  Additionally, anticipated 
consequences of moral actions are the result of the individual’s estimation of the magnitude of 
consequences.  The moral act in the context of the study is a physician’s decision with the intent 
of resolving a perceived conflict of interest in an ethical and moral manner and with 
consideration of the effect ranging from individuals to society as a whole.  The interview 
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protocol probed potential harms and benefits in the case scenarios with relevance to magnitude 
of consequences as well as probability of effect. 
Temporal immediacy. 
Temporal immediacy of the moral issue refers to “the length of time between the present 
and the onset of consequences of the moral act in question; shorter length of time implies greater 
immediacy (Jones, 1991, p. 376).”   Jones supported this component with tenets of economic 
theory – (1) individuals tend to disregard impact of events that happen in the future and (2) as 
time increases between the situation and the anticipated consequences, the probability of 
predicted harm decreases and potentially diminishes moral urgency. 
In this study, temporal immediacy is probably most evident in decisions that evolve 
around medical research involving human subjects.  Examples include the short-term and long-
term effects of certain classes of drugs, e.g. the effect of certain cholesterol-lowering statin 
products on the liver or the effect of certain NSAID products on stroke or heart attacks or other 
cardiovascular events.  The interview protocol examined the effect of time in terms of future 
effects as it did with the proximity of personal or professional relationships which is closely 
related to temporal immediacy.  
Proximity. 
To reiterate the influence of proximity previously discussed, Jones (1991, p. 376) stated 
that “the proximity of the moral issue is the feeling of nearness (social, cultural, psychological, 
or physical) that the moral agent has for victims (beneficiaries) of the evil (beneficial) act in 
question.”  Proximity, as a characteristic of moral intensity, represents the intuitive and 
observable explanation of the effect of moral intensity of ethical decisions.  
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In theory, individuals and the physician decision makers may instinctively care more for 
those near to them, e.g. by family relationships or close friendships, than those who are distant.  
To support the inclusion of proximity as a characteristic of moral intensity, Jones (1991) cited 
Milgram’s 1974 teacher-student obedience experiments in which increased physical proximity, 
the greater distance between student and teacher, decreased obedience.  This analogy implies 
that physicians’ close relationships with their patients would generate thoughtful decisions in the 
patients’ best interests regarding potentially beneficial or harmful effects on their patients.  
Although the National Institutes of Health (NIH) provides guidance in the protection of human 
subjects, decisions by researchers and the effects of those decisions on a cohort of random 
clinical trial subjects may be less proximate, i.e. a greater distance between researcher and 
subjects.   Another example that supports the moral nature of proximity as a characteristic is 
Charles Fried’s analogy of ‘lawyer as friend’ in legal relationships in which Fried professes that 
“not only do attorneys often tend to develop close (proximate) relationships with their clients, 
but also that these relationships are morally appropriate. (Fried, 1976, in Jones, 1991, p. 377)” 
Concentration of effect. 
Jones (1991, p. 377) defined the sixth and final characteristic of moral intensity, 
concentration of effect, as “an inverse function of the number of people affected by an act of 
given magnitude.”  Jones explained this characteristic well with an example – “cheating an 
individual out of a given sum of money has a greater concentration of effect than cheating an 
institution, i.e. a corporation or government agency out of the same amount (p. 378).”  Rawls’ 
Theory of Justice (1971, in Jones, 1991, p. 378) supported the principle expressed by the 
example through an assumption that those “who have a sense of the paramount importance of 
justice for the individual will abhor immoral acts that result in highly concentrated effects.”  The 
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study contemplates this characteristic through discussion of the effect of potential significant 
gain on the decision process discussed in each of three case scenarios. 
Bias 
As the six characteristics of moral intensity affect the moral issue in the four components 
of an ethical or moral decision-making process, Jones (1991) suggested that two sources of 
biases are inherent to the process – the individual who is acting as the moral agent and 
organizational factors that can influence moral behavior and test the cognitive ability of the 
decision-maker.  In referencing the work of others, Jones (1991) proposed that individual biases 
may present themselves in the form of an individual’s inability to process “what if” scenarios, 
perceive risk, recognize early indications of a problem, see oneself as an independent agent in 
moral situations, and possibly accept responsibility for a moral conflict.   On the opposite end of 
the individual’s bias spectrum is an ‘illusion of control’ (Langer, 1982, in Jones, 1991) in which 
an individual as the moral agent overestimates one’s control in the situation leaning towards 
personal choices. 
As discussed earlier in chapter two, accreditation, regulatory, and organizational policies 
provide oversight for capturing and resolving potential conflicts of interest with the intent of 
mitigating physician bias in teaching, research, and patient care.  With these oversight 
mechanisms taken into consideration, the study explores the influence of personal biases, values, 
and morals. It is a common and accepted practice for pharmaceutical and medical device 
companies to recruit physicians as key opinion leaders (KOLs) who are considered experts in 
their respective medical specialties or sub-specialties.  Industry trains its KOLs, e.g. as a member 
of a speakers bureau, in a manner that best represents and promotes the companies and their 
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interests.  With recognition and increased status, KOL physicians may also presume a greater 
sense of control including that of making unbiased decisions in the best interest of the patient. 
In summary, Jones’ (1991) ethical decision-making model of issue-contingency supports 
that moral behavior is connected to moral decision-making, individual and organizational 
influencing factors, and levels of moral intensity surrounding the significance of the issue.  The 
model also places a specific emphasis on magnitude of consequences, probability of effect, 
temporal immediacy, and concentration of effect.  As noted earlier, the study does not consider 
organizational factors and their influence but this theoretical component should provide 
opportunities for future research.  As the research instrument for the study with approximately 
twenty years of observation and interaction with academic physicians, I reviewed several 
decision-making models and determined that the issue-contingency model would provide the 
most meaningful opportunity to explore a process beyond what the environment dictates 
regarding disclosure and resolving potential conflicts of interest. 
Conclusion 
 Chapter two presented a comprehensive assessment of the context in which I conduct the 
grounded theory study.  The literature review began with a global view of higher education and 
its evolution in becoming more of a corporate entity through commercialization, adopting a 
decentralized responsibility center model, and fostering research and other types of partnerships 
with business and industry.  Secondly, the literature review offered an historical perspective of 
the principles that for centuries have defined faculty and higher education.  Those principles 
included ethics, academic freedom, and responsibilities to society for teaching, research, and 
public service. The third purpose of the review was to narrow the concepts to the field of 
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academic medicine and present the external forces and internal pressures that have imposed 
scrutiny and oversight.  The fourth and final goal was to connect with faculty and how, in that 
role and in the environment described in this chapter, one makes ethical decisions in resolving 
conflicts of interest for the advancement of medicine and the benefit of the common good. 
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Chapter III 
Methodology 
Purpose of the Study 
 The purpose of this qualitative, grounded theory study was to identify and investigate 
how physicians manage and resolve perceived conflicts of interest (COI) in their roles as 
teachers, researchers, and clinicians.  The study was specific to individual physician’s financial 
relationships with industry and within the context of university-industry relationships.  An 
academic physician’s financial relationship with industry may be in the form of consultancy, 
member of a speakers’ bureau, advisory or scientific board member, recipient of research grants 
directly or through an institutional agreement, patent agreements, royalties, or involvement in 
industry-funded studies.  Disclosures of a physician’s financial relationships also extend to the 
same types of relationships that an immediate family member may have, all of which must be 
disclosed if the relationships have existed within the previous twelve months, regardless of 
whether the relationship currently exists (ACCME, 2004; AMA, 2011; U. S. FDA, 1997; & U. S. 
DHHS OIG, 2003). 
 As such, a financial relationship may hinder the faculty member’s ability to make ethical 
decisions regarding how knowledge is framed and presented to future physicians in the 
classroom, how data are analyzed and manipulated in research projects or clinical trials, how a 
patient is treated and with which company’s drugs, and ultimately how decisions could influence 
the effects on society.   Regardless of academic discipline, the tenets of Academic Freedom 
(AAUP, 1940) protect faculty academic decisions.  The study explored the potential of these 
academic decisions being commercially-influenced through individual faculty financial 
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relationships with industry as previously described or through involvement in university-industry 
relationships. 
To thoroughly examine the stated purpose of the study, this chapter presents the research 
questions, describes the methodology for conducting the study, and explains the exclusion of 
other methodological approaches.  I also submit the rationale for a qualitative, constructivist, 
grounded theory study design and discuss my role as the researcher.  In the research plan section, 
I describe the institutional settings and detail the sampling procedures and participant selection 
for the study.  Finally, I outline methods of data collection and analysis.  The following research 
questions were central to confirming, refining, or developing a theory underlying the process of 
ethical decisions. 
Research Questions 
 The grounded theory study examined the following research question – How do 
physicians as academicians manage or resolve potential conflicts of interest in their roles as 
teachers, researchers, and clinicians? 
Secondarily, the study examined: 
 Factors that may influence ethical, commercially-unbiased academic decisions; 
 Characteristics of ethical, evidence-based decisions v. commercially-influenced 
decisions; and 
 Assessments of how relationships with industry may threaten academic freedom in 
ethical decision-making. 
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Design of the Study 
Rationale for a Qualitative Design 
 University-industry relationships, commercialized organizational structures, and faculty 
financial relationships with industry are well-known and common within the environment of 
institutions of higher education (AAMC, 2008 & 2010; ACCME, 2004; AMA, 2011; Bok, 2003; 
Duderstadt & Womack, 2003; Robbins, 2003; Shuger, 1990; U. S. FDA Office of Policy, 1997; 
U. S. DHHS OIG, 2003; U. S. Senate Committee on Finance, 2010).  As presented in chapter 
two, various laws and regulations, policies, guidelines, and voluntary codes of ethics and conduct 
govern or provide oversight mechanisms for the environment (AdvaMed, 2010; AAMC, 2008 & 
2010; ACCME, 2004; ACGME, 2007; AMA, 2011; PhRMA, 2010; U. S. FDA Office of Policy, 
1997; U. S. DHHS OIG, 2003; & U. S. Senate Committee on Finance, 2010).  As a result, 
regulators, accredited organizations, and other interested stakeholder groups have created 
quantifiable mechanisms, e.g., questionnaires, surveys, attestations, and third-party evaluations, 
that are intended to ‘manage and resolve’ perceived conflicts of interest that may impact a 
decision in the academic areas of teaching, research, or patient care.   
The above-mentioned regulators, Congress, and professional organizations continue to 
investigate the environment.  As presented in chapter two, a literature and research gap appeared 
to exist regarding how physicians have historically processed the resolution of perceived 
conflicts of interest (COIs) but also how in the future they may manage their resolution of 
potential COIs.  In the resolution process, physicians make ethical decisions about moral issues 
and, as such, the study explores physicians’ possible role as moral agents in the process (Jones, 
1991; Lo & Field, 2009).  Therefore, through application of Jones’ (1991) theoretical framework 
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to three case scenarios, the data presents evidence through interview data of how faculty as 
individuals may manage and resolve COIs which supported the rationale for a qualitative, 
grounded theory study. Strauss and Corbin (1998) define grounded theory as an existing or 
emerging theory that is grounded in the participants’ perspectives and observations and could 
provide insight, enhance understanding, or generate action.  Strauss & Corbin’s definition of 
grounded theory confirms that perspectives of physicians as interview participants were essential 
to studying ethical decision-making. 
The gap, in concert with the dynamic and interacting nature of the three constructs 
discussed in chapter two – university-industry relationships, commercialized organizational 
structures, and faculty financial relationships with industry – invited a naturalistic, inductive 
approach, encouraged insight and understanding, promoted rich descriptions and explanations 
from participants in the social context, and made the world visible for observation, interpretation, 
and experiencing.  In the study, I approach grounded theory from a constructivist viewpoint, 
even though I use a theoretical framework as a guide which would indicate a positivist approach.  
The constructivist approach also focuses on analyzing the process of ethical decision-making, 
results, and influencing factors of physician actions and interaction with industry.  Additionally, 
the constructivist approach permits physicians, as participants in their natural settings, to present 
various meanings and perspectives through case scenarios that confirm the social and historical 
significance of COI management and resolution.   The participants also shared personal 
experiences as confirming or divergent opinions and philosophical points of view either during 
the discussion of the case scenarios or as concluding comments to the interview which further 
contributed to affirming a grounded theory methodology (Charmaz, 2006; Creswell, 2003; 
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Denzin & Lincoln, 2000, in Ritchie & Lewis, 2004; Glesne, 1998; Maxwell, 2005; Miles & 
Huberman, 1994; Ritchie & Lewis, 2004).   
Scrutinizing the COI resolution process as a qualitative study contributes to a greater 
understanding of the concept by identifying and examining its features and how they inform the 
process of ethical decision-making.  An analysis of the interview data provides insight into 
physicians’ understanding of and approach to ethical decision-making.   
As the researcher, I did not consider quantitative methods for the study.  A quantitative 
approach would present a confirming or refuting picture of data outcomes of physicians’ 
financial relationships with industry.  Additionally, it would not have presented a full 
understanding of the processes that are inherent to making individual, ethical decisions within 
the context of that interaction.  Applying a qualitative, grounded theory research design 
emphasizes process rather than solely emphasizing results which is more indicative of a 
quantitative approach.  Processes viewed from different perspectives have duration whereas 
people, places, and their interactions are constantly changing and allows for interpretation of 
what is being studied (Charmaz, 2006; Creswell, 1998; Creswell, 2003; Glesne, 1998; Maxwell, 
2005).  Grounded theory provides insight into the processes that would lead to possible outcomes 
regarding ethical decisions, as defined in Maxwell’s five intellectual goals and three practical 
goals.  
 Maxwell’s (2005) five intellectual goals include (1) understanding the meaning, (2) 
understanding the particular context, (3) identifying unanticipated phenomena and influences, (4) 
understanding the process by which events and actions take place, and (5) developing causal 
explanations.  Maxwell’s three practical goals encourage (1) generating results and theories that 
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are understandable and experientially credible to those being studied and others, understanding 
the process, (2) conducting formative evaluations to improve existing practice, and (3) engaging 
in collaborative research with research participants. Maxwell’s intellectual and practical goals 
support and further demonstrate the viability of a qualitative, grounded theory study. 
 My pilot study supported Maxwell’s (2005) intellectual goals with a particular emphasis 
on understanding the context of my dissertation study.  The purpose of the pilot study was to 
examine the effect of commercialization on higher education, the increasing regulatory demands 
placed on continuing medical education (CME), and the consequential need of CME units to 
balance fiscal responsibility and commercial involvement.  Kurt Lewin’s Three-Step Change 
Model (Robbins, 2003) was the lens through which the changing environment and its effects on 
CME were explored, placing CME units between a ‘rock and a hard place.’  The pilot study was 
also a qualitative study incorporating two individual interviews in addition to one focus group of 
four consisting of two faculty members, one of whom was also a departmental administrator.  
The other two participants included an academic administrator and a hospital administrator. All 
participants had regularly interacted with CME and offered different perspectives of the 
commercialization trend in higher education often presenting a point-counterpoint discussion.  
Two findings emerged, the first of which indicated that, as higher education becomes a 
more corporate structure, the effect of commercialization encourages establishing external 
partnerships with industry to supplement budgets.  The second finding recognized a struggle 
between the ethics of relationships with industry and departmental fiscal accountability.  Both 
findings supported the need for further research and  a more in-depth examination, beyond CME, 
of the environment in a broader context of faculty involvement in teaching, research, and patient 
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care.  The pilot study also influenced the design of this study to explore ethical decision-making 
theory in a commercialized environment through one-on-one interviews.   
Rationale for Constructivist Grounded Theory 
 Constructivist grounded theory is an inductive approach that allows for the researcher’s 
interpretation of data gathered during the interviews.  This approach provides an abstract 
understanding of the interaction of the participants’ multiple viewpoints of their situations and 
experiences with other data sources.  As the researcher conducting one-on-one interviews, I have 
the opportunity to actively listen to how the participants construct and interpret meaning in the 
process of conflict of interest (COI) management and resolution through case scenarios. 
Researcher reflexivity, discussed later in this chapter under Role of the Researcher, was essential 
because constructivists connect facts and values which reinforces Jones’ (1991) ethical decision-
making model as a framework for the study.  A resulting theory that emerges from data analysis 
is, in and of itself, an interpretation that may confirm a presupposed theory, enhance or expand 
an existing theory, or develop a new theory (Charmaz, 2006; Creswell, 2003).   
Consideration of Other Methodologies 
 Phenomenology. 
 A phenomenological study promotes the exploration of the meaning of the subjective, 
everyday, lived experiences of individuals about a concept and, as in this study, from a 
constructivist perspective.  This approach allows participants to express their views through 
open-ended questions concerning a current issue   Phenomenology explores intentionality which 
is based on Husserl’s 1913 work and involves both the act and object of consciousness in human 
experiences. Phenomenology is also conducive for studies in the health sciences which is the 
 91 
professional environment of the study (Creswell, 1998; Creswell, 2003; Patton, 2002).  Creswell 
summarizes the procedure of a phenomenological study as follows: (a) the research should 
understand the philosophical perspective behind the study; (b) research questions should explore 
meaning and allow for description of the lived experiences; (c) data collection is from those who 
have actually experienced the phenomenon; and (d) data analysis should follow steps utilized in 
all psychological, phenomenological methods.  Fundamental to phenomenology is the 
description of lived experiences which could vary among the participants being interviewed.  
Grounded theory, on the other hand, allows for continuity of data collection and analysis.  As the 
research instrument, I accomplish this by presenting the same three case scenarios to all 
participants. 
 The focus of the study was ethical decision-making in individual resolution of conflicts 
of interest that present themselves to academic physicians in their roles of teaching, research, and 
patient care and their potential consequences.  A phenomenological approach appeared to be a 
propos to the study based on the study’s setting, Creswell’s criteria above, and supported by a 
quote from Patton (2002, p.14), “doctors who look only at test results and don’t also listen to 
their patients are making judgments with inadequate knowledge, and vice versa.” Although the 
study appeared to be obvious for a phenomenological study; with valued guidance from my 
committee, I chose grounded theory methodology.  Grounded theory places emphasis on the 
process of ethical-decision making as reflected in Jones’ model (1991) versus focusing on the 
issue at the center of a conflict of interest (COI) that generates the process.   
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Case Study. 
 Additionally, I considered a case study design which is defined as an in-depth 
investigation of a unit of analysis and of its characteristics within a bounded context.  A case 
may be an individual, group, culture, phenomenon, or entity; and a study may consist of one case 
or of several.  However, the focus of the study suggested the need for greater emphasis on 
process and anticipated outcomes rather than cases. Therefore, grounded theory was the best 
suited methodology for the study which examines the process that entails the management and 
resolution of conflicts of interest through ethical decision-making (Creswell, 1998; Creswell, 
2003; Gay & Airasian, 2000; Lincoln & Guba, 1985; Miles & Huberman, 1994; Patton, 2002; 
Strauss & Corbin, 1998).   
Role of the Researcher 
 In qualitative research, the researcher or investigator is the research instrument and must 
establish credibility which is dependent on the researcher’s skill, competence, and rigor of 
fieldwork while recognizing the effect of distractions.  Variations in skills and objectivity should 
be counterbalanced by the researcher’s flexibility, insight, and assumed knowledge base that is 
unique to being a human research instrument.  For these reasons, the researcher as the instrument 
of inquiry should adopt a position of empathic neutrality providing a balance between 
detachment and being too involved.  It is crucial for a qualitative researcher, as the instrument, to 
establish credibility and disclose assumptions and biases that could influence the study.  
Therefore, I describe my background and qualifications below for conducting the study.  I also 
disclose my assumptions and biases as well as how I address them with respect to fairness and 
balance of perspectives and findings (Lincoln and Guba, 1981 in Patton, 2002; Patton, 2002). 
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Professional Background 
 I have been a continuing medical education (CME) professional in an academic medical 
center since 1993 and director of CME since 2004.  Prior to my current position and with the 
exception of three years, my professional life has been in continuing education beginning in 
1979 and within a variety of disciplines that provided a breadth of professional experiences.  
Through my academic career, I have been exposed to three different institutional settings – a 
college of business in a four-year, public land-grant university, a general conference 
development department in a large community college, and currently, an academic medical 
center of a four-year private university.  The diversity of these institutional settings equipped me 
with a greater understanding of the governance and fiscal climates inherent to each institutional 
type and the general, yet varied, resources, challenges, and philosophies of funding. 
 The organizational structure of academic medical centers (AMCs) is the setting of the 
study and is reflective of my current professional environment.  As the research instrument and 
sensitive to the need for empathic neutrality; my knowledge of an AMC enhances my credibility 
to conduct the study through professional experience and institutional involvement with the 
responsibilities of: 
 Employing accepted mechanisms to resolve perceived conflicts of interest (COIs) of 
physicians who are participating in CME activities; 
 Interacting with industry, primarily pharmaceutical and medical device companies, to 
secure supplemental funding of CME activities;  
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 Assuring compliance with and maintaining documentation of accreditation as well as 
adhering to regulatory and institutional policy requirements in the abovementioned 
functions; and 
 Engaging in discussions to resolve apparent COIs using the requisite regulations, 
policies, and accreditation tools designed for that purpose. 
Contributing further to my background knowledge and qualifications is my institutional 
involvement on two university compliance committees, clinical and teaching/administration, in 
addition to the committee charged with writing a policy for physicians’ interaction with industry.  
The policy reflects the revised PhRMA Code as well as the essence of the revised AdvaMed 
Code and covers issues relevant to gifts, entertainment, samples, ghostwriting, speaker bureaus, 
etc.   
Pertinent to the focus of the study, it is important to disclose that my department received 
a grant from a pharmaceutical company in 2012 to conduct a non US-based evaluation study on 
the effects of a professional educational intervention on implementing the appropriate protocol 
for stroke prevention and treatment of patients with atrial fibrillation. As the principal 
investigator, I received no salary support or other funds from the commercial source.  I disclosed 
my financial relationship of research support to my university and, in all CME disclosure 
documents, as required by the ACCME, for the life of the project and exceeding the twelve-
month disclosure requirement. 
With a high prevalence of stroke in China, the symposium was held in Shanghai, China 
with a follow-up retrospective chart review to determine efficacy of the symposium content.  
Individuals involved with the study included physicians and other professionals with expertise in 
education, evaluation analysis, cardiology/atrial fibrillation, public health, and global health 
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systems and policy.  Since the grant was an educational grant, not a clinical research grant, and 
housed in my department; the IRB required that I, as the director, be the principal investigator for 
the study.  It was my responsibility to assure independence in content development and mitigate 
the potential of commercial influence and bias.   The IRB also required that all investigators in 
the study be HIPAA-compliant per university policy and CITI-certified by completing three 
courses offered through the Collaborative Institutional Training Initiative (CITI Program), which 
was established in 2000 for the purpose of supporting quality and public trust in research.  The 
courses covered the responsible conduct of research, human subjects research (social sciences 
module), and conflicts of interest (COI).  The COI module was case-based and encouraged the 
learner to be cognizant of all of the facts and to analyze and answer the questions based on the 
evidence.   
Concurrent with receiving the commercial grant funds and preparing for implementation 
of the evaluation study, I was scheduling interviews, as a graduate student, for my dissertation 
study, completing the CITI program, and continuing my professional responsibility of resolving 
potential COIs for CME educational activities which made me acutely aware of being embedded 
in the world that I was studying.  Being responsible for the integrity of these concurrent activities 
allowed for a triangulation of sources that continually informed and challenged me in avoiding 
potential conflicts of interest without bias and undue influence in each of my roles as a student, 
researcher, and professional.  While my experience and knowledge contribute to my capability to 
conduct this study, they are also fundamental to the effects of my personal and professional 
assumptions and biases on the study.  This premise is further supported by the American 
Psychological Association (APA) in its 2010 publication manual which states that “in all 
scientific disciplines, professional communications are presumed to be based on objective 
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interpretations of evidence and unbiased interpretation of fact…although such relations 
[commercial interests] do not necessarily constitute a conflict of interest, … (APA, 2010, p. 17).” 
Researcher Assumptions and Biases  
The challenges presented in resolving conflicts of interest and interacting with industry 
create a need for preserving a high degree of ethics and professionalism.  This balance is 
sustained through disclosure, transparency, and independence, which collectively constitute an 
academic ‘firewall.’  If a company is willing to provide funding to an academic medical center in 
the form of a research grant or funding for an educational activity, the company has a vested and 
commercial interest in collaborating with the institution and its faculty.  Industry’s involvement 
is documented through contracts or letters of agreement and managed by institutional conflict of 
interest and commitment policies and procedures, disclosure to relevant audiences, and federal 
regulatory oversight by the U. S. FDA (1997) and the U. S. DHHS OIG (2003).  A conflict can 
emerge with the intent of the funds.  For what purpose are funds being solicited and accepted – 
educational grants to offset costs, collaborative research, or other?  As grantors of commercial 
funds, are the companies participating for physician benefit, enhancement of medical knowledge, 
improvement of patient care, advancing research, or product promotion? 
Companies collectively referred to as industry are actively involved in conducting 
research studies and clinical trials with academic institutions, providing the most current, cutting-
edge information for practicing physicians and other healthcare professionals whose ultimate 
goal is to advance science for optimal patient care.  Are the findings of these studies that are 
released to the public reflective of untarnished data, or are the data manipulated to favor the 
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expected, positive outcomes of the drug or device?  Potential financial risks and benefits can be 
associated with research findings. 
 My biases are embedded in these assumptions.  As indicated previously, I assert that 
healthy university-industry relationships are important for the advancement of knowledge and 
science, the study of medicine, and technology transfer, thereby contributing to the marketplace. 
However, I struggle with specific and sometimes ambiguous views of commercialization of 
higher education and if the public good is always the beneficial recipient of these relationships.   
From an academic point of view, the long-standing tradition of the academy has changed with an 
increased emphasis on a corporate model in which knowledge can be viewed as a product for 
sale.   
Taking my limitations into consideration, I sought a theoretical framework that would 
address moral judgment and consequences inherent to individual ethical decisions, and I selected 
physicians as interview participants who may currently have or have had financial relationships 
with industry in the past.  I employed the following methods to address my biases. 
Methods to Address Subjectivity and Bias 
 I explored and continuously monitored my research subjectivity, intersubjectivity, and 
biases through personal and professional lenses and addressed my perspectives of the study in 
the discussion of my role as the researcher.  By writing field notes, member-checking, and 
including verbatim accounts from the transcribed interviews in the findings, I monitored my 
subjectivity, research reflexivity, and empathic neutrality.  Using direct quotes from the 
participants minimized the influence of my points of view and interpretation, regardless of 
whether they were confirming or opposing views (Charmaz, 2006; Creswell, 2003; Gay & 
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Airasian, 2000; Glesne, 1998; Maxwell, 2005; Miles & Huberman, 1994; Patton, 2002: Strauss 
& Corbin, 1998). 
Through research reflexivity, I enhanced the use of verbatim quotes by reflecting about 
my own voice and perspectives which, in turn, contributed to establishing my credibility as the 
research instrument.  A credible researcher’s voice communicates legitimacy and trustworthiness 
and is ‘reflexive in consciousness’ (Patton, 2002).   Maxwell (2005) discussed Hammersley and 
Atkinson’s (1995) definition of ‘reflexivity’ as the researcher being part of the social world he or 
she studies.  I am the researcher in that context. 
Glesne and Peshkin (1992, p. 38, in Maxwell, 2005) view subjectivity as “virtuous, 
something to capitalize on rather than to exorcise,” which better defines the role of empathic 
neutrality in addressing subjectivity.  Empathic neutrality suggests a balance between being too 
involved which can affect one’s judgment and remaining too distant which may lead to 
diminished understanding of the case (Patton, 2002).  As part of my conscious inquiry process, I 
drew upon my experiential background of knowledge, personal observations, and understanding 
as well as critical subjectivity or the quality of awareness (Strauss, 1987, in Maxwell, 2005; 
Reason, 1988 and 1994, in Maxwell, 2005). 
As my professional contributions were described above, my experience, awareness, and 
understanding of the study environment are intended to strengthen and add value to the study as 
well as credible depth to my role as the researcher, which should be viewed as an asset to the 
study.  However, the reader should also approach the interaction of my background and the study 
with caution with the intent of reducing the potential for researcher bias.   
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Research Plan 
Sampling 
 Purposeful sampling requires strategic and purposeful selection of information-
rich cases and is the technique by which I selected participants for the grounded theory study, 
implementing a theory-based or operational construct sampling strategy (Creswell, 1998; 
Creswell, 2003; Miles & Huberman, 1994; Patton, 2002).  “The strength of interviewing 
information-rich individuals allows the researcher to learn a great deal about issues of central 
importance to the purpose of the inquiry with insight and a more in-depth understanding (Patton, 
2002, p. 230).”  According to Miles and Huberman (1994), successful purposeful sampling, 
which is often theory-driven, requires two stipulations.  The first is that the researcher should set 
boundaries, defining aspects of the cases that can be studied within limits of time, place and 
means.  Upon receiving approval from the University of New Orleans’ Institutional Review 
Board (IRB), I acquired formal access to two institutions, one private and one public.  The 
institutional gatekeepers identified a group of twenty medical faculty participants from which I 
was able to successfully schedule and conduct ten interviews (50%).  I accomplished this in three 
ways – (1) by determining that the interview would take no more than sixty minutes unless the 
interviewee wished to continue the dialogue; the average interview lasted forty-five minutes;  (2) 
by conducting the interview on the interviewees’ campuses which are representative of the 
setting of the study and at locations of their choosing which were usually in their academic 
offices or conference rooms; and (3) by establishing selection criteria to achieve a strong 
representative cohort of interviewees including academic roles and financial relationships with 
industry.  Secondly, the researcher should create a framework that will assist in uncovering, 
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confirming, or qualifying the basic processes or constructs of the study (Miles & Huberman, 
1994) which is discussed later in this chapter.   
Maxwell (2005) discusses four of several important goals that Creswell (2003) identifies 
for purposeful selection: (1) achieving representativeness or typicality of the settings, 
individuals, or activities selected; (2) achieving the opposite of the first goal…capturing 
heterogeneity in the population; (3) deliberately examining cases that are critical for theories 
with which you begin the study or will develop; and (4) establishing particular comparisons to 
illuminate the reasons for differences between settings or individuals.  The process of purposeful 
sampling requires two additional conditions – clear objectivity of the researcher in order for the 
sample to be independently examined and the opportunity for the cases to be proven or disproven 
(Ritchie & Lewis, 2004). 
Participant Selection 
 The participants who were identified and selected for the interviews contributed to an 
understanding of ethical decision-making by physicians who have financial relationships with 
industry.  Furthermore, selecting interviewees in two academic medical centers, one private and 
one public, provided potential comparison and contrast of perspectives which could be affected 
by respective institutional, contextual settings (Creswell, 1998).  I met the heterogeneity goal by 
interviewing physicians who represented a gender mix, a diverse range of years of experience 
and academic titles as well as a variety of specialties in adult and pediatric medicine (Table 1).  
The two selection criteria, faculty members in an academic medical center or school of medicine 
and financial relationships with industry, met the goals stated above. 
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Table 1:  Faculty Participant Profile 
Participant 
Faculty 
Gender 
Specialty 
Institutional 
Type 
Years in 
Academic 
Medicine 
Amanda Female Pediatrics Private 25 
Ben Male Psychiatry Private 16 
Daniel Male Pediatrics Private 13 
David  Male Internal Medicine Public 25 
Edward Male Surgery Public 36 
Grace Female Pediatrics Private 10 
Karen Female Preventive Medicine Public 22 
Jim Male Anesthesiology Private 6 
Molly Female Pediatrics Public 18 
Oliver Male Internal Medicine Private 13 
 
Of the ten participants, six (60%) were men and four (40%) were women (Table 2) which 
proved to be representative of the population and context of the study.  The Federation of State 
Medical Boards (FSMB) data, reported in 2015, represent active medical licenses in the United 
States excluding medical residents for the 2014 calendar year (Young et al, 2015).  Also in 2015 
and specific to the academic setting of the study, the Association of American Medical Colleges 
(AAMC) data represent all clinical, medical faculty in U.S. medical schools for the 2014-2015 
academic year. 
Table 2:  Faculty Participants by Gender 
Faculty 
Gender 
Study 
Participants 
Licensed Physicians 
FSMB (2014) 
U.S. Medical Faculty 
AAMC (2014-2015) 
Female 4 (40%) 293,565 (32%) 52,179 (38.5%) 
Male 6 (60%) 604,926 (66%) 83,022 (61%) 
Unknown 0 (0%) 17,773 (1.9%) 73 (.5%) 
Total 10 (100%) 916,264 (100%) 135,274 (100%) 
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 The gender summary (Table 2) of the study participants is in proximate alignment with 
the FSMB and AAMC data.  The percentage of female participants (40%) in the study is in very 
close alignment and, by 1.5%, exceeds the AAMC percentage of female medical faculty at 
38.5%.   The percentage of male participants (60%) is below the FSMB percentage of 66% but in 
close alignment, by 1%, with the AAMC percentage at 61%.  These data indicate that the gender 
breakdown of the study sample (40% female and 60% male) is representative of the medical 
faculty population in U.S. academic medical centers (AAMC, 2015). 
Consistent with purposeful sampling and one-on-one interviews, the individuals who 
participated were ‘information rich’ providing insight and an in-depth understanding of the 
conflict of interest (COI) management and resolution process.  Therefore, I selected the 
participants by utilizing the theory-based, operational construct sampling strategy of purposeful 
sampling, also referred to as theoretical sampling, to examine the concept through their reactions 
to case scenarios, thereby contributing to an evolving theory.  Theoretical sampling continues 
until saturation of all categories or themes occurs.  The data collected from conducting ten 
interviews suggested that saturation was achieved (Creswell, 1998; Miles & Huberman, 1994; 
Patton, 2002; Strauss & Corbin, 1998).    
Only the two selection criteria, previously discussed, were used to identify study 
participants.  Age and years in academic medicine were not used as participant selection criteria 
for the following reason.  The physician-industry relationship has evolved considerably over the 
last thirty years and with a more recent acceleration of restrictions, primarily by Congress, that 
govern the relationships.  Therefore, a variety of participants from two institutions was a better 
representation and reflection of the population spectrum and the evolution of the process being 
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studied.  Gatekeepers at the two sites contributed to identifying potential participants who could 
possibly meet the relevant criteria. 
Institutional Descriptions 
 Schools of medicine at two institutions of higher education, one public and one private, 
both not-for-profits, were the settings for the faculty interviews.  The Carnegie Classification of 
Institutions of Higher EducationTM in its basic classification of 2010 categorized both institutions 
as Research Universities, very high research activity (RU/VH).  Of the 4,634 institutions that 
were classified in 2010, 73 public universities and 35 private, not-for-profit universities 
comprised the 108 (2.3%) that Carnegie categorized as RU/VH.  The Carnegie Foundation for 
the Advancement of Teaching offers the classification framework with the goal of characterizing 
institutional differences and confirming sufficient representation of institutions, students, or 
faculty for inclusion in research studies such as this one. 
 With the exception of the governance distinction, public versus private not-for-profit, the 
two universities were very similar.  Both universities have significant graduate and professional 
programs at the masters and doctoral levels. They have institutional conflict-of-interest policies 
for faculty and staff in addition to policies that govern and restrict physicians’ interaction with 
industry.  The interview participants, all ten of whom are actively engaged in research activity, 
frequently referenced their own policies during the interviews and, without exception, spoke of 
their policies with appreciation of intent and valued their contributions to the reputation of their 
respective universities.  The policy comments were offered especially when I inquired about 
their past or current relationships with industry, which are noted in the participants’ composite 
profile in chapter four. 
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Gaining Access. 
Purposeful selection of participants, who are representative of the context of the study, 
requires establishing clear selection criteria and rationale of the study prior to beginning the 
process of gaining access, negotiating relationships, and establishing rapport with participants 
and gatekeepers who could influence the study.  I initially contacted a faculty member who is in 
a senior leadership role within my own institution to introduce me to a professional colleague 
who would fulfill the role as gatekeeper at a private institution in another state that I had 
identified as one of two institutions for the study based on the selection criteria noted above.   
Secondly, I contacted a professional colleague at a public, out-of-state institution I had identified 
for the study who directed me to their IRB who, after review, declined my request to conduct the 
study with its faculty.  I subsequently contacted another public university in a different state who 
granted me permission to interview their faculty for my study.  The gatekeeper in the private 
institution gave me a list of thirteen potential participants to contact, and the gatekeeper in the 
public institution gave me a list of seven potential participants.   
 The gatekeepers at both institutions were in senior leadership roles and had the authority 
to grant access to their institution and faculty and to establish contact with their respective IRBs.  
Each IRB indicated that no further review and approval was necessary.  I presented the 
gatekeeper at each institution with a prospectus (Appendix F) for consideration of my request. 
The prospectus described the study including an explanation of why their institutions were 
selected, how the study would be conducted, assurance that disruption would be minimal, how 
the results would be reported, benefits from the study, and finally, that the aggregate results 
would be available to them upon successful completion of the study.  The negotiation process 
required continuous and professional communication that resulted in successful formal access 
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and verbal confirmation that the study has merit to the field (Creswell, 1998; Creswell, 2003; 
Glesne, 1998; Maxwell, 2005). 
Ethical access also demands that the researcher protect the confidentiality and identity of 
the participants.  I accomplished this by de-identifying the individual participants and the 
institutions as well as not discussing the specifics of what is learned in the interviews but rather 
presenting the data in terms of general concepts and de-identified quotes which uphold 
confidentiality.  I assured confidentiality by several methods:  (a) in a letter of invitation for their 
participation (Appendix G), (b) mutual signing of a consent form by the participants and the 
researcher (Appendix H), and (c) presentation of aggregate, conceptual data in the findings.  I 
protected identifiable participant information by de-identifying and maintaining confidentiality 
through the use of pseudonyms during the interview and/or with reference to Interviewee #1, 
Interviewee #2, etc. in the subsequent transcriptions, data analysis and discussion (Creswell, 
1998; Glesne, 1998; Patton, 2002).  Only descriptions of the institutions were used for the 
purpose of de-identifying them and adding another level of confidentiality for the participants. 
Data Collection 
In addition to the interviews that lasted thirty to sixty minutes, data collection for the 
study came from two other sources – environmental scanning and supporting documents 
(Creswell, 2003), which were presented in chapter two.  Since the documents and the 
environment are fundamental to the significance and purpose of the study, they were essential 
sources of data.  Both of these data sources were primarily intended to support triangulation, 
serving two purposes – (1) to validate interview questions about COI policies, regulatory 
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environment, and physicians’ financial relationships with industry, and (2) to either confirm or 
refute perceptions and interpretations of the participants.   
The participants’ responses to the concluding general questions presented observational 
data of their views of the professional environment.  The environment, policies, and related 
documents from the AMA, AAMC, IOM, ACCME, ACGME AAUP, FDA, DHHS OIG and 
other federal regulatory and institutional sources (see List of Organizational Acronyms, p. xi.) 
established the context of the study and continue to serve as professional guidance and 
governance of the medical profession. The purpose of interviewing individuals was to discover 
things that cannot necessarily be observed and to allow an opportunity to hear and understand 
another person’s perspective through the voice of the individual physician (Patton, 2002).  Of the 
three interview approaches that Patton (2002) describes (informal conversational interview, 
general interview guide approach, and standardized open-ended interview), I implemented the 
general interview guide approach for individual interviews.  The general interview guide 
approach employs a well-defined question list to be used during the interview for probing a 
specific subject area, which in this study is conflicts-of-interest. 
When conducting one-on-one interviews, the advantages of an interview guide are three-
fold: the guide (1) maximizes a limited time frame, (2) establishes continuity for a platform of 
emergent perspectives and experiences, and (3) provides a framework for more in-depth 
discussion.  Doing so strengthens consistency of information gathered and assures that I, as the 
researcher and interviewer, use time carefully and efficiently, allowing individual perspectives 
and experiences to emerge (Patton, 2002). 
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In developing the questions for the interviews, I paid particular attention to utilizing 
several of Patton’s (2002) six types of questions as well as what he describes as the appropriate 
sequence to encourage information building and maximizing interpretations of experiences.  His 
six types of questions evolve from (1) experience and behavior, (2) opinion and values, (3) 
feelings, (4) knowledge, (5) senses, and (6) background/demography.  It is the second (opinion 
and values), third (feelings), and fifth (senses) types of questions that may be the strongest in 
supporting Jones’ (1991) issue-contingent model of individual ethical decision-making.  This 
was due to the ethical decision-making model’s focus on moral intensity and its effects on 
recognizing a moral issue, making a moral judgment, establishing moral intent, and engaging in 
moral behavior.  The first (experience and behavior), fourth (knowledge), and sixth 
(background/demography) types of question gathered profile data of the individual participants 
that contributed to a composite profile. 
Rationale for Interview Method 
 Interviews provide access to observation and interaction.  They provide insight, a window 
on their past, into experiences, perceptions, feelings, exposure to settings otherwise not 
accessible, and effects of events on their lives (Weiss, 1994).  Of the several types of interviews 
methods considered for the study, one-on-one interviews were the most appropriate.  The one-
on-one interviews provided an opportunity for me, as the research instrument, to hear and share 
ideas and thoughts relative to the ethical decision-making in an academic setting (Creswell, 
1998).  Furthermore, it capitalized on the required ability of the interviewer to be an active 
listener, to respond to a spontaneous and unpredictable exchange, and to observe nonverbal and 
verbal feedback (Glesne, 1998; Patton, 2002).  Glesne stresses three key features of interviewing:  
structured – specific questions to address, open – questions as a result of unexpected points that 
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are raised, and depth-probing – points that prompt further explanation.  The individual 
interviews offered opportunities for structured, open, and depth-probing interactions between the 
interviewees and the researcher interviewer as demonstrated in the interview guide (Appendix I).  
Additionally, Glesne notes that the informal time after the taping ceases is a valuable learning 
opportunity providing casual discussion of the issue which occurred in five of the ten interviews 
and were very collegial conversations.  For example, at the end of Mary’s interview, she inquired 
about my project and its goals.  Beyond the brief introduction I gave at the beginning of each 
interview, her curiosity gave me an opportunity to articulate my ‘light-bulb’ moment, express my 
interest in the topic through experiential examples, and convey why I chose to study it through 
an ethical decision-making lens which was to give physicians a voice.  She responded, “It’s an 
interesting topic.” I agreed. 
Interview Guide  
The interview guide (Appendix I) consisted of stating the purpose of the study and then 
asking questions that, based on Patton’s (2002) six types of questions, explored individual 
abilities to make ethical academic decisions in the context of a commercialized and regulatory 
environment.  The questions encouraged more probing opportunities for in-depth discussions 
(Glesne, 1998; Patton, 2002). 
As the researcher, I piloted the interview guide with a peer debriefer within my institution 
to assure that the questions were unambiguous (Lincoln & Guba, 1985).  The peer debriefer has a 
strong working knowledge of the healthcare field in which the study was conducted as well as 
experience in conducting grounded theory studies.  She is also familiar with identifying and 
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resolving individual conflicts of interest (COIs) that emerge as a result of entering into a 
financial relationship with industry.  
 As suggested by Miles and Huberman (1994), to accomplish successful purposive 
sampling, the researcher should create a framework that will assist in uncovering, confirming, or 
qualifying the basic processes or constructs of the study.  I accomplished this by developing an 
interview guide (Appendix I) that consisted of three sections:  (1) general and demographic 
questions; (2) three case scenarios that examined the ethical decision-making model; and (3) a 
set of concluding questions about the environment pertinent to the study.   
Description of Interview Scenarios. 
 The case scenarios represented the three areas of academic medicine – teaching, research, 
and patient care – in which academic physicians could face potential conflicts.  The teaching 
case scenario involved a well-respected faculty member who teaches a skills-based course using 
donated equipment from three companies.  The faculty member owns stock in one of the 
companies and favors the use of that company’s equipment in demonstrating the procedure.  The 
second scenario presented a faculty researcher who is involved in a commercially-funded study.  
The researcher has extensive financial relationships with the funding company for whom the 
results are not evolving in a manner favorable to the company.  The researcher struggles with the 
unfavorable results and a sense of obligation to the company due to his financial relationships 
with the company. The final scenario involved an academic physician who retired from a 
successful career in the pharmaceutical industry (Company E) and is now clinical faculty at 
his/her alma mater. Because of the faculty member’s familiarity with Company E’s drugs, he/she 
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tends to prescribe Company E’s drugs more frequently when other treatments may be equally or 
more effective in certain cases. 
 Collection of Data from Interview Scenarios. 
 I audio-recorded the interviews (Creswell, 1998; Creswell, 2003; Patton, 2002).  Doing 
so allowed for greater attention to the interviewee versus taking verbatim notes which can hinder 
active listening, for careful observation of non-verbal reactions, and for actual quotations from 
the participants.  I began the interview with gathering participant profile information and then 
asking for their definition of a conflict of interest which provided a transition into the scenario 
segment of the interview.  For reference during the interview, I gave each participant 
descriptions of the scenarios as each was presented and a list of questions to examine.  Following 
their assessments of the three scenario discussions, I posed six concluding questions that 
addressed themes or assumptions relevant to the scenarios, such as reasons physicians enter into 
financial relationships with industry, risks and benefits of such, and bias avoidance.  I also gave 
each participant an opportunity to offer additional remarks.  During the interviews, I only made 
notes of key phrases or points for follow-up or clarification.  Following the interviews, I also 
made notes that were reflexive or observational in nature (Patton, 2002).  At the conclusion of 
one interview, the participant commented – 
I think it’s interesting to explore this.  I think the manner of doing it by cases is very 
interesting as well.  As someone who has also done qualitative research, I actually like 
the way you had some general questions, some cases, and the other things to digest.  I 
think, as an interviewee, that actually facilitated the process of thinking through this 
(Oliver). 
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Data Analysis 
Data analysis in grounded theory should always occur concurrently with data collection, 
a cyclical process which assists with shaping the study and presents an opportunity during which 
the researcher should consistently write reflections for greater depth of understanding of the data.  
Strauss and Corbin (1998, p. 13) emphasize that “analysis is the interplay between researchers 
and data.”  They further emphasize the importance of finding a balance between being creative 
while being systematic in the data analysis stage of the study.  Patton (1990, in Strauss and 
Corbin, 1998) advises grounded theory researchers to adopt behaviors that would promote 
creativity such as exploring multiple possibilities and options, using nonlinear forms of thinking 
to encourage fresh perspectives, trusting the process, and having fun.  I took precautions to 
minimize risks by engaging in epoché to refrain from my personal prejudices, beliefs, and 
viewpoints and in reflexivity to be continuously conscious and self-questioning of the same.  I 
also categorized the data allowing the voices of the participants to be heard in their own words to 
minimize subjectivity (Creswell, 2003; Patton, 2002).     
Coding Procedures 
In the grounded theory tradition, the systematic aspect of data analysis involves a three-
step coding procedure of the interview transcriptions. The initial step of the analytical procedure 
includes making reflexive notes immediately upon conclusion of the interview, while listening to 
the audio-recorded interviews, and during transcription.  In the course of re-reading the interview 
transcriptions, I made margin notes, identified key concepts, categories, and subcategories 
(properties) of information through the interviewees’ words and phrases.  A few words and 
phrases, e.g. bias, familiarity, influence, and ‘slippery slope,’ are considered in vivo codes which 
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were the participants’ distinctive terms that gave special meaning to their assessments of an 
ethical decision-making process (Charmaz, 2006). 
I initiated the data reduction process with open coding, the first step in the coding 
procedure, illustrating the process being explored which, for this study, was ethical decision-
making.  The second step was axial coding.  During this step, I identified interrelationships 
between concepts and categories (units of information) and narrowed down the most significant 
categories or central phenomena for theory development.  Selective coding, the third and final 
step was the point at which I modified Jones’ (1991) ethical decision-making model based on the 
perspectives of the participants (Charmaz, 2006; Corbin & Strauss, 2008; Creswell, 1998; 
Creswell, 2003; Patton, 2002; Strauss & Corbin, 1998).  The code list presented evidence of the 
theoretical framework and the moral intensity characteristics of Jones’ (1991) ethical decision-
making model (Miles & Huberman, 1994).  Coding links raw data to raw data then to contextual 
themes establishing the foundation for drawing and verifying findings (Coffey & Atkinson, 
1996).  I verified the findings through triangulation and establishing trustworthiness (Creswell, 
1998; Creswell, 2003; Lincoln & Guba, 1985; Miles & Huberman, 1994; Patton, 2002). 
Trustworthiness 
Lincoln and Guba (1985) define trustworthiness as the methods by which the researcher 
can persuade the audience that the study is worthy of their attention.  This may be achieved by 
establishing confidence in the “truth” of findings, as well as the applicability, consistency and 
neutrality of findings (p. 218).  Guba (1981a, in Lincoln and Guba, 1985) developed four 
qualitative terms to address and substantiate trustworthiness of a study – credibility (internal 
 113 
validity), confirmability (objectivity), dependability (reliability), and transferability (external 
validity).    
 Credibility. 
Credibility of the study, which is defined in quantitative research terms as internal 
validity, refers to the strength of findings through the eyes of the information sources and truth 
value (Lincoln & Guba, 1985; Miles & Huberman, 1994).   Lincoln and Guba suggest five 
techniques for establishing credibility of which I employed two:  (1) activities intended to 
increase the probability of credible results through prolonged engagement, persistent 
observation, and triangulation; and (2) member checks.  I accomplished the first technique by 
describing my role as the researcher and drawing on over twenty years of professional 
experience through studying, observing, and engaging with the culture and context in which I 
conducted the study (also Patton, 2002).  Emphasizing the role of the researcher, Patton (2002) 
connects the trustworthiness of the person conducting the research and his or her competence to 
the trustworthiness of the data.  Additionally, I achieved triangulation and contextual validation 
through detailed discussions in the literature review of the environment and documents that 
guide and govern faculty relationships with industry as well as thick descriptions by the 
participants which Patton (2002) and Miles and Huberman (1994) refer to as triangulation and 
consistency of data sources.  I employed a member-check procedure, the second technique, by 
giving the participants an opportunity to review their respective transcripts for feedback and 
assuring accuracy.  Two of the ten participants requested their transcripts for review and 
subsequently verified accuracy. 
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Confirmability. 
Confirmability assures objectivity by establishing researcher neutrality (Lincoln & Guba, 
1985; Patton, 2002).  I used triangulation and included my own written reflections to establish 
objectivity.  Triangulation again involved collecting data from multiple sources to reduce the risk 
of bias and to support, confirm, or contradict the findings of the study (Creswell, 1998; Lincoln 
& Guba, 1985; Maxwell, 2005; Miles & Huberman, 1994; Patton, 2002).  Miles and Huberman 
distinguished triangulation among five methods, the first four of which were classified by Denzin 
(1978, in Lincoln & Guba, 1985):  data source, method, researcher, theory, and data type.   
Triangulation for the study was accomplished by methods that included interviews, 
environmental scanning, documents, and researcher knowledge and experience to reinforce 
trustworthiness with a specific emphasis on the objectivity of the researcher (Lincoln & Guba, 
1985; Miles & Huberman, 1994). 
Dependability. 
Dependability refers to the reliability of the study by establishing stability, consistency, 
and predictability.  In quantitative studies, there cannot be validity without reliability; therefore, 
in qualitative studies, there can be no credibility without dependability (Lincoln & Guba, 1985).  
Lincoln and Guba suggest that, while it is not the strongest approach, the same techniques 
utilized to enhance credibility and confirmability can contribute to addressing stability and 
consistency aspects of dependability.   
Miles and Huberman (1994) suggest questions to substantiate the reliability or 
auditability of the dependability criterion in establishing trustworthiness.  Among the queries that  
should be addressed or described are clear research questions and a consistent study design, the 
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role of the researcher and status in the context of the study, triangulation of data sources, and 
breadth of data collection with appropriate settings and respondents.  
Transferability. 
The fourth element of trustworthiness, transferability, is also referred to as external 
validity and generalizability in quantitative research methods (Lincoln & Guba, 1985).  
Transferability assumes the same feature of representativeness of the population (receiving 
context) while not being confined only to the researcher (sending context).   Addressing the 
appropriateness of transferability in the study was achieved through determining the design of 
the study and thick description from information-rich sources through the audio-recorded, 
individual interviews (Lincoln & Guba, 1985; Miles & Huberman, 1994; Patton, 2002).  The 
findings of the study should be transferable to other academic disciplines such as law, 
engineering, and business in which individual financial relationships with industry or university-
industry relationships also exist.  Regardless of the field, these relationships could generate 
conflicts of interest that require resolution through an ethical, unbiased decision-making process. 
Peer Debriefers. 
Bias plays a key and dual role in my study.  It is critical to the theory of ethical decision-
making and was equally as critical in my role as the researcher.  To mitigate my biases and 
assumptions and to add a secondary element to the trustworthiness of the study, I incorporated 
the peer debriefer technique which Lincoln and Guba (1985) explain is a disinterested peer who 
can reinforce credibility of the study.  Lincoln and Guba outlined the advantages as well as the 
risks of using a peer debriefer.  Among the advantages, a peer debriefer is a professional who is 
not involved in the study and may provide guidance in methodology, is a supportive and 
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considerate listener, or helps assure the researcher’s honesty by playing ‘devil’s advocate’ in all 
aspects of the study.  The risk of using a peer debriefer evolves from the influence of the peer 
debriefer’s perspectives and criticisms that could lessen the researcher’s enthusiasm and energy 
about the study. 
The peer debriefers for my study were professionals who have worked in the same 
academic institution as I and understand the environment in which the study was conducted.  
One peer debriefer received his PhD in higher education administration and was a fellow 
graduate student.   My second peer debriefer received her PhD in a related educational field, has 
professional and experiential knowledge of the healthcare environment, and conducted her 
doctoral study in the qualitative, grounded theory tradition.  Both of them actively listened for 
the purpose of strengthening the study and minimizing my biases. 
Conclusion 
In this chapter, I presented my rationale for a qualitative, grounded theory study in 
exploring ethical decision-making and its impact on academic physicians as teachers, 
researchers, and clinicians in a regulated, scrutinized, and commercialized environment.  
Instituting a grounded theory study design strengthened the many voices to be heard about the 
process of ethical decision-making as well as of the environment which provided the context of 
the study.  The findings are presented in chapter four and their implications for policy and future 
research are discussed in chapter five. 
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Chapter IV 
Findings 
Introduction 
 The purpose of the study was to develop a theory that represents how academic 
physicians, who have financial relationships with industry, manage or resolve potential conflicts 
of interest in their roles as teachers, researchers, and clinicians.  Secondarily, the study examined 
factors that influence an ethical decision-making process, characteristics of an ethical decision 
and how physicians’ relationships with industry impact an ethical decision.  The financial 
relationships may take various forms including, but not limited to, research funding, 
consultancies, speakers bureaus, scientific advisory boards, stock investments, or patent 
agreements. Requirements for disclosure of these financial relationships also extend to 
immediate family members.  
Thirdly, determining if there were underlying threats to academic freedom as a result of 
financial relationships with industry added a potential outcome to contemplate during the 
discussion of the case scenarios.  Through these discussions, the participants determined that 
academic freedom was minimally affected.  Their comments regarding academic freedom are 
presented and discussed later in this chapter. 
Using Jones’ (1991) issue-contingent ethical decision-making model as the theoretical 
framework for the grounded theory study provided the opportunity to explore the research 
questions through three case scenarios in teaching, research, and patient care.  The participants 
frequently offered their own experiential or interpretive accounts as well as divergent 
perspectives to clarify or enhance a discussion point or question.  Finally, the participants’ 
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vision, awareness, knowledge of the environment, and personal and professional views shared in 
the preliminary and concluding general questions added depth to the findings, identifying 
characteristics of the academic physician as a moral agent and a refined theory.  In addition to 
reporting the data, findings, and refined theory; this chapter presents a demographic profile of the 
participants, their assessment of the environment, and revised characteristics of a moral agent.  
Profile of Faculty Participants 
As described in chapter three, I contacted twenty potential participants of which ten 
(50%) agreed to participate in the study (Table 1).  Of the ten, I interviewed four faculty 
members at the public institution and six at the private institution. The faculty selection provided 
a rich variety of combined training, professional interests, industry relationships, and specialties 
in both adult and pediatric medicine as well as in other non-clinical, health science disciplines 
including anesthesiology, cardiology, epidemiology, general pediatrics, infectious diseases, 
internal medicine, law, pathology, psychiatry, preventive medicine, public health, and surgery.   
Three of the participants were department chairs which occasionally added an 
administrative dimension to the discussion.  The participants’ years in academic medicine ranged 
from six (6) to thirty-six (36) years with an average of eighteen (18) years.  Eight of the 
participants are currently involved in research, teaching, and clinical/patient care; and two are no 
longer involved in patient care but are actively engaged in research and teaching.  Of the ten 
participants, six (60%) were men and four (40%) were women (Table 2) which proved to be 
representative of the population and context of the study based on the FSMB (2015) and AAMC 
(2015) data discussed in chapter 3.   
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Table 2:  Faculty Participants by Gender 
Faculty 
Gender 
Study 
Participants 
Licensed Physicians 
FSMB (2014) 
U.S. Medical Faculty 
AAMC (2014-2015) 
Female 4 (40%) 293,565 (32%) 52,179 (38.5%) 
Male 6 (60%) 604,926 (66%) 83,022 (61%) 
Unknown 0 (0%) 17,773 (1.9%) 73 (.5%) 
Total 10 (100%) 916,264 (100%) 135,274 (100%) 
 
Regardless of other profile characteristics, their reasons for choosing a career in academic 
medicine were unequivocally the three academic missions of research, teaching, and patient care.  
They emphasized the importance of each with comments such as “you can only really do 
independent, directed research in an academic setting (Daniel);” “[I] became interested in studies 
that really evaluate the interventions we use, the treatments we propose…do they really work, 
are they worth it… how medical students are taught about the evidence that we have; if they are 
being taught to evaluate the evidence and how to read the literature (Karen);” and “[to] provide 
the best clinical care in the best sorts of environments (David).”  
The participants’ composite profile represents an academic physician that supports the 
advancement of the field of medicine through a commitment to scholarship and research and 
with consideration mindful of industry’s involvement in pursuit of these two missions.  The 
participants viewed and expressed the potential conflict between mission and having financial 
relationships with industry as a two-fold concern in which “a dual relationship may affect one’s 
objectivity in approaching a topic or…one relationship interferes with the performance of the 
other” (Oliver). Secondly, there was concern “when the interest of the mission of the physician is 
at odds with the interest of a commercial entity, and so choices are made that would advantage 
one entity versus another” (David). As conveyed in these quotes, the participants’ profile reflects 
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the academic physician’s awareness and sensitivity to ethical balance in the dual academic-
industry relationship when the participants identified research funding as the leading reason for 
industry support whether in support of clinical trials, industry-sponsored research, or 
investigator-initiated research.  Additionally, in collaborative research with industry, the majority 
of funding is given directly to the institutions, not to the individual, thereby creating a natural 
firewall against the potential for undue influence, bias, and mission conflict.  In essence, the 
moral and ethical responsibilities of academic physicians as scholars and researchers to various 
stakeholders involve independence and objectivity of thought, establishing implicit firewalls 
among roles, gatekeeper obligations, fiduciary commitment of trust and protection, and 
thoughtful balance of what one can or should not do for a company. 
Environmental Assessment and Observations 
 The study data offered an assessment of the environment and a deeper insight into what 
constitutes a conflict of interest (COI) and its effects on physicians and institutions by 
delineating reasons for entering into financial relationships with industry (Table 3) as well as 
associated risks and benefits.   The study data also suggested potential barriers to faculty 
performance, how bias should be avoided, potential effect of the Sunshine provision (Open 
Payments) of the Affordable Care Act, which will be discussed in chapter five, and finally, what 
factors could influence ethical, unbiased decision-making.  
In considering possible reasons physicians enter into financial relationships, the 
participant data presented several broad, environmental or institutionally-based, influencing 
factors that impact a decision to enter into a financial relationship with industry – (1) 
opportunities just present themselves when being in a certain specialty connects physicians to 
industry which can evolve into a mutually beneficial relationship, (2) the advantages of 
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academic-industry relationships including shared resources for the advancement of science and 
medicine, (3) institutional pressure to secure external funding due to a decrease in federal 
support of research as well as a decrease in institutional financial resources, (4) institutional 
culture and mission, and (5) tenure and promotion, although not considered to be a major 
influence. These influencing factors and other data supported specific reasons for entering into 
financial relationships with industry that evolved into three categories – reputation, money and 
funding, and research (Table 3).   
Table 3:  Reasons for Entering into Financial Relationships with Industry 
REPUTATION MONEY & FUNDING RESEARCH 
 
 Recognition in the 
professional community 
 Professional growth through 
engagement outside of day 
job 
 Contribution of expertise and 
background 
 Mutually beneficial 
 Shared expertise and 
networking 
 Opportunity to obtain better 
perspectives of a field 
 Ethical responsibility 
 Pride 
 Fame (narcissistic) 
 
 
 Student loans; debt 
 “Want money!” 
 Augmenting personal income; 
personal financial gain; salary 
supplement; minimal family 
income – should consider 
other options 
 Should be compensated if 
right person (expertise) to 
work with industry 
 Another revenue stream to 
institutions in support of 
mission; medical education is 
not directly supported by those 
who benefit from it. 
 Buy back more of my time for 
the institution 
 
 
 Promote advances in 
medical science 
 Contribution to medicine 
and patient care 
 Bring new drugs to market 
 Funding very beneficial to 
research 
 Source of research support 
 Survival as a researcher 
 Supplement research 
portfolio 
 Ethical responsibility 
 “on the ground” with 
development of drugs and 
devices.  
In assessing the risks and benefits associated with each category, the data corroborated 
the importance of the physician’s role as a moral agent in Jones’ (1991) model and suggested 
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characteristics or conditions that could create an obstacle or barrier to academic performance as 
well as ways to avoid the financial relationship becoming an obstacle.  The participants 
identified potential barriers or obstacles to performance that included the ability of money to 
shape the relationship; restrictive involvement based on institutional policies representing a 
firewall of sorts; the tendency to be more biased and scrutinized by peers; impaired decision-
making; conflicts with interests of learners and patients; and the frequency of interaction with 
company representatives that could increase the physician’s use of the company’s product, 
suggesting an individual’s human nature and need to express gratitude.  To avoid the relationship 
becoming an obstacle, the data proposed that physicians must be very conscientious; should, as 
part of their decision-making process, assess the effect of engaging in a financial relationship 
with a company prior to entering into a relationship; and finally, as the participant Ben conveyed, 
“…in the current, more challenging environment, be alert for biases that can easily creep in.” 
Reputation 
The first of the three reason categories for entering into financial relationships with 
industry focuses on the individual faculty’s reputation which is defined as professional and 
personal.  The professional reasons emphasize individual recognition in the professional 
community, professional growth, and contributing and sharing expertise, collaboration, and 
perspectives.   The personal aspects of a faculty member’s reputation may be identified as pride 
or fame, in a narcissistic sense, for entering into a financial relationship with industry, e.g., as a 
consultant, author, member of a speakers’ bureau, which the data suggest is secondary to one’s 
professional reputation and that of the institution. 
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Daniel articulated professional contribution as the ability to influence industry – 
“…industry might be making decisions based purely on financial considerations, and physicians 
and other faculty members in academia can sort of educate them [industry] sometimes towards 
areas that we [academicians] think are important.”  Oliver emphasized the value of professional 
gain and growth,  
There is also a degree of growth that can occur by engagement in a different activity 
so…there is natural curiosity.  I, for example, am a better doctor because of, I would say, 
all of the things I have done outside my day job…every single one of them either because 
of the people I have met….  I can think of activities I did where I met other people who 
helped me get a better perspective of the field and other academic physicians I had 
contact with. 
Examples of the participant’s activities were legal review of cases or writing board review 
questions; however, the participant “drew the line” with speaking on behalf of industry because 
“…I think everybody has different things that they are seeking from these relationships” 
(Oliver).  The  comment reflects a choice or decision of not being influenced or biased by 
industry in activities outside the institution.   
The data also connected reputation to institutional culture and climate surrounding the 
decision to enter into a relationship with industry and melded the professional and personal 
aspects – 
I think every individual physician has to decide what their own criteria are, and it’s going 
to be influenced by the culture and environment in which they work.  If they work in a 
place where these relationships are viewed with scrutiny, they will be more selective than 
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if they work in an institution or even in a microcosm of that institution where it’s 
commonplace so…they would be more likely to join in that (Oliver). 
This quote supports the study data which emphasized the importance of academic-
industry relationships and respect for the institution as a community of scholars, whether the 
faculty role is that of a teacher, researcher, or clinician.  Faculty and industry each brings 
different perspectives, knowledge base, and expertise to the relationship, focuses on the mutual 
nature of the relationship and as such, may provide an implicit balance and mitigate bias.  The 
data also indicated, as articulated above, that characteristics of the personal reputation, such as 
pride and fame, are shadowed by the individual’s professional reputation that contributes to and 
reflects the reputation of the institution and respects its culture.  However, as Karen suggested, “I 
think some physicians feel like, as consultants, they really are helping a company to be more 
responsive to patients, helping a company to see that physicians really want this product.” As 
this quote and others imply, the relationship between faculty and industry can be valuable to the 
professional and personal reputation of faculty as well as to their respective institutions. 
However, regardless of the nature of the relationship, there are potential and sometimes 
significant reputation risks and benefits associated with the relationship. 
Potential Reputation Benefits. 
Potential benefits of a positive relationship with industry may include industry’s grateful 
recognition of the supporting institution usually in research collaboration, although it is 
important that the funds “…be managed in a way that those funds are not benefitting that person” 
(Ben).  Added prestige and strengthened reputations of the faculty and institution follow if good 
research is published in peer-reviewed journals.  A positive institutional and faculty reputation 
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may result in investigator-initiated research that is deemed worthy of industry funding.  
Institutional and faculty partnership and collaboration with industry are generally viewed in a 
very positive manner.  For faculty, the ability to influence industry in clinical areas of 
importance is significant in the discovery of new and effective drugs which may result in 
recognition by one’s institution and career advancement, tenure and promotion. 
Potential Reputation Risks. 
While the benefits offer positive recognition to the reputation of the individual and 
institution, potential risks can contribute to a significant, negative reputation of both.  Bad 
research, wrong decisions in teaching and patient care due to industry bias and undue influence 
can taint the reputations of the institution and faculty.  Academic-industry relationships may also 
be perceived as questionable or unethical resulting in conflicts of interest, commitment, purpose, 
or mission.  As a result, faculty and/or institutions may be considered an extension of a company 
rather than regarded as independent in thought and decisions that are based on scientific evidence 
and best practices.  Additionally, faculty or institutional objectivity may be lost and subject to 
bias and undue influence. 
Beyond the individual and institutional risks are risks for patients and society.  It is 
deemed wrong for patients if conflicts of interests result from a financial relationship with 
industry and cannot be resolved thereby resulting in care that is not optimal or cost-effective.  
Patient and public perspectives of faculty and institutional reputations can result in lack of public 
trust of the medical profession and industry. 
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Money and Funding 
The second reason for entering into financial relationships with industry focuses on the 
individual faculty’s connection with money and funding which, as with reputation, may be 
described in professional and personal terms.  The professional aspect relates more to funding or 
compensation such as salary supplements from consultancies, providing expertise in other roles 
such as research or scientific advisory boards, or as another revenue stream to the institution.  As 
Daniel expressed, 
In most institutions, there are pressures to secure external funding because, if you get 
money from industry, that’s money the institution doesn’t have to pay you.  Federal 
dollars are more restrictive…institutions definitely seek industry support, and it’s not so 
much for personal gain of the institution as [it is] another revenue stream to support their 
missions. 
The quote represents explicit institutional encouragement and reasons to secure funding, but the 
participant also referred to the implicit encouragement that is representative of the culture of the 
institution.  Regardless of whether faculty motivation is explicit or culturally accepted by the 
institution, the reasons behind securing external industry funding are the same – the lack of 
funding to support the high cost of medical education and shrinking federal support.  
Additionally, “government funding has the highest value to the institutions but is also linked to 
priorities of certain conditions, certain innovations all that are drive by politics” (David).  The 
political influence creates an inherent conflict of interest implying lack of independent decisions 
in awarding the funds. 
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 The personal reasons for faculty entering into relationships with industry vary from just 
wanting additional money, irrespective of the purpose behind the relationship, to supplementing 
salary income due to minimal family income or to pay off student loans and debt.  The data 
produced differing views of personal financial reasons:  
Most people who are in academics, academic medicine, or other areas…they don’t go 
into it to make money, otherwise, they would be in private practice; but most of us have 
or had lots and lots of loans…many people hundreds of thousands of dollars, and since 
you don’t make as much in academia as you do in private industry, that is not a trivial 
consideration at all…so personal compensation is actually a big factor and legitimate 
(Daniel). 
Another perspective did not see medical school debt so much as influencing decisions to be in 
financial relationships with industry but rather “buying back more of my time…the ability of an 
institution to support my efforts and my time is, I think, more important than any impact of 
medical debt (Jim).”  Regardless of perspectives, the data suggested assessment of personal 
motivations as well as the potential risks and benefits of interacting with industry . 
Potential Benefits Associated with Money and Funding. 
The benefits of money and funding are stronger for institutions mainly because the 
revenue to the institution supports research whether through funding a study, physician 
investigator salary support, or being a research site.  Additionally, successful study findings may 
result in patents and tech transfer which would generate a richer source of revenue to the 
institution.  For the individual physician, the benefit is a significant increase in earnings to 
supplement a university salary.  As with Dr. Carlat’s example (2007), he supplemented his 
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$140,000 private practice income with approximately $30,000 from the Wyeth “Lunch and 
Learn” talks in 2001. 
Potential Risks Associated with Money and Funding. 
The data suggested that risks associated with money were related more to the individual 
and could create unresolvable conflicts of interest (COI).  Viewing Dr. Carlat’s (2007) example 
described in chapter two as a risk instead of a benefit, 
“I began thinking that the money was affecting my judgement.  I was willing to dance 
around the truth in order to make the drug reps happy.  Receiving $750 checks for 
chatting with some doctors during a lunch break was such easy money that it left me 
giddy.  Like an addiction, it was very hard to give up.” 
In addition to Wyeth, Dr. Carlat gave a couple of talks for Forest Pharmaceuticals.  Also 
reflective of the risks associated with money, Amanda (participant) advocated that holding stock 
in a company that produces products that the stockholder physician uses and prescribes has “zero 
benefit” and creates a significant COI.  Another risk involved a physician just wanting additional 
revenue without regard for what role he or she has in the industry relationship which may result 
in a lack of independence of thought or action and being subject to industry bias.  As will be 
discussed under research, the role of physicians in industry relationships and interaction among 
individual multiple roles are important considerations in supporting independent, unbiased 
thinking, conduct, and decisions as well as mitigating risks and conflicts of interest.   
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Research 
The third and final reason faculty enter into relationships with industry involves research 
and is the most prominent of the three.  The three primary reasons, reputation, money and 
funding, and research categorize individual reasons for entering into relationships with industry, 
but they also have overlapping and interconnected features.  Research, for example, can have a 
tremendous effect on reputation and funding opportunities for both faculty and institutions.  The 
data also indicated that establishing and maintaining ethical responsibility was a reason for 
securing a positive reputation of faculty and institutions as well as conducting responsible 
research with industry.  NIH policies and courses, institutional policies, and programs such as the 
Collaborative Institutional Training Initiative (CITI) provide compliance mechanisms and assure 
adherence to accepted research standards and practices.  Institutional policies may not allow 
faculty who have industry funding for research to have other financial relationships or roles with 
the funding company to avoid bias, undue influence, and a conflict of purpose or mission.  For 
example, having stock in a company with which a physician is conducting research creates a 
conflict of interest as one participant stated, “the desire to make money from that [relationship] is 
a direct COI with your patients, with the interests of your learners or of your patients” (Amanda). 
Additionally, “…for researchers, they often have to really develop relationship with companies.  
If they do that, they have to be researchers and not do other things” (Ben).  In essence, the 
participant data suggested that in order to conduct ethical, responsible research, physician 
investigators should resolve all conflicts of interest including participation in other roles with the 
funding company such as consultant, speaker’s bureau, or owning stock which could reap 
financial gain from a successful study outcome. 
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Notwithstanding the concerns expressed above, the data strongly supported the research 
benefit of academic-industry relationships with physicians or institutions for the purpose of 
advancing science through shared, collaborative research as expressed through the participants’ 
beliefs. “I think shared expertise and networking is also a very important and valuable reason [to 
enter into a financial relationship with industry].  We clearly need both industry and academia to, 
for example, bring new drugs to market” (Daniel).  Additionally, “physicians want drugs to come 
to market and they want to give their expertise to make sure that drugs are coming to market or 
vaccines are coming in an appropriate manner” (Grace).  Another participant, David, pointed out 
that “some people view industry-funded research as tainted while others view it as 
entrepreneurial; but regardless, many view it as necessary to move things forward…especially 
the area of research.” 
For the institution, the research and funding partnership with industry is very beneficial to 
the research enterprise by promoting advances in medical science, contributing to improved 
patient care by, e.g., bringing new and effective drugs to market.  Industry may also be able to 
provide resources other than funding that institutions may not be able to obtain.  For the 
individual faculty researcher, having industry funding for research studies provides a significant 
source of revenue that supports the faculty and institution, helps build research portfolios, and 
contributes to survival as a researcher. 
The participants discussed potential research harms with concern and how bad, unethical 
decision-making can generate adverse effects on physicians, patients, the public-at-large, 
institutions, and faith in research findings.  Expanding upon the effect of ethical responsibility as 
it relates to reputation and research, one participant’s comment was reflective of the moral agent 
in Jones’ model (1991), “I really consider corporate sponsorship not different from federal or 
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government or foundations.  It’s not bad money, but they [physician researchers] have to really 
work as researchers and be true to what they are and what they should be” (Ben).  Funding from 
industry is different from federal and state government or foundation funding with the main 
difference being organizational mission.  Industry’s structure is corporate; and therefore, one of 
its goals is to generate profit for the company and its stockholders.  The company, however, is 
also generally purpose-driven by disease states in a specialty, e.g. diabetes.  Government and 
foundation funding, however, first identifies and supports the clinical or medical need for 
patients and society with a financial focus on cost-recovery which requires tight budget controls 
so that the not-for-profit research grant funds cover or offset research study expenses.   Because 
of these organizational differences, researchers, regardless of funding sources, must be moral 
researchers, first and foremost without regard for the source of funding.  In other words, let the 
data and evidence speak for themselves and produce an outcome, negative or positive, which is 
beneficial to and informs the medical profession, patients, society, and industry. 
Potential Research Benefits. 
The benefits of academic-industry shared research can have significant effects especially 
in the discovery of new drugs that can result in patents and financial gain for faculty, institutions, 
and companies.  Industry funding can provide infrastructure for clinical trials and contribute to 
opportunities to develop local expertise/techniques especially for benefit of patients and trainees. 
Industry-funded research can also fill time and provide resources between larger NIH studies and 
clinical trials.  
In addition to the financial and resource benefits, there is a social benefit.  “The 
interesting thing is that…getting research grants for development of new drugs or new devices 
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can create generalizable new knowledge…if you can be sure that they [researchers] are doing the 
study right and analyzing the data right, there is a real social benefit of that” (Amanda).  Shared 
research should also support and respect the institutional mission and be reflected in the 
physician faculty’s role as a research study investigator. 
Potential Research Risks. 
 Benefits and risks accompany all research; however, the risks associated with industry-
funded research can produce damaging effects on physicians, patients, the public-at-large, 
institutions, and faith in research as previously discussed.  These effects can result from tainted 
research, inappropriate conflict-of-interest (COI) management, industry-biased or influenced 
data reporting and research findings, or research misconduct.  The purpose of the compliance and 
oversight mechanisms of the NIH and others are intended to provide guidance for preventing 
these harmful effects. Oversight is conducted through mechanisms such as required education, 
IRB review and approval processes, data safety monitoring boards, and institutional research 
policies and procedures.  From a financial perspective, if all funding goes away; the lost revenue 
potential can be significant for the researcher and the institution through, for example, loss of 
patenting opportunities and technology transfer.   This statement reflects the resource-rich nature 
of industry-funded research and how lack of funding would hinder the discovery of new drugs 
and medical devices. 
Bias Avoidance 
The participants expressed concern for undue commercial bias and influence in the 
missions of academic medicine, teaching, research, and patient care, and the importance of being 
responsible and alert to the daily battle of potential conflicts of purpose in the three roles of 
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educator, researcher, and clinician.  The data and literature indicated that it is human nature to 
think that individuals don’t have conflicts of interest, can never be biased or influenced, or are 
necessarily good at recognizing bias and influence.  This observation of human nature suggests 
that even subtle influences can prejudice decision-making ability. The participants offered 
consideration of methods for avoiding bias and proposed good litmus tests for detecting and 
mitigating bias and undue influence.  Their suggestions fell into two different approaches that 
should work interactively with each other.  The first is a pragmatic approach which promotes an 
understanding of what bias is through education, policies, and procedures.  They emphasized the 
importance of participating in training about bias in COIs, becoming educated about bias in 
general, and being aware of “how we think as people in the first place” (Ben). 
The second should be an intuitive and reflective approach which requires recognizing the 
moral agency aspect of being honest to oneself and alert to a consistent presence of bias that can 
create a conflict of interest, purpose, and/or mission.  As one participant, Edward, expressed: 
I think that [avoiding bias] is just behaving like hopefully your mother taught you, to be 
fair and objective, and I would think that with all the education that people at this level 
have, they should know enough to exclude bias.  Saying that, I’m fully aware that what 
I’m expressing is an ideal that too often is not met. 
The moral agency characteristics in Table 4 below delineate the study participants’ main 
concerns of undue bias and influence, morality, and familiarity representing core values in a 
basic social process (Glaser, 1998). 
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Table 4: Methods for Bias Avoidance 
PROCEDURAL MORAL AGENCY 
 Conduct an annual review of disclosures and 
potential COIs (process). 
 Be honest with yourself; acknowledge inability to be 
fair & objective (3). 
 Observe practical, real-time, full disclosure in all 
professional roles (2). 
 “Behave like hopefully your mother taught you…to 
be fair and objective.”  
 Assess purpose and merit of research and the benefit 
to society v. personal financial remuneration. 
 Ask yourself ‘are you a good person? Do you have a 
moral compass? 
 Consider investing in a different industry. 
 Behave in the same manner for family, friends, or 
society (proximity). 
 Exert caution with research data collection & 
analysis. 
 Be open and honest about the ‘why’ of actions: “Am 
I doing the best for students, patients, others?” (2) 
 Effectively use institutional guidelines and policies 
for individual guidance. 
 Assess possible issues of professionalism in other 
roles that may contribute to a COI. 
 Involve a third, objective party for bias mitigation. 
 Reflect on decisions/choices before an issue arises; 
recognize human imperfection. (2) 
 Completely eliminate all gifts from industry. 
 Submit to the ‘local newspaper’ test – “can I defend 
my decision?” 
 Recognize what one can/cannot do with financial 
relationships; be willing to not participate, if 
necessary. 
 Carefully consider all aspects and effects of decision 
beyond immediate situation. 
 Make decisions that are very transparent. 
 Feel comfortable with your decision. 
 
Theory Development 
Jones’ (1991) ethical decision-making model was the process representing the unit of 
analysis for the grounded theory study and guided the development of the interview protocol 
(Appendix I).  Jones’ model, which was described and discussed in chapter two, consists of four 
components, requiring the moral agent to (1) recognize the moral issue, (2) make a moral 
judgment, (3) establish moral intent, and (4) act on the moral concerns.  Jones identified moral 
intensity as a construct that focuses on the issue at the center of the decision.  Jones’ six 
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characteristics of moral intensity included (1) magnitude of consequences, (2) social consensus, 
(3) probability of effect, (4) temporal immediacy, (5) proximity, and (6) concentration of effect.  
Building on the six characteristics, the interview protocol offered an opportunity to assess each 
case scenario and determine if there was a moral issue at the center of the decision process and 
how physicians, as moral agents, recognized and assessed the moral issue. 
Themes from Academic Physicians’ Responses to COI Scenarios 
The participants’ assessments of the cases and study data generated three themes – 
morality, bias, and familiarity – and contributed to the development of moral agent 
characteristics that could impact the roles and responsibilities of the physician as a teacher, 
researcher, or clinician.  Table 5 displays the three themes, sub-themes which further delineate 
the themes, and elements of the sub-themes which are descriptive terms or phrases that the 
participants cited frequently and independently.  The number of times participants mentioned 
each descriptor is noted in parenthesis following the term or phrase.   The nine sub-themes are 
honesty, morality, and human nature for the morality theme; bias, objectivity, and proximity for 
the bias theme; and volition, beliefs and actions, and decisions for the familiarity theme.     
Although the themes of morality, bias, and familiarity are also considered sub-themes and 
used as descriptions in the elements; they best represent the collective nature of each theme.  
Morality represents how individuals conduct themselves in personal and professional decision-
making and accordingly encompasses characteristics and effects that relate to human nature, 
capacity to be honest, and variable aspects of morality.  Therefore, for this discussion, morality is 
a theme, a primary sub-theme, and an element.  
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Similar to morality, bias is a collective term that embodies a theme, a predominant sub-
theme, and a descriptor of the sub-theme which is reinforced in two of the moral agent 
characteristics. As discussed previously in this chapter, bias was a major concern of all 
participants and required a discussion that suggested procedural and moral approaches for 
avoiding bias.   
As with morality and bias, the term familiarity exemplifies the essence of the third theme 
and can possess both positive and negative effects. Applicable to the sub-theme proximity, 
familiarity poses a concern about physicians who would, for example, treat a close family 
member different than a patient.  In the context of this study, proximity refers to the closeness of 
the relationship between a physician and family members, friends, patients, research participants, 
students, or society-at-large as explored in the case scenarios and how a physician’s financial 
relationship with industry may affect personal or professional relationships.  Familiarity also 
impacts volition, a sub-theme, culminating with a decision that is affected by one’s beliefs, 
actions, and choices. 
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Table 5: Development of Themes 
THEMES MORALITY BIAS FAMILIARITY 
Sub-
Themes 
HONESTY MORALITY 
HUMAN 
NATURE 
BIAS OBJECTIVITY PROXIMITY VOLITION 
BELIEFS 
& ACTIONS 
DECISIONS 
Elements of 
Themes 
 
(Participant 
Descriptors) 
 
Honesty / 
being honest 
(3) 
 
Truth (2) 
 
Fiduciary 
responsibility 
(2) 
 
Reputation (2) 
 
Integrity 
 
Credibility 
 
Accountability 
 
Awareness 
Morality (11): 
 
-Moral 
 
-Moral person 
 
-Moral 
compass 
 
-Recognized 
as a moral, 
ethical 
teacher 
 
-Moral duty 
 
-Moral 
obligation 
 
Ethics /  
ethical / 
ethical 
principles (4) 
 
Peer pressure 
Human  
Nature 
 
Being “human”  
 
Financial 
pressure 
 
Culture 
 
Good person? 
Bias (9) 
 
Influence / 
undue 
influence (9) 
 
Full / absolute 
disclosure (6) 
 
Mission 
Conflict 
 
Relevance 
of COI 
 
Corruption 
 
Damage 
 
Fraud 
 
Morally 
bankrupt? 
 
Objectivity / 
being Objective 
(5) 
 
Fair (3) 
 
Balance (3) 
 
Independence / 
independent (3) 
 
Unfairness 
to company (2) 
 
Autonomy 
 
Impartiality 
 
Familiarity /  
Preference:  
benefit or 
harm (9) 
 
Duty to patient 
 
Patient trust  
 
Harm to 
students, 
patients, 
society, etc. 
 
Treat all the 
same; “right 
thing to do” 
 
Sacred trust 
 
 
 
Familiarity / 
Preference:  
benefit or harm (9) 
 
Evidence (listen to…) 
(3) 
 
Obligation to 
company (3) 
 
“Slippery slope” (2) 
 
Scientific integrity 
 
Clouded judgment 
 
Intention 
 
Experience/expertise 
 
Moral problem  / 
issue / dilemma 
 
Compliance: 
appearance v. spirit 
 
Consequences 
Ethics /  ethical / 
ethical principles 
(4) 
 
Professional 
obligation / 
responsibility (3) 
 
Effect on behavior 
 
Mission 
(physician) 
 
Role (physician) 
 
Role performance 
 
Leadership 
 
Modeling 
 
Professional trust 
 
Professionalism 
 
Unbiased / 
unbiased 
decision-
making (5) 
 
Transparency 
(4) 
 
Transparent (2) 
 
Gatekeeper 
responsibilities 
 
Local 
newspaper 
“test” 
 
Moral decision 
 
Residual effects 
Moral Agent 
Characteristics 
 
(representing 
sub-themes) 
 
Honesty 
with self 
and others 
 
 
Enduring 
moral 
compass 
 
 
Recognition 
of human 
imperfection  
 
 
Continual 
awareness 
of biases & 
potential 
conflicts 
 
Fairness and 
objectivity 
 
 
Respect for 
proximity 
effect 
 
 
Constant 
reflection of 
choices / 
consequences 
 
 
Congruence of 
moral beliefs 
and actions 
 
 
Transparent, 
unbiased 
decisions 
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Morality 
The participants expressed and questioned moral issues and concerns by discussing the 
three case scenarios in terms of the physician’s moral duty and obligation, ethics, truth, and 
integrity.  In support of morality as a theme, the AMA Code of Medical Ethics Opinion1.01 
(Appendix C) states that “ethical” refers to one’s respect of moral principles and social policy 
involving issues of morality, and “unethical” refers to one’s failure of professional conduct by 
not abiding by moral standards.  This theme encompasses three sub-themes – honesty, morality, 
and human nature – which represent the individual physician’s self-reflection of beliefs, morals, 
and ethics.   
[…] what is more important here – being recognized as a moral, ethical teacher who 
really doesn’t have that conflict, or do you continue to resolve those conflicts every time 
you teach?”  So, my advice would be “resolve this, move on, and avoid that conflict in 
the first place (Ben). 
 Moral issues and responsibility were evident in all three cases, but this quote expresses 
the essence of awareness and responsibility.  In offering advice to the faculty in the teaching 
case, the role of teacher could be replaced with researcher or clinician and apply to the heart of 
one’s ethical and moral obligation. 
Bias 
The theme of bias was equally as prominent in all three case scenario discussions 
exploring the effects of undue influence, mission conflict, objectivity, and patient trust on the 
physician’s ability to make an unbiased decision.  The sub-themes of bias represent a more 
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descriptive, detailed interpretation of bias and how it interacts with objectivity and proximity.  
The bias theme also represents how the individual physician interacts with others and the 
professional environment as the following quote from the research case scenario demonstrates: 
OK, I have a long-standing relationship with this company in many different roles.  I 
cannot be objective. Yes, I think I am a scientist.  I’m objective, but we are all human.  I 
think the faculty member should have recognized that ‘I cannot be objective’ so the 
future effect is ‘I am not going to be able to objectively serve as an investigator for this 
study’ (Daniel). 
In the physician researcher’s different roles with the company funding the research study, he or 
she could, for example, be a consultant, be on a speakers’ bureau, or own stock, any of which 
would create a conflict of interest and commitment.  As the participant data has suggested, 
institutional policies are critical and probably the most effective  in avoiding conflicts especially 
in research.  However, the principle still applies in the management and resolution of all conflicts 
of interest. 
Familiarity 
Familiarity, the third theme, gleaned differing opinions among the participants, viewing it 
as both a potential harm and benefit with particular relevance to proximity and volition.  The 
familiarity effect on proximity and volition was described as a duty to patients and that 
physicians should treat all the same whether a family member, society, or patient.  Additionally, 
the participants emphasized the importance of listening to the evidence and being aware of 
consequences of choices in making decisions.  Familiarity can be a benefit and have a positive 
influence when equated to professional knowledge, confidence, preference, and expertise.  
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Familiarity was also viewed as a harm when the best drug for treatment or alternatives are not 
considered or selected which may be the result of a physician’s financial relationship with a 
company whose drugs the physician prescribes more frequently than other options.    
The theme of familiarity involves sub-themes or final steps in the end phase of an ethical 
decision-making process which are represented by volition, beliefs and actions, and decisions.  
The third theme of familiarity is the culmination of the individual physician acting upon his or 
her introspection (morality) and interaction with others and the professional environment (bias).  
Jones’ (1991) model establishes the link between an individual’s ethics and actions which 
involves determining the correct thing to do within a situation, following through by acting upon 
one’s ethical assessment without influence of environmental factors, and seeking approval of 
oneself and/or from peers (Jones & Ryan, 1997).  The third theme further suggests an 
undercurrent of reflection, interaction and action by continuously contemplating the moral agent 
characteristics in the ethical-decision making process.  Familiarity had the greatest effect in the 
clinical case scenario as the following quotes illustrate, identifying the benefits and potential 
harm: 
[Physicians] will tend to pick one [drug] and stick with that one, usually independent of 
any conflict of interest.  It is just because they develop a familiarity with it; and that is a 
benefit because…if you use the same drug in a number of patients over a long period of 
time, you really become…you have a degree of expertise with the benefit and the side 
effects and sort of just the practical, hands-on use of it in patients (Daniel). 
The harm to the patient is that they are not getting the optimal treatment.  The harm to 
society is that it may be adding to overall medical costs.  Benefits to the patients here 
 141 
would be familiarity…the physician has tremendous experience and familiarity with 
Company E’s product lines and is probably perhaps more able to help patients use those 
products compared to others (Jim). 
In these quotes, familiarity is synonymous with knowledge, experience, and expertise.  However, 
familiarity in these terms is also narrowed to one drug or one line of products that could result in 
not prescribing the best drug for a condition, or as in the teaching case, have a delayed and 
potentially negative effect.  The faculty member in the teaching case scenario preferred to use 
equipment from one company instead of exposing the students to equipment from several 
companies.  In this particular case, it also created a conflict of interest due to his owning stock in 
the preferred company.  The effect on the students may not present itself until they go into 
practice with limited knowledge of one company’s equipment. 
Theory Refinement 
 In refining Jones’ (1991) model, the study data generated nine moral agent characteristics 
(Table 5 and Figure 3) from the elements of the themes. The moral agent characteristics are 
applied to the role of the physician, whether as a teacher, researcher, or clinician, in each of the 
four steps of the ethical decision-making process.  The characteristics represent the sub-themes 
and emphasize the physician’s ethical and moral responsibility in making decisions.  Moreover, 
depending on the setting of the case scenario, not every characteristic of moral intensity in Jones’ 
model had the same effect on each step in the process.  As discussed in chapter two, Jones 
identified moral intensity as a construct that focuses on the issue at the heart of a decision and 
how the decision-maker assesses the moral intensity without consideration of professional or 
environmental context.   
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Figure 3: Modified Ethical Decision-Making Model for Resolving Conflicts of Interest
 
Source: Modified from An Issue-Contingent Model of Ethical Decision Making in Organizations. Jones, T. M. 
(1991, April).  Ethical decision making by individuals in organizations: An issue-contingent model.  The Academy of 
Management Review, 16(2), p. 379.  Used with permission from the author, Thomas M. Jones, PhD (Appendix J). 
With that in mind, I identified one or more characteristics of moral intensity that 
appeared to have a dominant effect on each step of the process which is illustrated and discussed 
below.  The refined components of the ethical decision-making model include the moral agent 
characteristics produced by the study data, the addition of the final step of making an ethical 
decision, and a suggested redistribution of the moral intensity characteristics. 
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Moral intensity effect on the process of ethical decision-making 
 Step I – Recognize moral issue. 
Three characteristics of moral intensity – magnitude of consequences, probability of 
effect, and temporal immediacy, which are expressed in terms of harms, benefits, and future 
effects, should be taken into consideration when the decision-maker is in the first step of the 
process, recognizing the moral issue.  As Jones (1991) indicated, this is the point at which an 
individual acknowledges his or her role as a moral agent and should take into account that ethical 
decision-making may be proportional to the potential consequences, suggesting that potentially 
serious consequences encourage ethical behavior, produce harms and/or benefits to various 
stakeholders, and have short or long-term negative effects as Karen (participant) indicated 
regarding research:   
[…] can harm a lot of people.  It could also come back to hurt the university if there was 
some sort of fraud or problem with scientific integrity or the way it was presented; and 
that could hurt the whole standing of the university as far as funding in the 
future…besides his own career.  It could hurt the institution, hurt patients, and while he 
might help the company, ultimately, it could hurt the company too. 
The participants affirmed this assertion especially with their responses to the research 
case scenario in which they stated clearly that there is no justification for biased research or 
obligation for findings other than what the data suggest could result in harm, as stated above, to 
research participants, patients, institutions, companies, and society. With obligation to the 
company described by Molly and David as a “slippery slope”, the researcher and possibly the 
institution could be branded due to scientific misconduct.  Other participants recognized 
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potential harms to healthcare systems, the overall enterprise of industry-sponsored research, and 
the scientific process as well as possible patient and public loss of trust in physicians and the 
profession.  The harm to society could also result in increased medical costs. 
The data from the teaching scenario suggested that favoring one company’s equipment 
would produce harm to students and trainees by teaching and creating choice preferences or 
biases as well as entering the profession with limited knowledge that could affect them later in 
their practices. By limiting exposure, the faculty member is not offering a full educational 
experience and sets a poor example for the learners.  As one participant stated, this is an example 
of “inaccuracy at best and dishonesty at worst in teaching if all companies are equal.”  There is 
embedded harm to other companies through omission of their equipment which could affect 
institutional reputation if purchasing agreements are in place. 
From the clinical case scenario, the data identified harm to patients as the primary 
consequence from favoring one company’s products and was expressed as patients not getting 
optimal treatment, which another participant labeled as a moral issue or “one’s duty as a 
physician” (Oliver). Oliver also expressed and supported the need for unbiased, evidence-based 
clinical care and the lack of oversight: 
In practice, there is a whole spectrum of ability to practice; that’s just the way it is, and 
it’s always going to be that.  There is no way to make sure everybody is practicing at the 
absolute highest level.  That is tested from time to time.  When people come up for 
accreditation, they have to have their peers vouch for them that ‘yes,’ they have an 
acceptable practice standard.  I think it’s only through those occasional tests that we get a 
‘check-in.’ 
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This quote identifies a flaw in the healthcare system that would assure balance and continuity of 
practice in addition to identifying practice patterns that could represent inadvertent or intentional 
bias in prescribing patterns or balance in treatment options. 
One leading benefit involved physician familiarity which was best conveyed in the 
teaching and clinical case scenarios and had positive and negative conditions.  In the teaching 
scenario, familiarity was identified as preference of equipment used by the faculty instructor and 
represented extensive knowledge and expertise.  One participant, however, suggested a negative 
benefit based on the faculty member’s stock in the favored company’s equipment as a potential 
financial benefit to the faculty member. This would, however, be negative for the students or 
trainees by their not being exposed to equipment from various companies. In both cases, Amanda 
suggested that the faculty member “should consider divesting” and relative to the clinical case, 
“be more self-aware.” 
In the clinical case scenario, ‘positive’ familiarity was identified as the physicians’ ability 
to pick a drug and stay with it based on experience or expertise with the drug even if they have 
no financial relationships with industry.  This approach can provide an advantage for a patient by 
the physician prescribing favorite drugs for different conditions, “all drugs equal, prescribe what 
is familiar” (David).  The negative aspect of familiarity is that, all drugs not equal, prescribing 
what is familiar is not necessarily what is best; physicians should consider effects and 
consequences before prescribing. 
Step II – Make moral judgment. 
Social consensus and temporal immediacy were two of the moral intensity characteristics 
that appeared applicable to the second step in the process, making a moral judgment, the point at 
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which an individual would exercise moral reasoning and define what is considered morally 
correct.  Social consensus suggests that moral reasoning may be proportional, issue dependent, or 
context dependent.   A high degree of social agreement was essential at this point to confirm the 
ethical appropriateness of the behavior.  As with the first step, consideration of short or long-
term consequences (temporal immediacy) implied that moral urgency correlated with the time 
between the present and the onset of consequences indicating that the greater amount of time, the 
less urgent (Jones, 1991).  The teaching case illustrated more of a potential delayed effect or 
potential consequences into the future, e.g. when the trainees are in practice with potentially 
limited knowledge and limited familiarity of equipment for the benefit of their patients.  The 
participants thought that institutional policies, more so than federal regulations, should have the 
greatest impact in assuring an unbiased breadth of training…“what we learn in training heavily 
influences what we do in practice” (Oliver).  The data suggested that policies should also reflect 
the culture of the institution and have conflict of interest (COI) policies that define disclosure 
and COIs, heighten awareness, and offer guidance, processes, and education about COIs.  
Everyone has biases, and “most academics, we take pride in… ‘we’re independent; we’re not 
merely a shell for industry” (Daniel).  
This same sense of being independent decision-makers was evident in the clinical case 
scenario.  The data indicated that prescribing patterns that are favorable or disproportionate to 
industry are currently hard to detect, manage, and monitor because preferences happen in 
practice without necessarily knowing why or what influenced the choice.  As one participant, 
Karen, noted, “we teach young doctors; we say ‘beware of where this information is coming 
from and what the bias is for why this one [drug] is better than the other.”  The participants 
suggested methods for consideration that could mitigate bias such as identifying prescribing 
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patterns and biases toward drugs by reviewing physician EMRs and pharmacy records and cross-
referencing preferences with institutional disclosures.  Another method involved peer review and 
creating a culture of education and interaction among peers and consultants. 
As with the Step I above, the research case illustrated the greatest effect of social 
consensus.  Unlike the teaching and clinical case scenarios, the participants felt that federal 
oversight had the most potential for avoiding damaging consequences since it is the common 
denominator for all clinical research.  Examples of federal oversight and regulatory mechanisms 
are the Clinical Trial Registry (CTR), Data Safety Monitoring Boards (DSMB), and Institutional 
Review Boards (IRB) which are designed to protect faculty in their academic and research roles.  
The IRBs may be the most influential because of its representative presence within the institution 
connecting institutional policy with federal research requirements and guidance to “ensure that 
the data are being…that the study is conducted ethically and appropriately, and that things are 
not inappropriately misconstrued” (Jim).  If faculty are receiving industry funds to support a 
study, the data strongly indicated that faculty should be forbidden from having any other 
financial relationship with a company, described as the “most incredible potential risk for 
corruption” (David), to avoid creating a COI by feeling obligated to the company for favorable 
findings which represents natural characteristics of being human and being grateful. 
Humans, all of us, think we are more objective than we are.  We think we can be 
objective and that we can be truthful.  [In a financial relationship], you do become 
friendly with people and develop positive relationships, and nobody likes to give bad 
news.  So, you're both in a position of giving bad news to your friends in the company… 
“oh, your drug does not really work”…and you are hurting yourself because…you’re not 
going to have the same financial benefit (Daniel). 
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 This quote demonstrates why policies and regulations are in place, which is to fulfill 
research’s social responsibility through implementing safeguards to review data in an unbiased 
manner, determining how findings will be disclosed, and reporting accurate, positive or negative 
findings. 
Step III – Establish moral intent. 
The moral intensity characteristic, concentration of effect, had the most significant effect 
on the third step, establishing moral intent.  Fishbein and Ajzen (1975, p. 381, in Jones, 1991, 
pp. 386, 387) suggested that “the best predictor of a person’s behavior is [one’s] intention to 
perform the behavior” which reinforced a tension that can exist between what people believe and 
do.  Due to the faculty’s financial relationship with the company in the teaching case, one 
participant, David, described the case as a “slippery slope between teaching people and selling 
people.”  It is important that students understand disclosure and what constitutes a conflict of 
interest and its implications.  The institution has an important role in recognizing, mitigating, and 
managing COIs with students, allowing for a learning experience outside the clinical curriculum.  
The data suggested that with the students in mind, faculty should revisit their COIs frequently 
and inform their students on a regular basis of any financial relationships and how their 
disclosures or COIs, real or perceived, may reveal bias. 
The data suggested that there is a high degree of faculty autonomy in research, especially 
in the data analysis phase, giving the researchers the opportunity to make decisions that may be 
biased and subject to undue influence from industry.   Research can be difficult to monitor.  Data 
analysis, for example, can be monitored by a Data Safety Monitoring Board (DSMB) to assure 
appropriate analysis and concentration of effect on the findings.  The big issue as discussed 
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previously is that, if a physician is participating in an industry-funded study, he or she should not 
have any other financial relationships with that company due to the risk of company influence. 
In fact, there [would be] concern that their [faculty] decision-making about treatment of 
the study and how they are going to be reporting it is being influenced by those 
relationships in their decision-making process (Jim). 
There [could be] a perception that the relationship with a company will be reduced if, for 
example, he proceeded with publishing unfavorable findings.  One could also imagine a 
scenario where the company increases investment in this person to try to influence the 
outcome of this particular decision (Oliver). 
These viewpoints were expressed by other participants as well.  One participant reminded 
researchers that they shouldn’t need to be reminded of their ethical responsibilities.  However, 
and without exception, the participants often and respectfully referenced their own institutional 
policies and procedures and how the policies establish firewalls to prohibit conditions, such as 
multiple financial relationships, from occurring when engaged in industry-funded research. 
 In the clinical setting, transparency and full and frequent disclosure with patients is 
essential in the same manner as with students.  The participants proposed that physicians disclose 
to every patient because patients could lose trust if, for example, they know that their physician 
has stock in a company that manufactures the drug that their physician is prescribing to them 
frequently.  It is important for physicians to be sure that patients understand what they are taking 
and feel comfortable with their care.  As Oliver stated, “I think it’s more about the moral 
obligation as a physician prescriber to keep up with the literature and do what’s best for the 
patient.”  
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 Step IV – Engage in moral behavior. 
 Three of the moral intensity characteristics appeared to have an influencing effect on the 
fourth and final step, engaging in moral behavior, which was the point of acting on moral 
concerns and then making an ethical decision.  Temporal immediacy, proximity, and 
concentration of effect represent and emphasize distance in terms of levels of urgency (time), 
social, cultural, psychological, or physical proximity (relationships), and the potential number of 
people affected (concentration).  Responses to all three cases accentuated the fact that it should 
not matter whether the effects or consequences are immediate or in the distance future, whether 
the relationship is a family member, patient, or society-at-large, and whether the decision affects 
one person or a population.  Additionally, faculty members should disclose relationships with 
industry; and as one participant commented…“once disclosed, the individual should consider 
what are the consequences of my conflict?  The appearance of complying is different than the 
spirit of complying” (David).  It is important for physicians to be open with disclosure and 
potential COIs and aware of evidence in support of engaging in moral behavior and making 
ethical decisions and of the need to overcome and challenge one’s own biases. 
Concerning the proximity characteristic, individuals should be considered “morally 
bankrupt” (David) if they treat close or distant relationships differently; care should be the same 
regardless.  “The ‘bar’ should be similar regardless of friend or patient; high level of 
responsibility when prescribing for either” (Oliver).  Physicians must be familiar with disclosure 
requirements, effect of their professional opinions, and expectations in their official role.  The 
data suggested that disclosure may not be expected with a close relationship, such as a family 
member; however, it should be required with patients, as previously noted, because the 
physician-patient relationship is considered a “sacred trust,” thereby putting the patient’s best 
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interest first and foremost.  The data identified one potential negative effect concerning 
proximity in research – the potential for corruption.  A researcher may advise a friend not to take 
a drug but may present it favorably to others with possible harm to the reputation of the 
researcher, institution, and company involved in the study. This is contrary to the participants’ 
consensus view that treatment should be the same, regardless of the relationship to the physician, 
and whether it affects one person or a cohort of research study participants and level of urgency. 
Academic Freedom Concerns 
Although not addressed in Jones’ (1991) model, consideration of the effect of academic 
freedom on ethical decision-making is certainly related to the model and process and provided a 
different lens through which the decision-making process may be examined in the context of 
academic medicine.  When considering a decision-making model and process in resolving 
conflicts of interest (COIs) as my research focus, I recalled a professional experience several 
years ago when an invited speaker challenged the requirement for disclosure and subjective 
resolution of his COI.  He felt that I was violating his academic freedom rights because 
‘everyone has biases’ and that he should be allowed to express his views.  I agreed in principle 
but stated that I was only interested in resolving his commercially-influenced biases that could 
impact what should otherwise be an independent, unbiased, balanced, and evidence-based 
presentation.  He had several financial relationships with industry.  As I reflected upon our 
conversation and discussed it with my peers, I began to wonder if he had a valid point.  As a 
result, I researched academic freedom during the literature search and its potential for having an 
impact on an individual’s ethical decision-making process for COI resolution.   
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Resources such as the American Association of University Professors (AAUP), J. K. 
Ryan (1949), and others revealed enough evidence to include a secondary research question 
regarding academic freedom that addressed the concern as well as a question in the interview 
protocol.  The research question contemplated if and / or how faculty perceive that their 
academic freedom is threatened in their relationships with industry.  During the discussions, the 
participants expressed viewpoints concerning potential threats to academic freedom in each of 
the three case scenarios.  Ryan’s (1949) definition of academic freedom, “a particular kind of 
liberty in a moral order,” supported exploring the possible effect, positive or negative, of 
academic freedom on Jones’ (1991) model. 
 According to the AAUP 1940 Statement of Principles on Academic Freedom and 
Tenure, academic freedom intends to protect faculty autonomy in the search for ‘truth’ through 
teaching, research, and when representing a discipline or a community of professional scholars to 
the public.  Relevant to the current environment and the study, the AAUP released the following 
in 1999 regarding corporate involvement in research: 
The freedom to pursue research and the correlative right to transmit the fruits of inquiry 
to the wider community—without limitations from corporate or political interests and 
without prior restraint or fear of subsequent punishment—are essential in the 
advancement of knowledge. (Mangan, 1999, p. A14). 
One participant suggested that if academic-industry relationships were disengaged due to 
circumstances that suggest abuse of academic freedom, e.g. the freedom to report negative 
findings; the collaborative nature of research and moving new and effective products and 
innovations into the marketplace could be compromised and be an ultimate loss to society. 
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In general, the interview data suggested that academic freedom concerns were not 
significantly evident in the case scenarios.  The participants expressed greater concern for 
physicians assuming responsibility in being mindful of preferences, influence, and bias in 
resolving conflicts of interest.  They emphasized the importance of being transparent and not 
advocating for or favoring specific products.  Their views about academic freedom were not 
necessarily specific to the cases.  One participant referred to a “limitation of some freedom” but 
not academic freedom through institutional policies inferring that institutional policies actually 
protect, rather than restrict, scholarly inquiry.  The institution “sets the tone” (Amanda).  Another 
participant agreed that in higher education, one should be able to speak what he or she considers 
the truth, but “academic freedom is not a complete license to say whatever one wants to say 
either” (Daniel); and as another stated, “[there] needs to be a balance between freedom and 
potential COIs…you don’t get to do just whatever you want just because you are in an academic 
setting so the freedom needs to be within limits” (Grace).  With reference to the research case 
scenario, there were comments alluding to academic freedom’s strength behind the ability to 
“publish irrespective of what the findings show” (Oliver) and to report negative findings of a 
study.  The interview data also suggested that academic freedom may have minimal effect under 
actual circumstances, indicating that physicians’ awareness of their biases and how to resolve 
conflicts of interest would have greater impact in their academic roles of teaching, research, and 
patient care.  
Conclusion 
 The study examined the primary research question how do physicians as academicians 
manage or resolve potential conflicts of interest in their roles as teachers, researchers, and 
clinicians?  Additionally, the study examined factors that may influence ethical, commercially-
 154 
unbiased academic decisions as well as characteristics of ethical, evidence-based decisions v. 
commercially-influenced decisions.  As discussed above, the study also assessed the potential 
effect of academic freedom on their relationships with industry which provided informative data 
but was deemed inconsequential to the study. 
Through their own words and descriptions, the physicians who participated in the study 
contributed to the purpose and significance of the study and to answering the research questions 
by articulating, in a meaningful way, a comprehensive list of moral agency traits for refinement 
of Jones’ (1991) model. Their thoughtful viewpoints and observations confirmed that academic 
physicians are or should be aware of their moral and ethical duty to resolve conflicts of interest 
in their roles as researchers, teachers, and clinicians.  They stressed that policies, federal 
regulations, and accreditation guidelines, to some degree, support academic physicians’ 
disclosure and COI resolution with frameworks that encourage considerate, appropriate, and 
ethical choices for all, regardless of whether ‘all’ is defined as family, friends, patients, research 
participants, or society.  They further emphasized the importance of the responsibilities of 
leadership, modeling, professionalism, and integrity that are essential in academic physicians’ 
interactions with trainees and the physicians of the future. 
During the case scenario discussions, bias was the main concern explicitly expressed by 
all, which they agreed had the greatest impact in dealing with issues of familiarity and expertise, 
and specifically, were they rationalizing their actions.  They indicated that, at minimum, full, 
absolute, continual disclosure, and conflict of interest (COI) mitigation were imperative whether 
caring for patients or interacting with research participants or a classroom of medical students 
and trainees.  Doing so empowers the medical students, trainees, research participants, and 
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patients to understand and contribute to their own assessments of the healthcare situation and 
decisions that affect them.  
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Chapter V 
Discussion 
Purpose of Study 
 Various concerned stakeholders and stakeholder groups continue to examine conflicts of 
interest (COIs) that may result from physicians’ financial relationship with industry and how 
COIs potentially affect patient treatment and satisfaction, prescription costs, and society as a 
whole.  Stakeholders are represented by patients, researchers, physicians, and other healthcare 
professionals and have a vested interest in the successful and thoughtful navigation of an ethical 
disclosure and COI resolution process.  Interested stakeholder groups are represented by federal 
regulators, Congress, professional associations, accreditation bodies, institutions of higher 
education, industry and other related and interested groups such as insurance providers and 
patient advocacy groups.  The stakeholder groups shoulder the responsibility, oversight, and 
evolution of disclosure and COI resolution requirements through regulations, guidelines, 
policies, and voluntary codes of ethics. 
These regulatory and procedural mechanisms are designed to provide continuity in the 
control and management of disclosure and COI resolution.  The Institute of Medicine (IOM) and 
Association of American Medical Colleges (AAMC), based on their assessment of the 
environment in 2009 and 2010 respectively, indicated that there was a need for evidence-based 
COI research.  Therefore, a key purpose of this study was to understand how physicians 
themselves, as moral agents, resolve conflicts of interest through an ethical decision-making 
process. 
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The physician participants in the study had been or continue to be involved in their 
academic roles of teaching, research, and patient care with research being the most active 
engagement.  They were fully aware of the potential of commercial bias and undue influence that 
exists in academic medicine and the responsibility physicians have in mitigating that effect 
through disclosure, COI resolution, and more importantly, through individual moral beliefs and 
actions as illustrated by the refined ethical decision-making theory (Figure 3). 
 The paucity of evidence-based literature presented a research opportunity to contribute to 
that gap.  The purpose of the study was to develop a theory that represents how academic 
physicians, as moral agents, identify, manage, and resolve perceived conflicts of interest (COI) 
in their academic roles as teachers, researchers, and clinicians.  A secondary purpose was to 
assess if financial relationships with industry may threaten academic freedom in ethical decision-
making.  The study concluded that academic freedom was inconsequential to COI resolution.   
Summary of Findings 
Reasons for Physician Relationships with Industry 
Preliminary to theory development was learning why physicians enter into financial 
relationships with industry.  The findings identified reasons (Table 3) as well as risks and 
benefits that may be associated with those relationships.  The reasons evolved into three 
categories – reputation, money and funding, and research.  The findings presented reputation in a 
predominantly positive manner in terms of professional recognition and growth, contribution of 
expertise, or a mutual benefit to both the physician and company.  The findings assessed money 
and funding from two perspectives – personal and professional.  An example of a personal 
reason may be supplementing one’s salary for the purpose of reducing personal debt, e.g. 
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medical school tuition loans.  Professional reasons were generally focused on providing 
additional revenue streams to the university in support of institutional mission and research. 
Research was the strongest reason of the three and supported collaboration with industry 
to bring new drugs to market, promoting advancement in medical science, and contributing to 
improved patient care.  Research also encompassed residual, positive effects on reputation to the 
individual physician scientist and institution as well as the value of receiving external funding to 
support research.  University-industry research collaboration is considered a significant benefit 
that brings with it recognition, prestige, institutional research support, and mission support. 
These three reasons give us a picture of why academic physicians engage in financial 
relationships with industry.  Acknowledging this relationship through disclosure is the first step 
in resolving any potential conflict of interest. 
The findings identified risks associated with these relationships that could have a 
substantial effect on the individual or institution through tainted research, evidence of bias, or 
misconduct resulting in damaging public or societal perceptions of the academic physician’s or 
institutional relationship with industry.  Perkins (1973) stressed an implicit trust that society has 
in higher education and the accompanying responsibility that higher education has in providing 
guidance for society, a principle that underlies a physician’s decision to enter into financial 
relationships with industry. In addition to the physician and institutional responsibility to society, 
the findings indicated that institutional culture and climate also influence physicians’ decisions to 
enter into financial relationships with industry as the following viewpoint suggests: 
I think every individual physician has to decide what their own criteria are, and it’s going 
to be influenced by the culture and environment in which they work.  If they work in a 
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place where these relationships are viewed with scrutiny, they will be more selective than 
if they work in an institution…where it’s more commonplace….(Oliver) 
 The literature supported this view and the influence of culture and climate on faculty 
decisions and behavior.  Peterson and Spencer (1990) define climate as the common patterns and 
current attitudes of the institution; whereas, culture focuses on embedded ideologies and 
uniqueness of the institution, both of which are expressed in the participant’s viewpoint.  
Additionally, Austin’s (1990) definition of culture is implicit in the quote signifying the 
complexity of a physician’s decision to enter into a relationship with industry.  Austin identified 
four aspects of culture – mission and collegiality of the academic profession, identification and 
socialization of the faculty, the academy’s responsibility to do “good work” (also Perkins, 1973), 
and institutional missions of producing knowledge and research.  As the literature suggests, the 
quote above emphasizes the importance of the physician’s and institution’s responsibility to 
society and respect for institutional mission, culture, and climate. 
Influence of Morality, Bias, and Familiarity 
The findings resulted in three themes representing factors that can influence ethical 
decisions regarding conflicts of interest in the academic physician’s teaching, research, and 
patient care roles and responsibilities.  I outlined the three themes of morality, bias, and 
familiarity (Table 5) with sub-themes, described the sub-themes with elements, and then 
articulated them as characteristics of a moral agent in the refined theory, recommending that 
these characteristics should be consistently present in all steps of the decision-making process as 
I have illustrated in the modified theory (Figure 3).  I applied the nine moral agent characteristics 
to all four steps of the decision-making model with the intent of assisting the decision-makers in 
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constant reflection of their role as a moral agent as they navigate the COI process. As briefly 
illustrated in Figure 4below and described in detail in Table 5 in chapter four, all three factors 
influence decision-making in the COI resolution process, but they also can influence each other.  
Morality factors express an individual’s core values and beliefs; they epitomize the essence of 
who we are.  Our moral character affects our professional conduct, may induce bias, or affect 
how we approach decisions in an objective and trusting manner.  Factors of familiarity involve 
our ability to make choices that interact with our beliefs and actions, resulting in ethical and 
moral decisions. 
Figure 4.  Influencing Factors of Morality, Bias, and Familiarity  
 
Morality Factors. 
 Morality speaks to the heart of what an individual espouses and is expressed as one’s 
moral obligation, commitment to truth, and recognition of being a ‘good person.’  These 
representative elements of morality generated three sub-themes involving honesty, ethical 
principles, and human nature.  As with the 2007 Symposium hosted by Baylor College of 
Medicine and the AAMC, “The Scientific Basis of Influence and Reciprocity;” the AMA Code 
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of Medical Ethics Opinion 1.01 (Appendix C) reinforces this theme by focusing on the 
physician’s moral and ethical responsibility with reference to one’s respect of moral principles.  
The AMA Code also identifies unethical behavior as failure to abide by moral standards in one’s 
professional conduct.   
Moral Agent Characteristics Associated with Morality. 
The three characteristics associated with Morality include: 
 Honesty with self and others, 
 Enduring moral compass,  and 
 Recognition of human imperfection 
The three morality characteristics support physicians’ ability to conduct themselves with an 
awareness of truth, moral responsibility, and human nature.  Honesty was associated with terms 
such as awareness, truth, integrity, and credibility.  Honesty is a core value in the COI resolution 
process that drives the ability to assess a situation or relationship with objectivity and make a 
moral and ethical decision. The lack of honesty undermines the trustworthiness and objectivity of 
a decision. Similar to the effect of honesty, the findings describe the second, and strongest, 
characteristic as the essence of moral duty, moral obligation, and ethical principles with the third 
characteristic acknowledging the influence of ‘being human’ on decisions and the need to 
recognize the good and the bad aspects of ‘being human.’     
Bias Factors. 
Bias was the main concern expressed by all participants and, as such, developed as one of 
the three themes that contributed to theory refinement.  Bias was evident in all three case 
scenarios and was described in terms of undue influence, lack of objectivity and independence, 
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and potential harm to patients and society.  Because bias was a substantial concern of the 
participants and central to the study, the findings acknowledged that even subtle influences can 
prejudice decision-making and cause harmful effects which the following quote illustrates:  
I think it’s a daily struggle.  Every day is an optimization algorithm for thinking ‘has this 
achieved the best overall outcome for all of these missions [teaching, research, patient 
care], and if I devote myself to this, what deleterious effects potentially will that have on 
these other missions that I’m supposed to be involved in.’ (David) 
In support of this ever present struggle of recognizing and avoiding bias in decision-
making, the findings revealed methods for bias avoidance (Table 4) through procedural aspects 
of identifying and resolving conflicts of interest (COIs) and the application of  moral agency 
attributes that foster bias avoidance.  The procedural methods recognize the importance of full 
disclosure, assessing merit of research, effective use of policies and guidelines, and providing 
education about COIs and bias.  The procedural methods are supported by the regulations, 
policies, guidelines, and codes discussed in the assessment of the environment in the chapter 
two.  These external controls are essential to the management of COIs.  They level the playing 
field by establishing standards that require submission to the same disclosure and COI resolution 
process of all who are involved in conducting medical research or developing content for a 
continuing medical education symposium, for example.  The following quote emphasizes the 
importance and need for a regulatory environment, 
[…] there is a lot of potential for misconduct and bad things; and as much as I abhor red 
tape and bureaucracy, there has got to be some regulation of this.  There is simply no way 
to expect people to completely regulate themselves (Daniel). 
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The medical education accreditation bodies and medical associations offer guidance and 
mechanisms to implement the regulatory requirements for physicians and other individuals 
involved in research, medical education, and patient care.  These organizations have conducted 
research in the areas of bias and ethics and released opinions and recommendation that support 
the need for an understanding of the disclosure and COI resolution and embrace the effect of the 
moral agent characteristics that evolved in the study on bias avoidance and ethical decision-
making in the COI process.   For example, the AMA’s Council on Ethical and Judicial Affairs 
offers ten ethical areas regarding professional and ethical conduct in medical education, research, 
and patient care.  The AAMC identifies conflicts of interest as “a clash between professional 
responsibilities and economic interests (2007, p. 19),” and disclosure as a “moral license” (2007, 
p. 22).  In 2009, the IOM released a consensus report that defined elements of a conflict of 
interest and recommended methods for mitigating undue bias and commercial influence for the 
purpose of protecting the integrity of professional judgment and proactively preserving public 
trust. 
Similar to the moral agent characteristics applied in the refined theory, the findings 
recognized moral attributes for avoiding bias (Table 4) such as the importance of being honest, 
of treating everyone the same (proximity), of reflecting on choices before issues arise, and of 
remembering “how we think as people in the first place” (Ben).  The participants suggested 
several litmus tests for avoiding or eliminating bias in the decision-making process.  Examples 
include asking yourself “are you a good person” (Ben); theoretically submitting your decision to 
the local newspaper test; considering “how is this going to look or wondering if I’m going to 
have to defend [my decision]” (Amanda); and continually asking yourself “am I doing the best 
for this patient, not the best for me, and in research…what I think is the truth or the most valid 
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interpretation of the results” (Karen). Avoiding bias involves a continual awareness as stated in 
one of the characteristics.  It is critical to have an opportunity to make sure that you are making 
the right decision for the right reasons in a fair and objective manner, without bias.  My litmus 
test, as I shared with one of the participants, is if I hesitate, there is generally a valid reason to 
step back and to consider reviewing and assessing my impending decision, regardless of its focus 
and whether it affects my personal or professional life. 
Moral Agent Characteristics Associated with Bias. 
The three characteristics associated with Bias involve: 
 Continual awareness of biases and potential conflicts, 
 Fairness and objectivity, and  
 Respect for proximity 
The first bias characteristic is the most prominent among the three and recognizes the potential 
of undue commercial influence, mission conflict, and the damage that can occur from either.  
This characteristic also suggests the need for full and absolute disclosure and the relevance of 
identifying and resolving conflicts of interest which is supported by the regulatory and guidance 
documents and policies that exist in the environment, as discussed above.  The second 
characteristic relates to objectivity and addresses the need for fairness in the process with respect 
for all stakeholders.  In addition to fairness, I described objectivity as balanced, independent, or 
impartial.  This is especially true in medical research and in the delivery of content in medical 
education.  The third characteristic addresses “the right thing to do” for all, regardless of 
personal or professional relationships and one’s financial relationship with industry.  This was 
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especially evident in the patient care case scenario in which ‘duty to patient’ and ‘patient trust’ 
were described as a “sacred trust.”   
Familiarity Factors. 
The findings recognize familiarity, the third and final theme, in terms of being either 
potentially harmful or beneficial.  Familiarity was considered beneficial when equated to 
expertise and when decisions are made based on professional knowledge, confidence, or 
preference.  It was viewed as a harm when the best drug or treatment or alternatives are not 
considered or selected, suggesting that a decision may be unduly biased or influenced due to a 
financial relationship with a company whose drugs the physician is prescribing.  This example 
reflects the clinical care case scenario in which the physician had retired from industry and 
returned to clinical practice.  The physician was very familiar with the drug he frequently 
prescribed which was manufactured by his former employer.  However, prescribing that drug 
may or may not be the best for the patient.  This example represents a COI that is not easily 
resolved as well as the potential harm to the patient.   
As expressed by this example, familiarity can be a positive or negative influence in the 
choices we make resulting in a decision that should be the best for the patient, in this case, and 
not just because that’s ‘what I know and prefer.’  Familiarity establishes the link between one’s 
beliefs and actions, determining the right thing to do (volition), and consequently, making a 
decision that is ethical.  In making a decision to resolve a COI, it’s critical to weigh all options 
for those the decision will affect, whether they are patients, students, or professional colleagues.  
With reference to this case scenario, the study findings indicated the tracking prescribing patterns 
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in the current healthcare system is difficult but suggested that tracking through electronic 
medical records may be a method to identify unusual prescribing patterns in the future.   
Moral Agent Characteristics Associated with Familiarity. 
The three characteristics associated with familiarity require: 
 Constant reflection of choices/consequences, 
 Congruence of moral beliefs and actions, and 
 Transparent, unbiased decisions. 
The first characteristic identifies the point at which actions are considered based upon reflection 
of the characteristics associated with morality and bias.  This characteristic involving choice 
requires listening to the evidence behind the impending decision, relying on professional 
expertise, and being aware of potential clouded judgment and consequences.  The second 
characteristic associated with familiarity suggests the point in the process where ethics and 
professional responsibility influence behavior.  It is linked with physician mission and role 
performance.  The third characteristic, decisions, is intended to confirm that the decision will be 
unbiased, transparent, and moral as David suggested, 
[…] making decisions that are very transparent and making sure that you are making a 
decision, that you are OK if other people know, that you can stand by your decisions in a 
transparent way. 
 A few of the nine characteristics based on morality, bias, and familiarity may be more 
obvious in some steps of the decision-making process than others.  However, the decision-maker 
should consider all characteristics of his / her role as a moral agent in all four steps of the 
process. Doing so should result in a decision made for the right reasons and based on moral, 
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ethical, and unbiased criteria.  In reference to the research, Daniel summed up the essence of 
making ethical decisions: 
[…] I think if you think about all of the aspects of it in trying to make an ethically correct 
decision, it’s not just about one trial.  It’s the perception and the relationship of the public 
and the people doing the trial, and the public with the drug companies, and people’s faith 
in research and public science.  There are a lot of factors, and I think that is one important 
part of making a good ethical decision…just to actually take the time to think about those 
factors beyond the immediate, obvious factors. 
Although specific to a research setting, the underlying principle in the quote also applies to 
teaching, patient care, and professional relationships, regardless of any financial relationships 
with industry.  It is important to think through the consequences of a decision in the COI 
resolution process and its potential effects on students, research study participants, patients, and 
society. 
Ethical Decision-Making Model in the COI Process 
As a result of conducting this study, I have developed the belief that consideration of 
factors related to morality, bias, and familiarity should offer a basis for providing thoughtful 
reflection as individuals proceed through the steps involved in the COI resolution process.  The 
steps, adapted from Jones’ (1991) model involve a sequential order of (1) recognizing a moral 
issue, (2) making a moral judgment, (3) establishing moral intent, and (4) engaging in moral 
behavior that results in an ethical decision.   
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Figure 3: Modified Ethical Decision-Making Model for Resolving Conflicts of Interest
 
Source: Modified from An Issue-Contingent Model of Ethical Decision Making in Organizations. Jones, T. M. 
(1991, April).  Ethical decision making by individuals in organizations: An issue-contingent model.  The Academy of 
Management Review, 16(2), p. 379.  Used with permission from the author, Thomas M. Jones, PhD (Appendix J). 
During the first step, the decision-maker acknowledges her/his role as a moral agent and 
potential consequences, whether harmful or beneficial.  The findings recognized that the second 
step requires moral reasoning, determining what is morally correct, and recognizing that ‘being 
human’ has its imperfections. The third step can create tension between what the decision-maker 
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actually believes and his/her actions.  This step was summed up in the teaching case scenario as a 
“slippery slope between teaching people and selling people” (David). The fourth step represents 
the decision-maker’s choice to act upon moral beliefs and make an ethical decision, the essence 
of which was best also described by David, “the appearance of complying is different than the 
spirit of complying.”  With continuous reflection on issues related to the influence of morality, 
bias, and familiarity; ethical decisions in the COI resolution process should produce decisions 
that are based on truth, objectivity, and professional knowledge and expertise.   
Moral Intensity Effect 
Jones (1991) identified moral intensity as a construct that focuses on the issue at the heart 
of a decision and the possible inability of the decision-maker to recognize the moral issue or 
assess its moral intensity which in this study would be the issue that creates a COI and requires 
resolution.  With that in mind and as exhibited in Figure 3, I identified one or more 
characteristics of moral intensity that I determined to have a predominant effect on each step of 
the process, suggesting a redistribution of the moral intensity characteristics.  In my study, I did 
not place primary focus on recognizing or assessing the core moral issue at the heart of the 
decision but propose consideration of such for future research at which point the six moral 
intensity characteristics should have a more significant impact on a study. 
Implications for Practice and Policy 
The stakeholder groups identified in the study continue to refine conflict of interest (COI) 
regulations and general guidelines as well as offer ethical guidance to physicians, other 
healthcare professionals, and non-healthcare professionals who contribute complementary 
expertise to the healthcare field.   Guidelines alone are inadequate in reducing conflicts of 
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interest, ensuring unbiased education, and reducing healthcare costs (Coleman et al, 2006).   
Institutional policies, however, are designed to protect the institution and the scholarly ideology 
and autonomy of its faculty, but their purpose is also to define what constitutes a COI and offer 
guidance on how to manage and resolve COIs and avoid bias.  It is a goal of this study that the 
findings will contribute to and inform revision of policies, procedures, and processes in the 
management of conflicts of interest through sequential steps of identifying, assessing, and 
resolving COIs.   
It is important for individuals and institutions to recognize that disclosure is the first step, 
not the only step, in a process that is designed to be transparent and resolve perceived conflicts-
of-interest as a result of financial relationships with industry.  Understanding the full process 
from an ethical decision-making perspective, as discussed in this study, is essential for 
identifying conflicts of interest, their potential effects, and how to manage them in a manner that 
is balanced, free of bias and undue commercial influence.  For the benefit of many affected 
stakeholders, whether they are students, research participants, patients, peers, or society; 
academic medical centers should offer education and case-based training in ethics, ethical 
decision-making, and how to identify, resolve, and manage a conflict of interest or commitment.  
In support of the need for education and training and as an adjunct to institutional conflict-of-
interest committees, an ethics policy and committee of faculty and other institutional leaders 
could assume oversight of the training and contribute to the resolution step in the COI process.   
The training should be required of all faculty and residents with refresher courses offered every 
few years or more frequently as deemed necessary.  The training should also contribute to 
addressing situations or complaints involving perceived ethical misconduct.  Additionally, 
institutions should consider creating a firewall in their COI policies, as some already have, that 
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prohibits multiple financial relationships with industry, especially when research funding support 
or academic-industry research collaboration is involved.  Doing so would inhibit potential 
conflicts of purpose or mission. 
The findings also encourage policy writers and the authors of ethical and professional 
conduct codes to listen to physicians and consider their voice in how the COI process should be 
navigated and what factors influence the process and decision, such as those presented in this 
study.  The findings accentuate the importance of understanding how we, as human beings first 
and foremost, process issues imbedded in a moral and ethical context which should support a 
more objective and independent approach to the COI resolution process.   
Sunshine Act 
 Among the regulations referenced above that may influence the COI process is the 
recently enacted Sunshine Act, a provision of the Patient Protection and Affordable Care Act.  I 
sought the participants’ views on existing or potential effects of the Sunshine Act on physicians’ 
financial relationships with industry.  Their knowledge of the legislation ranged from none to 
comprehensive with most participants having minimal knowledge of it.  After explaining the act, 
they generally considered that the effect will be virtually none at this point.  The Sunshine Act 
places the burden of disclosing physician and institutional financial relationships with industry 
on the companies.  The companies must post all funding recipients, the nature of the funding, 
e.g. research, and the value of the funding.  As a result of congressional investigations that began 
in 2004, the act was predicated by the need for improved transparency. 
The participants’ viewpoints speculated that financial relationships with industry will 
continue as is and some will sever the relationships to avoid having it made public, ‘out in the 
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sunshine.’  One participant observed that “…some colleagues…have told me that they wear it as 
a ‘badge of honor’ while others…have morally moved themselves to accept it and say ‘that’s just 
how the world works’” (Ben).   The general opinion suggests that it should be a deterrent to 
financial relationships with industry or at least an opportunity to pause and consider the effects 
on one’s professional role.  An opportunity for future research of the effect of the Sunshine Act 
is evident because its implementation is ongoing and outcomes data are not available at this 
point. 
Future research 
 In addition to the future research potential of the Sunshine Act, several other 
opportunities emerged for future research.  The focus of the study has considered the individual 
physician’s financial relationship with industry; however, institutions also have relationships 
with industry primarily in the forms of grants to fund research initiative, university-industry 
research collaboration, or program grants.  As with the individual financial relationships, there 
are inherent conflicts of interest that may exist in these institutional level relationships; therefore, 
application of a similar study may have merit. 
 In my study, I examined the process of making ethical decisions through a grounded 
theory approach based on Jones’ (1991) model.  Jones’ model and my refined theory offer 
several opportunities for further research.  Jones (p. 391) suggested that future research “should 
include consideration of the effect of the moral agent’s failure to recognize the moral issue.”  
Recognizing the moral issue is the first step or component in the decision-making model which 
is fundamental to an effective navigation of the process.  Future research should also consider 
whether ethics is proportional or rationalized in consideration of an issue, situation, or 
circumstances.  Additionally, I excluded the organizational factors of Jones’ model from the 
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study which includes constructs of group dynamics, authority factors, and socialization 
processes.  The effects of these organizational factors on ethical decision-making and in the 
context of the COI resolution process may reveal the impact of peer influence as well as the 
effect of institutional culture and climate. 
 Due to a relatively small sample in this study, a replication of the study would be 
valuable in continuing the discussion among stakeholders in determining how academic 
physicians assess and resolve potential conflicts of interest because as several participants 
indicated, we all have biases.  Furthermore, it would give them an ongoing voice in the dialogue 
and an opportunity to consider the moral agent responsibility that exists in all of us.  The study 
purpose and methodology should be generalizable to other professions and academic disciplines, 
such as law, business, engineering, or education, in which financial relationships exist between 
external organizations and faculty.  Conflicts of interest (COIs) in these fields could be 
represented by financial relationships such as consulting agreements with private firms in the 
legal, management, or engineering communities.   COIs could also present themselves through 
stocks and stock options with e.g., oil and gas companies or book publishing companies.  As 
with medicine, these examples could create a conflict of interest with the individual faculty 
member but could also result in a conflict of commitment between time and effort dedicated to 
academic responsibilities and secondary, external commitments that are more financially 
beneficial.  Many universities address external allocations of time and effort in their institutional 
policies to avoid an imbalance of responsibilities between internal and external professional 
roles.  With the appropriate balance, the external relationship can be viewed as a complement to 
the faculty member’s academic role and institutional mission as well as an academic-industry 
collaborative opportunity for both faculty and institution. 
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Conclusion 
 Bias and conflicts of interest have existed over time in many aspects of our lives, but as I 
discussed with the speaker who suggested that I was violating his academic freedom, I was only 
concerned with his bias that may be inappropriately influenced by industry thereby creating a 
conflict of interest (COI) that may not be conducive to resolution.  At the heart of COI resolution 
is an ethical decision-making process in a manner such as the refined theory demonstrated with 
the findings from my study.  The academic physicians who agreed to participate in my study 
expanded my understanding of the role and responsibilities of individuals as moral agents in a 
refined theory of ethical decision-making that may contribute to the literature.   
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Appendix C 
 
AMA Code of Medical Ethics 
 
Principles of Medical Ethics 
Adopted June 1957; revised June 1980; revised June 2001. 
Preamble 
The medical profession has long subscribed to a body of ethical statements developed primarily for the 
benefit of the patient. As a member of this profession, a physician must recognize responsibility to 
patients first and foremost, as well as to society, to other health professionals, and to self. The 
following Principles adopted by the American Medical Association are not laws, but standards of 
conduct which define the essentials of honorable behavior for the physician. 
Principles of medical ethics 
I. A physician shall be dedicated to providing competent medical care, with compassion and respect for 
human dignity and rights. 
II. A physician shall uphold the standards of professionalism, be honest in all professional interactions, 
and strive to report physicians deficient in character or competence, or engaging in fraud or deception, 
to appropriate entities. 
III. A physician shall respect the law and also recognize a responsibility to seek changes in those 
requirements which are contrary to the best interests of the patient. 
IV. A physician shall respect the rights of patients, colleagues, and other health professionals, and shall 
safeguard patient confidences and privacy within the constraints of the law. 
V. A physician shall continue to study, apply, and advance scientific knowledge, maintain a 
commitment to medical education, make relevant information available to patients, colleagues, and 
the public, obtain consultation, and use the talents of other health professionals when indicated. 
VI. A physician shall, in the provision of appropriate patient care, except in emergencies, be free to 
choose whom to serve, with whom to associate, and the environment in which to provide medical care. 
VII. A physician shall recognize a responsibility to participate in activities contributing to the 
improvement of the community and the betterment of public health. 
VIII. A physician shall, while caring for a patient, regard responsibility to the patient as paramount. 
IX. A physician shall support access to medical care for all people. 
Opinion 1.01 – Terminology   
Issued prior to April 1977; Updated June 1994 and June 1996. 
The term "ethical" is used in opinions of the Council on Ethical and Judicial Affairs to refer to matters 
involving (1) moral principles or practices and (2) matters of social policy involving issues of morality in 
the practice of medicine. The term "unethical" is used to refer to professional conduct which fails to 
conform to these moral standards or policies. 
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Many of the Council’s opinions lay out specific duties and obligations for physicians. Violation of these 
principles and opinions represents unethical conduct and may justify disciplinary action such as 
censure, suspension, or expulsion from medical society membership. (II) 
Opinion 8.03 - Conflicts of Interest: Guidelines 
Issued July 1986; Updated June 1994 
Under no circumstances may physicians place their own financial interests above the welfare of their 
patients. The primary objective of the medical profession is to render service to humanity; reward or 
financial gain is a subordinate consideration. For a physician to unnecessarily hospitalize a patient, 
prescribe a drug, or conduct diagnostic tests for the physician’s financial benefit is unethical. If a 
conflict develops between the physician’s financial interest and the physician’s responsibilities to the 
patient, the conflict must be resolved to the patient’s benefit. (II) 
Opinion 8.061 - Gifts to Physicians from Industry 
The previous Opinion 8.061, also entitled “Gifts to Physicians From Industry,” issued June 1992, updated June 1996 and 
June 1998, was replaced by the current Opinion 8.061, “Gifts to Physician From Industry.” Adopted November 2013. 
Relationships among physicians and professional medical organizations and pharmaceutical, 
biotechnology, and medical device companies help drive innovation in patient care and contribute to 
the economic well-being of the community to the ultimate benefit of patients and the public. 
However, an increasingly urgent challenge for both medicine and industry is to devise ways to preserve 
strong, productive collaborations at the same time that they take clear effective action to prevent 
relationships that damage public trust and tarnish the reputation of both parties.  
Gifts to physicians from industry create conditions that carry the risk of subtly biasing—or being 
perceived to bias—professional judgment in the care of patients. 
To preserve the trust that is fundamental to the patient-physician relationship and public confidence in 
the profession, physicians should: 
(a) Decline cash gifts in any amount from an entity that has a direct interest in physicians’ treatment 
recommendations. 
(b) Decline any gifts for which reciprocity is expected or implied. 
(c) Accept an in-kind gift for the physician’s practice only when the gift: 
(i) will directly benefit patients, including patient education; and 
(ii) is of minimal value.  
  
(d) Academic institutions and residency and fellowship programs may accept special funding on behalf 
of trainees to support medical students’, residents’, and fellows’ participation in professional 
meetings, including educational meetings, provided: 
(i) the program identifies recipients based on independent institutional criteria; and 
(ii) funds are distributed to recipients without specific attribution to sponsors. (II) 
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Opinion 9.011 - Continuing Medical Education 
Issued December 1993. Updated June 1996. Updated June 2013 based on the report "Amendment to E-9.011, 'Continuing Medical 
Education,” adopted November 2012. 
Physicians should strive to further their medical education throughout their careers, to ensure that 
they serve patients to the best of their abilities and live up to professional standards of excellence. 
Participating in certified continuing medical education (CME) activities is critical to fulfilling this 
professional commitment to lifelong learning. As attendees of CME activities, physicians should: 
(a) Select activities that are of high quality and are appropriate for the physician’s educational needs. 
(b) Choose activities that are carried out in keeping with ethical guidelines and applicable professional 
standards. 
(c) Claim only the credit commensurate with the extent of participation in the CME activity. 
(d) Decline any subsidy offered by a commercial entity other than the physician’s employer to 
compensate the physician for time spent or expenses of participating in a CME activity.  
(I, V) 
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Selected Text and related Endnotes from 
AAUP 1940 Statement of Principles on Academic Freedom and Tenure 
In 1915 the Committee on Academic Freedom and Academic Tenure of the American Association of 
University Professors formulated a statement of principles on academic freedom and academic tenure 
known as the 1915 Declaration of Principles, which was officially endorsed by the Association at its 
Second Annual Meeting held in Washington, D.C., December 31, 1915, and January 1, 1916. 
In 1925 the American Council on Education called a conference of representatives of a number of its 
constituent members, among them the American Association of University Professors, for the purpose of 
formulating a shorter statement of principles on academic freedom and tenure. The statement 
formulated at this conference, known as the 1925 Conference Statement on Academic Freedom and 
Tenure, was endorsed by the Association of American Colleges (now the Association of American 
Colleges and Universities) in 1925 and by the American Association of University Professors in 1926. 
In 1940, following a series of joint conferences begun in 1934, representatives of the American 
Association of University Professors and of the Association of American Colleges (now the Association of 
American Colleges and Universities) agreed upon a restatement of principles set forth in the 1925 
Conference Statement on Academic Freedom and Tenure. This restatement is known to the profession 
as the 1940 Statement of Principles on Academic Freedom and Tenure. 
Following extensive discussions on the 1940 Statement of Principles on Academic Freedom and Tenure 
with leading educational associations and with individual faculty members and administrators, a joint 
committee of the AAUP and the Association of American Colleges met during 1969 to reevaluate this key 
policy statement. On the basis of the comments received, and the discussions that ensued, the joint 
committee felt the preferable approach was to formulate interpretations of the 1940 Statement from the 
experience gained in implementing and applying it for over thirty years and of adapting it to current 
needs.  
The committee submitted to the two associations for their consideration Interpretive Comments that are 
included below as footnotes to the 1940 Statement.1 These interpretations were adopted by the Council 
of the American Association of University Professors in April 1970 and endorsed by the Fifty- Sixth 
Annual Meeting as Association Policy. 
 
The purpose of this statement is to promote public understanding and support of academic freedom and 
tenure and agreement upon procedures to ensure them in colleges and universities. Institutions of higher 
education are conducted for the common good and not to further the interest of either the individual 
teacher or the institution as a whole.2 The common good depends upon the free search for truth and its 
free exposition. 
Academic freedom is essential to these purposes and applies to both teaching and research. Freedom in 
research is fundamental to the advancement of truth. Academic freedom in its teaching aspect is 
fundamental for the protection of the rights of the teacher in teaching and of the student to freedom in 
learning. It carries with it duties correlative with rights.3 
Tenure is a means to certain ends; specifically: (1) freedom of teaching and research and of extramural 
activities, and (2) a sufficient degree of economic security to make the profession attractive to men and 
women of ability. Freedom and economic security, hence, tenure, are indispensable to the success of an 
institution in fulfilling its obligations to its students and to society. 
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Academic Freedom 
1. Teachers are entitled to full freedom in research and in the publication of the results, subject to 
the adequate performance of their other academic duties; but research for pecuniary return 
should be based upon an understanding with the authorities of the institution. 
2. Teachers are entitled to freedom in the classroom in discussing their subject, but they should be 
careful not to introduce into their teaching controversial matter which has no relation to their 
subject.4 Limitations of academic freedom because of religious or other aims of the institution 
should be clearly stated in writing at the time of the appointment.5 
3. College and university teachers are citizens, members of a learned profession, and officers of an 
educational institution. When they speak or write as citizens, they should be free from institutional 
censorship or discipline, but their special position in the community imposes special obligations. 
As scholars and educational officers, they should remember that the public may judge their 
profession and their institution by their utterances. Hence they should at all times be accurate, 
should exercise appropriate restraint, should show respect for the opinions of others, and should 
make every effort to indicate that they are not speaking for the institution.6 
Endnotes: 
1. The Introduction to the Interpretive Comments notes: In the thirty years since their promulgation, the 
principles of the 1940 “Statement of Principles on Academic Freedom and Tenure” have undergone 
a substantial amount of refinement. This has evolved through a variety of processes, including 
customary acceptance, understandings mutually arrived at between institutions and professors or their 
representatives, investigations and reports by the American Association of University Professors, and 
formulations of statements by that association either alone or in conjunction with the Association of 
American Colleges. These comments represent the attempt of the two associations, as the original 
sponsors of the 1940 “Statement,” to formulate the most important of these refinements. Their 
incorporation here as Interpretive Comments is based upon the premise that the 1940 “Statement” is not 
a static code but a fundamental document designed to set a framework of norms to guide adaptations to 
changing times and circumstances.  
Also, there have been relevant developments in the law itself reflecting a growing insistence by the courts 
on due process within the academic community which parallels the essential concepts of the 1940 
“Statement”; particularly relevant is the identification by the Supreme Court of academic freedom as a 
right protected by the First Amendment. As the Supreme Court said in Keyishian v. Board of Regents, 
385 US 589 (1967), “Our Nation is deeply committed to safeguarding academic freedom, which is 
of transcendent value to all of us and not merely to the teachers concerned. That freedom is therefore a 
special concern of the First Amendment, which does not tolerate laws that cast a pall of orthodoxy over 
the classroom.” Back to text. 
2. The word “teacher” as used in this document is understood to include the investigator who is attached 
to an academic institution without teaching duties. Back to text. 
3. First 1970 comment: The Association of American Colleges and the American Association of 
University Professors have long recognized that membership in the academic profession carries with it 
special responsibilities. Both associations either separately or jointly have consistently affirmed these 
responsibilities in major policy statements, providing guidance to professors in their utterances as 
citizens, in the exercise of their responsibilities to the institution and to students, and in their conduct 
when resigning from their institution or when undertaking government-sponsored research. Of particular 
relevance is the “Statement on Professional Ethics” adopted in 1966 as Association policy (AAUP, Policy 
Documents and Reports, 11th ed. [Baltimore: Johns Hopkins University Press, 2015], 145– 46). Back to 
text. 
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4. Second 1970 comment: The intent of this statement is not to discourage what is “controversial.” 
Controversy is at the heart of the free academic inquiry which the entire statement is designed to foster. 
The passage serves to underscore the need for teachers to avoid persistently intruding material which 
has no relation to their subject. Back to text. 
5. Third 1970 comment: Most church-related institutions no longer need or desire the departure from the 
principle of academic freedom implied in the 1940 “Statement,” and we do not now endorse such a 
departure. Back to text. 
6. Fourth 1970 comment: This paragraph is the subject of an interpretation adopted by the sponsors of 
the 1940 “Statement” immediately following its endorsement: 
If the administration of a college or university feels that a teacher has not observed the 
admonitions of paragraph 3 of the section on Academic Freedom and believes that the 
extramural utterances of the teacher have been such as to raise grave doubts concerning the 
teacher’s fitness for his or her position, it may proceed to file charges under paragraph 4 of the 
section on Academic Tenure. In pressing such charges, the administration should remember that 
teachers are citizens and should be accorded the freedom of citizens. In such cases the 
administration must assume full responsibility, and the American Association of University 
Professors and the Association of American Colleges are free to make an investigation. 
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AAUP 1990 Statement on Conflicts of Interest and Research 
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IRB-approved Institutional Prospectus 
 
 
DEPARTMENT OF EDUCATIONAL LEADERSHIP, 
  COUNSELING AND FOUNDATIONS 
 
 [date] 
[Name/address] 
Dear [name]: 
I am currently a PhD candidate at the University of New Orleans in the Higher Education Administration 
program, Department of Educational Leadership, Counseling, and Foundations.  I am in the process of 
fulfilling the university and college degree requirements for completion of the program. 
I am writing to ask if you would allow me to conduct taped interviews with six to ten faculty members 
that should last approximately 60 minutes as a component of my qualitative research study and 
dissertation entitled Truth or Consequences—Academic Physicians’ Perspective in the Management 
of Commercially-influenced Conflicts of Interest:  An Issue-Contingent Ethical Decision-Making 
Model.  The study will focus on conflicts of interest that emerge from academic physicians’ financial 
relationships with industry, i.e. pharmaceutical, medical device, or biotech firms in their roles of teaching, 
research, and patient care.  The faculty responses will be framed as perspectives to case scenarios, not 
their real-life experiences. 
 
I will follow all federal regulations regarding conducting research involving human subjects and have 
attached relevant documentation for your review in allowing my access to your institution and faculty.  
Additionally, please advise if further review and approval is required by your Institutional Review Board. 
If you have additional questions and/or would like to receive a summary of my findings, I may be reached 
at 504-442-2143 (cell) or at mleppers@uno.edu.  Additionally, if you wish to discuss the study or 
requirements with my major professor and dissertation committee chair, Belinda M. Cambre, JD, PhD; 
you may reach her at 504-280-3210 or at bmcambre@uno.edu. Thank you for your consideration of my 
request, and I look forward to hearing from you. 
Best regards, 
Melinda Epperson, M.Ed., CMP 
504-442-2143 (cell) 
mleppers@uno.edu 
 
Attachments: Institutional Prospectus 
  Participant Recruitment Flyer 
  UNO IRB Approval letter 
  Interview Consent Form 
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Institutional Prospectus 
 
Purpose:  The purpose of this qualitative research study is to explore academic physicians’ perspectives 
in the management of conflicts of interest (COI) that emerge from financial relationships with industry, 
i.e. pharmaceutical, medical device, or biotech firms.  Your academic medical institution was selected 
based on three sets of criteria: 
 
(1) Either of the following descriptions applies: 
(a) a relatively new medical school accredited within the past ten years OR 
(b) a long-standing academic medical institution 
(2) Type of governance: 
(a) private OR 
(b) publicly-funded, i.e. state institution. 
(3) Willingness to participate in a study that may contribute to 
(a)  the literature and a better understanding of the environment AND 
(b)  policy reform and change  
 
Research Activities at the site during the study:  With the institutional administration’s permission, I 
will conduct one-on-one interviews with identified faculty who have met the selection criteria.  The 
interviews will be conducted with minimal disruption and with respect to confidentiality of data and 
participant identity.  Please refer to the attached Interview Consent Form that provides additional details 
regarding participant selection, terms of participation, access to information, and the benefits and risks 
that may result from participation in the study. 
Findings:  Also noted in the attached Interview Consent Form, the results of the study will be reported in 
aggregate without any identifiable information to protect the participants and the institution with which 
they are affiliated.   
Institutional Benefits:  As explained in the Interview Consent Form, there are minimal risks to 
conducting this study.  A sample of benefits that the study may provide include further discussion with 
faculty of the research topic, a better understanding of the university-industry environment, the barriers 
that faculty may encounter in industry relationships, and an opportunity to inform institutional policy. 
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[Flyer wording, if applicable] 
Faculty Study Participants Requested 
for a 
Qualitative Dissertation Study 
 
How do physicians as academicians manage or resolve potential conflicts of interest in their roles as 
teachers, researchers, and clinicians? 
 
Participate and contribute to the body of literature through your 
faculty perspectives of case scenarios during a single, 
60-minute interview between [date] and [date]. 
Participant Criteria 
Medical Faculty who are: 
 involved in the three roles of teaching, research, and patient care 
 have or have had one or multiple financial relationships* with industry (biotech firms, 
pharmaceutical or medical device companies) 
[*For example: speakers’ bureau, consultant, stock or stock options, research grants, etc.] 
Please call or email by [date] with questions and/or 
to schedule an interview date and time. 
 
CONTACT 
Melinda Epperson (PhD candidate) 
504-442-2143 
mleppers@uno.edu or mlecmp@aol.com 
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IRB-approved Interview Request Letter 
 
 
DEPARTMENT OF EDUCATIONAL LEADERSHIP, 
  COUNSELING AND FOUNDATIONS 
 
 
 [Date] 
Dear Dr. [name]: 
I am currently a PhD candidate at the University of New Orleans in the Higher Education Administration 
program, Department of Educational Leadership, Counseling, and Foundations.  I am in the process of 
fulfilling the university and college degree requirements for completion of the program. 
I am writing to ask if you would allow me to conduct a taped interview with you as a component of my 
qualitative research study and dissertation entitled Truth or Consequences—Academic Physicians’ 
Perspective in the Management of Commercially-influenced Conflicts of Interest:  An Issue-
Contingent Ethical Decision-Making Model.  The study will focus on conflicts of interest that emerge 
from academic physicians’ financial relationships with industry, i.e. pharmaceutical, medical device, or 
biotech firms in their roles of teaching, research, and patient care. 
If you are willing to participate, I have included a consent form defining the parameters of the interview 
and how I will use the information and perspectives that you will contribute.  I appreciate your 
consideration of my request and I will assure confidentiality of your identity and of your responses as 
noted in the attached consent form.  If you agree to be interviewed, I will contact you to arrange a time 
convenient with your schedule.  I ask that you call or email me to let me know of your willingness to 
participate.  My contact information is given below. 
If you have additional questions and/or would like to receive a summary of my findings, I may be reached 
at 504-442-2143 (cell) or at mleppers@uno.edu.  Additionally, if you wish to discuss the study or 
requirements with my major professor and dissertation committee chair, Belinda M. Cambre, JD, PhD; 
you may reach her at (225-931-8852),  bcambre@cox.net, or bmcambre@uno.edu. I look forward to 
talking with you. 
Best regards, 
Melinda Epperson, M.Ed., CMP 
504-442-2143 (cell) 
mleppers@uno.edu 
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IRB-approved Interview Consent Form 
 
 
DEPARTMENT OF EDUCATIONAL LEADERSHIP, 
  COUNSELING AND FOUNDATIONS 
 
Interview Consent Form 
Conditions of interview participation: 
1. Purpose:  The purpose of this qualitative grounded theory study is to explore academic physicians’ 
perspectives in the management of conflicts of interest (COI) that emerge from financial relationships 
with industry, i.e. pharmaceutical, medical device, or biotech firms. 
 
2. Selection and Participant Rights: The selection of an academic physician engaged in the academic 
roles of teaching, research, and patient care for the single, individual interview provides a faculty 
member’s perspective of how one may manage and resolve any potential COIs in case scenarios in 
the areas of teaching, research, and patient care. The interview will be taped and transcribed 
maintaining confidentiality of identity and with due respect to anonymity of responses.  You will be 
described only by your academic role (faculty level, specialty, type of institution, e.g. academic 
medical center, school/college of medicine, teaching hospital, etc., other administrative/faculty 
responsibilities, and general descriptive demographics) in the institution with no reference to a 
specific department or institution. 
 
3. Access/Confidentiality/Anonymity:  The graduate student-interviewer, Melinda Epperson, will omit 
your name and all other identifying features in transcription as well as discussion of the interview 
technique of qualitative research in the dissertation, assuring confidentiality. You will only be 
identified with a pseudonym of your choosing or with an assigned interviewee #.   This interview is 
for my dissertation and resulting presentations or publications for which your identity will be 
protected.  All written notes, records, and electronic documents, i.e. tapes or CDs of interviews will 
be protected in a locked cabinet in my office for a period of three (3) years after which all will be 
shredded or destroyed in an appropriate manner. 
 
4. Participation: Your participation in the interview for the study is strictly voluntary and will last no 
longer than 60 minutes.  I will take notes during the interview to supplement the audio-taping.  Once 
transcribed, I will ask you to review my transcription for accuracy.  Your signature below 
acknowledges your willingness and agreement to participate and to answer the questions to the extent 
of your knowledge and experience, contributing to the integrity of the study.  Please understand that 
your role is strictly voluntary and that you may choose at any time to discontinue your participation in 
the interview and the study.  There is minimal risk, but if you decide to withdraw, your decision will 
not affect any future contact with the University of New Orleans or impact on the study. 
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5. Benefits and Risks: The benefits to you in participating include learning new perspectives, ideas, 
opinions concerning how an academic physician as an individual manages conflicts of interest (COI) 
that emerge from financial relationships with industry, i.e. pharmaceutical, medical device, or biotech 
firms..  As an experienced faculty and/or administrator, you may as well enlighten and further my 
understanding of the environment.  Although there is minimal risk, you may discover opinions that 
would differ from previously conceived perspectives.  Additionally, disclosure of your responses may 
be damaging to your financial standing, employability, or reputation.  I will protect your identity and 
the confidentiality of your participation as indicated above in #3. The additional benefit of your 
participation is to society and may contribute to future research and/or inform policy. 
 
Any questions regarding my study may be directed to Belinda M. Cambre, JD, PhD (225-931-8852), 
bcambre@cox.net, or bmcambre@uno.edu.  Thank you for participating. 
I have read and understand the conditions of participating in the interview exercise and am willing to 
participate. 
 
Signature 
Participant Interviewee:  ________________________________________  Date:__________ 
 
Name Printed: __________________________________________________________ 
 
 
I have explained the conditions of participating to the best of my ability and have answered questions 
concerning participation. 
 
Signature 
Student Interviewer:  ___________________________________________  Date:___________ 
 
Name Printed:             Melinda Lawrie Epperson, M.Ed., CMP 
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IRB-approved Interview Guide 
 
Interview Guide 
PART A—Purpose and demographics:  The purpose of this study is to explore and gain insight into 
how academic physicians, who have financial relationships with industry, make ethical decisions in 
resolving potential conflicts of interest (COIs).  Therefore, the objectives of the interview, based on three 
case scenarios, are to:  
(1) Hear your perspectives of the decision-making process that physicians may use in resolving 
COIs; 
(2) Identify factors that may influence the decision-making process; 
(3) Generally understand how the decision-making process may or may not affect an academic 
physician, who has financial relationships with industry,  in his or her roles as research, teaching, 
and patient care; and  
(4) Synthesize observations of the environment. 
Your insight as both clinician and faculty will be valuable.  Thank you for your willingness to participate 
in the interview.  Please provide the following background information about yourself: 
a. Specialty 
b. Years in practice 
c. Years in academic medicine, if different than years in practice 
d. Why you chose to participate in academic medicine 
e. How many years you have had financial relationships with industry 
f. The nature of those relationships, e.g. speakers’ bureau, consultant, research funding, 
stock or stock options, advisory boards, other. 
g. How would you generally define conflict of interest as it relates to physicians’ financial 
relationships with industry?   
 
PART B—Case Scenarios:  [NOTE:  The following questions will be presented with each of three case 
scenarios in teaching, research, and clinical/patient care.] 
 
In making ethical decisions in this scenario, did or how should have the physician considered the 
following?  Please feel free to answer with other examples: 
 
a. Is there a moral issue at the center of his/her decision? (moral intensity1) 
b. What potential harms and benefits should the physician have considered and based on 
what criteria? (magnitude of consequences and probability of effect1) 
c. What could be the effect of institutional policies, federal regulations, accreditation 
guidelines, etc., on the physician’s decisions, and what could determine the level of 
effect, e.g. strong influencing effect or minimal consideration? (social consensus1) 
d. Did or should have the physician consider(ed) future effects or consequences of his/her 
decisions? Why?  Examples? (temporal immediacy1) 
e. Would his/her decisions be different for a close friend than, for example, a class of 
patients, a cohort of students, society, etc.? (proximity1) 
f. How would the decision be affected if the potential for significant financial gain were 
apparent? (concentration of effect1) 
g. Any advice that you would offer him/her? 
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PART C—General environmental assessment:  The following are concluding questions for the purpose 
of gaining your assessment of the current environment.  Taking the three scenarios we have discussed into 
consideration, please offer your professional perspectives about the following: 
 
1. What are the possible reasons physicians enter into financial relationship(s) with industry?  If not 
mentioned, will present the follow-up questions below for reaction: 
a. Q1:  Reputation? 
b. Q2:  loans (debt-load) from medical school? 
c. Q3:  institutional pressures to secure external funding? 
d. Q4:  tenure rewarded by department/institution for securing external funding? 
 
2. What are the benefit(s) for a physician and his/her institution?  Risks? 
 
3. Do financial relationships present obstacles or barriers to physicians’ performance in research, 
teaching, and patient care? 
 
a. Q1: …such as? 
b. Q2: Do or could they impact independent and professional judgment in interaction with 
(i) professional colleagues, (ii) research subjects, (iii) students, and (iv) patients? 
 
4. How does/should a physician avoid bias and COIs in (a) teaching, (b) research, and (c) patient 
care? 
 
5. Is the Sunshine Act a deterrent to physicians entering into financial relationships?  Why or why 
not? 
 
6. One final question…what factors have you observed that may influence ethical, unbiased 
decisions?  What could be a good litmus test? 
 
In concluding the interview, I want to give you the opportunity to offer additional opinions, perspectives, 
or observations concerning ethical decision-making either in reference to the case scenarios we discussed 
or the environment in general. 
Thank you again for your time, your observations, and for participating in my study!  I will be happy to 
share the aggregate findings with you. 
 
 
 
1 Jones, T. M. (1991, April).  Ethical decision making by individuals in organizations: An issue-
contingent model.  The Academy of Management Review, 16(2), 366-395.   
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Copyright Permission 
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NIH Certificate of Completion 
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 212 
Vita 
 
Melinda Lawrie Epperson 
 
 
The author holds a BS degree in Secondary Education (French and English) from 
University of Tennessee at Martin, a Master’s degree (MEd) in Higher Education Administration 
from the University of New Orleans.  Her formal education is complemented by her designation 
as a Certified Meeting Professional (CMP).  With conference development and management 
being an essential component of continuing education, she obtained her initial CMP designation 
in 1992 and has recertified every five years.  With her most recent recertification in 2012, she 
will be eligible for an emeritus recertification in 2017.  
She began her Tulane University continuing education career as Program Coordinator in 
May 1993 followed by positions as Program Manager, Assistant Director, and Interim Director 
and was appointed director in March 2004.  Her professional experience includes 33 of the last 
36 years in academic-based continuing education with positions in the University of Kentucky’s 
College of Business and Economics in Lexington, Kentucky and Valencia Community College 
in Orlando, Florida in addition to her current position in Tulane University.   
The author’s current professional memberships include the Society for Academic CME 
(SACME), Association for the Study of Higher Education (ASHE), International Association of 
Continuing Education and Training (IACET), and Meeting Professionals International (MPI).    
